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1 Definition of Disease 
Inflammatory Bowel Disease (IBD) is the common denominator for at least two distinct pathological 
entities, Crohn’s disease (CD) and ulcerative colitis (UC). Both disorders are characterized by chronic 
inflammation of the gastrointestinal tract and share several clinical characteristics, including 
abdominal pain, diarrhea, occult blood loss, fever and fatigue. Despite these similarities, they are 
regarded as two different diseases with their own characteristics and etiology. This can be inferred 
from differences in the development, localization, histological and immunological features, and 
complications of the disease. Therefore, both diseases will be described as two distinct pathologies. 
First a summary of the general clinical presentation of the diseases and their epidemiology will be 
given, followed by a general discussion of the environmental factors implicated in the etiology of IBD. 
Finally, a description of the immunological processes involved will be given, followed by a discussion 
of the genetic factors that are implicated in the susceptibility to and pathogenesis of intestinal 
inflammation. 
 
1.1 Crohn’s Disease 
Crohn’s disease was coined after the description by Burrill B. Crohn, Leon Ginsberg and Gordon D. 
Oppenheimer in 1932 as ‘a disease of the terminal ileum, affecting mainly young adults, characterized 
by a sub acute or chronic necrotizing and cicatrizing inflammation’ 1. Although Crohn gave his name 
to the disease, it was already described in detail some 20 years before, by T. Dalziel, as chronic 
interstitial enteritis 2. 
When patients with this disease first report to their physician, most of them suffer from abdominal 
pain, diarrhea, weight loss, and fatigue. Disease can manifest anywhere in the gastrointestinal (GI) 
tract, with predilection sites in the terminal ileum, the colon and the perianal region. Endoscopically, 
the tissue appears swollen, with a narrowed lumen of the bowel. Histologically, the inflammation 
extends throughout the entire bowel wall, affecting the mucosa and the underlying muscular and 
serosal layers of the intestine. The inflammation is characterized most typically by non-caseating 
granulomas, and so called ‘skip lesions’ in which affected parts of the intestine are segmented by 
healthy patches, which may result in a cobblestone aspect of the mucosa. 
In a subgroup of patients, the upper gastrointestinal tract is affected. The typical non-caseating 
granulomas can be found in any area of the upper GI tract, from the esophagus to the duodenal bulb. 
Some patients even have disease manifestations in the oral cavity, and may present with a swollen 
upper lip or mucocutaneous lesions. In addition to the gastrointestinal symptoms, there can be extra 
intestinal manifestations, including inflammation of the joints, eyes, skin, and liver. 
Usually, the first onset of CD is during adolescence or in early adulthood, affecting mainly people 
between 15 and 35 years of age. A small second incidence peak occurs in individuals in their 6th or 7th 
decade of life. 
So far, there is no curative treatment for CD. Conventional treatment of the disease involves anti-
inflammatory and immunosuppressive medication including aminosilicates and corticosteroids, 
sometimes combined with antibiotics. More severely affected patients are also being treated with 
immunomodulatory agents including azathioprine/6-mercaptopurine, and methotrexate. More recently, 
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cytokine modulating agents, in particular anti-tumor necrosis factor (TNF)-α based treatments, have 
been added to the therapeutic arsenal (discussed in more detail in section 3.2.1.1). Although these 
therapies may effectively suppress the disease activity in the majority of patients, a substantial 
number of patients will experience flare-ups of the disease. In the more severely affected patients, 
complications like bowel obstruction, stenoses and fistulas may occur, and resection of the affected 
area may be necessary. Patients with longstanding CD have increased risk for carcinomas in the 
affected areas 3. 
 
1.2 Ulcerative Colitis 
Ulcerative colitis was first described as early as 1859 by Wilks as ‘the morbid appearance of the 
intestine of miss Banks’ 4. Although publications dating as far back as the 18th century describe UC-
like illnesses, Wilks’ description led to the recognition of UC as a separate, non-infectious pathology. 
The main symptom of UC is diarrhea, which is generally bloody and may be associated with crampy 
abdominal pain. Loss of appetite and subsequent weight loss are common, as is fatigue. In cases of 
severe bleeding, anemia may also occur. The symptoms of ulcerative colitis do tend to come and go, 
with fairly long periods between flare-ups, in which patients may experience no distress at all. 
Contrary to CD, UC only involves the colon. Typically, the inflamed area starts at the level of the 
rectum. In the mildest form of UC, only the distal part of the large intestine is involved, referred to as 
proctitis. In more severe cases it can extend to the left side of the colon, or extend throughout the 
entire colon as a pancolitis. The inflammation seen in UC is continuous, with no interspacing healthy 
tissue. It involves only the mucosal layer of the bowel wall, and is histologically characterized by large 
infiltrates of lymphocytes, plasma cells, and polymorphonuclear granulocytes, accompanied by 
depletion of Goblet cells and crypt hyperplasia. Endoscopic examination of the colon shows a tender 
colon, which is easily damaged, swollen and hyperemic with superficial ulcerations, which can be 
deeper in the more severely affected patients. Furthermore, pseudopolyps are commonly found. 
Similar to CD, UC is usually diagnosed in young adults, but can occur at any age. There is a second 
incidence peak in individuals between 50 and 60 years old, and in this group, incidence is slightly 
higher in men than in women. 
Treatment is aimed at controlling the inflammatory reaction and restoring losses of fluid, salts, and 
blood. Treatment of UC involves anti-inflammatory and immunosuppressive drugs including 
aminosilicates and corticosteroids. Treatment with azathioprine/6-mercaptopurine and cyclosporine is 
used in the more severely affected patients. If there is no improvement, surgery may become 
necessary. Since UC is restricted to the colon, complete resection of the colon will be curative, 
although disease may manifest in the rectal stump (proctitis), or in the case of ileoanal anastomosis in 
the newly formed ileoanal pouch (‘pouchitis’). 
Complications of the disease include perforation of the colon. This may be preceded by severe 
inflammation of the entire colon with accompanying weakening and ballooning of the intestinal wall, in 
which case the dilated colon becomes at risk of rupturing. Similar to Crohn’s disease, patients with UC 
have an increased risk of developing colon cancer 3. 
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1.3 Indeterminate colitis 
In approximately ten to fifteen percent of patients with colitis, no definitive diagnosis of either 
ulcerative colitis or Crohn’s disease can be made by colonoscopy or histological examination. This 
type of IBD is called indeterminate colitis, after introduction of the term in 1978 by Ashley B. Price 5. 
Most cases of indeterminate colitis are characterized by fulminant colitis, a condition in which the 
classic features of ulcerative colitis or Crohn’s disease may be obscured by severe ulceration with 
early superficial fissuring ulceration, transmural lymphoid aggregates, and relative rectal sparing. 
Currently, it is not clear whether these patients represent a distinct entity within IBD. The ability to 
discern if IC is in fact a predecessor for CD or UC is specifically important in patients that need to 
undergo surgery in which a pouch needs to be formed, since the risk of developing pouchitis is three 
to four times higher in patients that prove to have CD 6. 
 
2 Epidemiology 
It can be stated that inflammatory bowel disease is predominantly a disease of the industrialized, 
Western world, especially of Northern America and Europe. Incidence rates are typically expressed as 
new cases per 100.000 people per year, and can be as high as 20,2 for CD 7 and 25 for UC 8 (Table 1). 
Roughly, this leads to an estimated 3,2 million people that are affected by either CD or UC worldwide. 
Incidence rates are much lower in Asian and African countries, and even lower in Latin American 
countries, although here should be added that there is limited data available for these countries. 
 
Table 1 Incidence and Prevalence rates of Crohn’s disease and Ulcerative Colitis  throughout the world 
Area Incidence Prevalence 
 CD UC CD UC 
Europe8 
   Scandinavia 9-15 
   United Kingdom 16-18 
   Northern Europe (Netherlands, N.W France, Germany) 19, 20 
   Southern/Central Europe (Croatia, Italy, Spain, Greece) 21-27 
0,7-9,8 
 3,6-5,8 
 5,6-9,8 
 4,9-6,9 
 0,7-3,4 
1,5-24,5 
 9,2-24,5 
 13,9 
 3,2-10,0 
 1,5-9,6 
8,3-214 
 54 
 144-147 
 54,6 
 8,3-40 
21,4-243 
 161,2 
 122 
 24,8 
 21,4-121 
North America7, 28-33 3,6-20,2 2,3-19,5 161-319 162-249 
Asia34-38 0,5-4,2 1,2-6,0 3,6-50,6 6,0-70,6 
Africa39 0,3-2,6 0,6-5,0 N/D N/D 
Latin America40 0-0,03 1,2-2,2 N/D N/D 
 
Incidence rates are given in number of new cases per year, per 100.000 people. Prevalence rates are given in 
number of known cases at a certain time point, per 100.00 people. N/D Not determined 
 
The highest incidence rates are found in the Scandinavian countries and the north of the North 
American continent, with a strong north-south geographical gradient in prevalence. This geographical 
gradient seems to get less pronounced over years, but is still clearly present 8. One could plead that 
this is due to mixing of genetic backgrounds between the populations of these areas, but another 
possibility could be that the people in the south of Europe are changing their daily habits, in such a 
way that they resemble more those in the north. In this respect it is noteworthy that Ashkenazi Jews 
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living in Eastern Europe have a high incidence of Crohn’s disease, however, the incidence rates are 
significantly lower in the group of Ashkenazims that has moved to Israel. This implies that there must 
be other than genetic factors that influence CD susceptibility 41, 42. 
 
3 Etiology 
The exact etiology of IBD remains to be elucidated. So far, general consensus has come to the 
recognition that IBD is an ongoing and unwanted perpetuating activation of the immune system 
directed towards the normally non-pathogenic intestinal flora in a genetically susceptible host. The 
exact mechanism by which these factors come together and result in IBD however, largely remains to 
be determined. 
In the following sections, the different etiological factors and how they fit in our current understanding 
of the etiology of IBD will be discussed. We will start with ‘the outside world’ (the environmental 
factors), then move on to the ‘outside world inside the host’ (the bacteriological factors), and finally the 
host factors themselves, i.e., the immunological and genetic factors. 
As mentioned above, the different forms of IBD (CD, UC and IC) are illnesses that are related, but 
despite the fact that they share many characteristics, they also exhibit distinct features. Therefore, the 
etiology of these diseases could conceivably share some mechanisms, but may also differ 
significantly for others. For all the factors discussed below, I will first focus on the general impact on 
IBD, and then, when applicable, discuss how these factors are implicated in the different forms of IBD. 
 
3.1 Environmental and exogenous factors 
Virtually every environmental factor one can think of has been implied as an etiological factor for IBD. 
These include climate, dietary factors, (personal) hygiene and life-style habits like smoking. 
The diet has been studied as an obvious environmental factor in the etiology of IBD. However, 
although some IBD patients find that they do not tolerate certain food-substances, and benefit from 
excluding these substances from their diet, there are no convincing data that any food substances 
would be causative for IBD, nor that certain diets would influence the cause of disease 43. One 
exception to this thesis may however be a high fat intake 44. Excessive intake of fat results in high 
levels of deoxycholate, a substance that is associated with increased risk for IBD. In addition, it was 
recently shown that mice fed deoxycholate develop colitis 45, providing some circumstantial evidence 
that indeed in some cases, dietary changes may be advisable. 
Another environmental factor that, in epidemiological studies, has been implicated as a risk factor for 
IBD, in particular CD, is the use of oral contraceptives 46-49. The use of non-steroid anti-inflammatory 
drugs (NSAIDs) has been shown in some studies to aggravate the disease activity of IBD 49, 50. 
The strongest exogenous risk factor for IBD known so far is smoking, although it has opposite effects 
on CD and UC. The risk for developing CD is twice as high in smokers vs. non-smokers. Also, the risk 
of relapses and need for operations is twice as high in smokers 46, 51-53. On the contrary, the risk for 
developing UC is approximately 2,2 times lower in smokers as compared to non-smokers, and 
smoking has been associated with a positive effect on disease severity 52-55. The highest incidence of 
UC is found in former smokers. Why smoking exerts these effects on IBD, especially the contradicting 
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effects in CD versus UC, remains to be elucidated. Studies assessing the different substances in 
cigarette smoke have pointed towards nicotine as the substance that dampens the immune response 
in UC, but not in CD, however the results are inconclusive and the possibility that other substances 
may also contribute to the effects cannot be ruled out 55-57. In conclusion, while many environmental 
factors have been implicated to be of some influence on IBD pathogenesis and disease course, there 
are currently not enough data available to deduct generally applicable conclusions from these 
findings. 
 
3.1.1 Microbiological factors 
When thinking of the pathogenesis of IBD, one has to keep in mind that the gut lumen belongs to the 
milieu exterieur, which is in direct contact with the outside world. In fact, it is a highly specialized 
environment, that houses approximately 100 trillion (1014) bacteria, 10 times more than the number of 
cells that make up the human body. Several of these bacteria are necessary for the breakdown of 
certain food substances that cannot be processed by the human digestive system, as well as for the 
production of certain essential amino acids and vitamins. In addition, the presence of non-pathogenic 
bacteria prohibits colonization with pathogenic bacteria to which the GI-tract is frequently exposed. In 
this respect microbiological entities are obvious candidates as causative agents in any inflammatory 
disease like IBD. Although the commensal intestinal flora is typically harmless, and in fact essential 
for a functional digestion, the symbiosis with the host is a delicate balance. An ever-growing amount 
of data is pointing towards this normal enteric flora as one of the key players in IBD development 58. 
Clinical observations of beneficial effects of antibiotics in the treatment of CD, and to a lesser extent 
UC, have been appreciated for years. In addition, it has been demonstrated in IBD patients that the 
numbers and concentrations of bacterial populations that make up the biofilms covering the 
epithelium is much higher than in healthy subjects 59, and loss of immune tolerance against the 
autologous enteric aerobic and anaerobic flora has been reported 60. More recently, the use of 
probiotics, primarily lactic acid bacteria, in the treatment of IBD has shown some clinical effectiveness. 
It is believed that probiotics beneficially affect the host by not only modulating gut microbial balance 
and induction of tolerance towards the non-pathogenic flora 61, but also by their ability to modulate gut 
permeability 62, 63. The epithelial barrier is eminently important in protecting the host from invasion of 
pathogenic organisms. This concept is further discussed in section 3.2.2.2. Finally, as will be more 
extensively discussed in Chapter 2, it has been amply shown that in virtually all animal models for IBD 
known so far, colitis does not develop when the animals are kept in a germ-free environment. This 
implies that, since these animals lack an intestinal flora, the commensal bacteria are needed to 
develop colitis. 
 
3.1.2 Infectious agents 
Several micro-organisms, including Listeria monocytogenes, Escherichia coli (E. coli), Cytomegalovirus, 
and Saccharomyces cerevisiae, have been proposed in the etiology of IBD 64-67. Whether they truly do 
have a role in the pathogenesis of IBD remains a topic of debate, since most organisms have only been 
found in individual studies and have not been confirmed by others. An exception may be Mycobacterium 
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(para) tuberculosis. There are quite some striking similarities between CD and intestinal tuberculosis in 
man, caused by M. tuberculosis. Additionally, in cattle, the closely related Mycobacterium avium 
subspecies paratuberculosis (MAP) has been shown to cause Johne’s disease, a chronic 
granulomatous ileitis in ruminants. These observations have led to the theory that a zoonosis could be 
involved in the development of CD. Indeed, MAP has been detected more frequently in CD patients than 
in controls by polymerase chain reaction (PCR) techniques 68, 69, microscopy 70, and by detecting 
antibodies to MAP in serum 71, although not all studies confirm these data 72. Also, anti-mycobacterial 
treatments have proven inconclusive and disappointing 73-75. Therefore, despite the fact that there 
seems to be a relationship of MAP and CD, so far it remains to be determined whether MAP is really a 
causative agent or whether its increased prevalence in Crohn’s disease is an epiphenomenon. This 
concept of a pathogenic microorganism causing IBD is further corrobated by the demonstration of the 
ability of E. coli to colonize and cause inflammation 76, 77 and higher prevalence of adhesive E. coli 
strains in CD patients 65, 78. 
More recently, the role of viruses, in particular the measles virus (rubeola), as causative agents have 
received a fair amount of attention. It was shown in some studies that early childhood infection with the 
virus, or infection of the mother during pregnancy, increased the risk of developing CD. The finding of 
paramyxovirus-like particles in endothelial granulomas of CD patients led to the suggestion that CD is a 
chronic vasculitis caused by the persistence of the measles virus in the mucosa 79. Also, vaccination 
with live virus was implicated as an increased risk of developing both CD and UC. However, data on this 
topic so far are scarce and contradictory. In this respect it is interesting to note that the progressive 
decline of measles virus infection in the last decades coincides with a concomitant rise of CD during the 
same period 80-82. 
 
Summarizing, it remains very difficult to either imply or rule out the role of either pathogenic or 
commensal micro-organisms in the etiology of IBD, especially in CD, in which MAP stays a topic of 
debate. So far, there is no conclusive data to prove whether the occurrence of certain microorganisms is 
either causative for IBD in general or in specific sub-forms of IBD, or alternatively, an epiphenomenon. 
 
3.2 Host factors 
So far, the discussion has focused on potential external factors that can influence the pathogenesis of 
IBD. Although all these factors may have their own contribution to the disease, probably the most 
important factor that determines whether or not IBD develops in a person, is the type and strength of 
response of the host to the ‘outside’ world. In essence, the immune system has a pre-set manner of 
responding to many different stimuli. The strength and type of this response is not only dependent on 
the type of stimulus, but is at least in part also determined by the genetic make-up of the host. Here, first 
a brief overview of the immunological aspects of IBD will be given. In subsequent sections the different 
approaches in finding the genes involved in IBD will be discussed followed by an overview of the genes 
that are currently known to be relevant for IBD susceptibility. 
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3.2.1 Mucosal Immunology 
As already alluded to in the previous sections, CD and UC are two distinct pathologies that share several 
clinical characteristics, but differ substantially upon closer examination. In recent years it has become 
apparent that the underlying immune responses are fundamentally different in these diseases. First, a brief 
description of these processes in general will be provided, followed by an overview of the diseases-specific 
immunological phenomena. 
 
Maybe the most striking property of the intestinal immune system is its ability to discern between the myriad 
of antigens present in the gut lumen. Against the potentially dangerous antigens from pathogenic organisms 
a sound and strong immune response is mounted, whereas under normal conditions, there is no response 
against harmless food antigens or the commensal flora. This process of not mounting an unwanted response 
against these ‘safe’ antigens that could be potentially harmful for the host, is referred to as tolerance. This 
process has been found to involve several different mechanisms, including anergy and deletion as well as 
active suppression through specialized T-cells, known as regulatory cells. An in depth description of all the 
processes involved is beyond the scope of this overview; for reviews, see 83, 84. 
As in all immune responses the mucosal immune response in the gastrointestinal tract consists of two main 
pillars, the innate and adaptive immune response. 
The innate immune system is comprised of cells and mechanisms that defend the host from infection by 
other organisms in a non-specific manner. It is able to promptly respond to pathogens, but it does not provide 
long-lasting or protective immunity. Recognition of pathogens relies on the recognition of well preserved 
patterns, so called pathogen associated molecular patterns (PAMPs), through pattern recognition receptors 
(PRRs) 85. An example of an important family of these PRRs is the Toll-like Receptor (TLR) family 86, 87. There 
are currently 11 different mammalian TLRs known, all with their own ligand specificity and cellular expression 
(Table 2). These receptors are found on many effector immune cells, including macrophages, dendritic cells 
(DCs), and B cells. One of their modes of action is by triggering immune cells to produce chemoattractant 
substances to attract more effector immune cells to come to the site of infection. In addition, they also 
function on non-immune cells to secrete anti-microbial substances, including defensins and angiogenins 
produced by Paneth cells 88-90 (see also sections 3.4.2.2.a and b). The broad spectrum of ligands that is 
recognized by these receptors, and their widespread expression illustrates that the innate immune system 
provides a broad first line of defense that also involves non-immune cells, but is rather non-specific. The 
innate immune response is quick and general, but it does not provide long-lasting immunity, or memory to 
specific antigens. However, activation of the innate immunity may induce antigen presenting cells (APCs) to 
stimulate T cells to trigger an adaptive response, and in this way it is involved in inducing antigen specific 
immune responses and long-lasting memory. 
The adaptive immune response is mediated by T cells, which can be divided in either cytotoxic T cells, 
characterized by the expression of CD8 on the cell surface, or T helper cells, characterized by the expression 
of CD4. T helper cells can be further divided based on their cytokine secretion patterns. 
In Th1 type responses, APCs like DCs or macrophages express high levels of the cytokine interleukin  
(IL)-12 after antigen recognition. IL-12 is one of the hallmark cytokines in Th1 responses and mainly functions 
in the stimulation of Th1 lymphocytes and natural killer (NK) cells 91. These cells in turn produce the second 
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hallmark cytokine in Th1 responses, interferon (IFN)-γ. Via positive feedback, IFN-γ stimulates the DCs and 
macrophages to produce more IL-12, thereby promoting the Th1 profile. Th1 type responses have a major 
role in cell-mediated immunity, mainly mounting a response to intracellular pathogens by activation of 
macrophages, NK cells, antigen-specific cytotoxic T lymphocytes, and by induction of opsonizing antibodies 
by B cells. In addition to IL-12 and IFN-γ, typical Th1 cytokines involve lymphotoxin (LT-α, also known as 
TNF-β) TNF-α, IL-6, and IL-18. Also, the production of typical Th2 cytokines, including IL-4, IL-5 and IL-13 are 
inhibited by IFN-γ. 
Th2 cells on the other hand, have a key role in inducing B-cell proliferation. They induce B-cell antibody class 
switching, and increase antibody production. Therefore, Th2 responses are eminently important in the 
antibody driven humoral immune response. In addition to B cells, other cell types including eosinophils are 
activated by Th2 cells to proliferate and differentiate. Similar to Th1 responses, the Th2 response promotes its 
own profile by producing and responding to certain cytokines. Thus, IL-4 acts on Th2 cells to promote the 
production of more IL-4 as well as IL-10, which in turn is capable to strongly suppress Th1 responses. 
During the last decade, an additional subset of T cells is recognized that has regulatory functions (Tregs). 
Originally described as CD4+CD25+ T cells 92, they express T cell-inhibitory receptor cytotoxic T lymphocyte 
antigen-4 (CTLA-4, cell bound transforming growth factor (TGF)-β, glucocorticoid-induced TNF receptor 
related protein (GITR) 93, and are typically expressing the regulatory T cell specific transcription factor 
forkhead box P3 (Foxp3) 94. Tregs have a T cell receptor (TCR) that is specific for self antigens 95 and are 
actively involved in controlling the Th1 or Th2 effector cells, either by direct cell-cell contact or by the secretion 
of TGF-β 96-99. Another seemingly distinct group of regulatory T cells, called TR1 cells, produce high levels of 
IL-10, using this cytokine as their main means for dampening the functioning of the effector cells 100, 101. 
In murine models of IBD, it has been shown that there is an important protective role for Tregs 100, 102-104. 
These findings have prompted studies in human IBD, in which various differences in Treg expression and 
functioning have been identified. For example, patients with IBD have been found to be defective in their 
expression of gp180, a glycoprotein expressed by intestinal epithelial cells that is a ligand of CD8, which may 
contribute to a defect in generation of CD8+ Tregs. Indeed, decreased CD8+ Tregs are found in IBD lamina 
propria, and these cells are decreased in their ability to suppress CD4+ T-cell responses 105-107. Furthermore, 
IBD patients have been shown to have defects in their ability to generate Tregs in vivo after oral challenge 
with the experimental antigen, keyhole limpet hemocyanin (KLH). Patients with IBD did not develop oral 
tolerance and continued to have proliferative responses to KLH in spite of oral administration prior to 
immunization 108, 109. 
The above studies only exemplify some of the possible roles of Tregs in IBD. The seemingly controversial 
finding that in some IBD patients larger numbers of Tregs are found than in healthy subjects 110, while another 
study shows that in fact IBD patients may have sufficient numbers of Tregs, but seem to be defective in the 
recruitment of sufficient numbers of Tregs to the inflamed intestine 111, reflects once more that the symptoms 
seen in IBD could be due to several different underlying (genetic) defects, and that further studies are needed 
to clarify the role of Tregs in IBD. 
Table 2    Summary of known human Toll-Like Receptors 
Receptor Ligands Origin of Ligand Adapter molecules Cell type Location 
TLR1 Triacyl lipoproteins 
Soluble factors 
Bacteria and mycobacteria 112 
Neisseria meningitidis 113 
MyD88/TIRAP Myofibroblasts 114 
Circulating PMNs 115, 116 , 117 
Cell surface 
TLR2 Lipoprotein/lipopeptides  
Peptidoglycan  
Lipoteichoic acid  
Lipoarabinomannan  
Phenol-soluble modulin  
Glycoinositolphospholipids  
Glycolipids  
Porins  
Atypical lipopolysaccharide  
Atypical lipopolysaccharide  
Zymosan  
Heat-shock protein 70* 
Various pathogens 118 
Gram-positive bacteria 119,120 
Gram-positive bacteria 120 
Mycobacteria 121 
Staphylococcus epidermidis 122 
Trypanosoma cruzi 123 
Treponema maltophilum 124 
Neisseria 125 
Leptospira interrogans 126 
Porphyromonas gingivalis 127 
Fungi 128 
Host 129 
MyD88/TIRAP Lamina propria macrophges (low) 
130 
Myofibroblasts 114 
Circulating PMNs 115, 116, 131 
Cell surface 
TLR3 Double stranded RNA 
poly I:C 
Viruses 132 TRIF DCs 133 
Myofibroblasts 114 
Circulating PMNs 115 , 116, 131 
Cell surface 
TLR4 Lipopolysaccharide  
Taxol  
Fusion protein  
Envelope protein  
Heat-shock protein 60*  
Heat-shock protein 70*  
Type III repeat extra domain A of 
fibronectin*  
Oligosaccharides of hyaluronic acid*  
Polysaccharide fragments of heparan 
sulphate*  
Fibrinogen* 
Gram-negative bacteria 134 
Plants 135 
Respiratory syncytial virus 136 
Mouse mammary-tumour virus 
137 
Chlamydia pneumoniae 138,139 
Host 140 
Host 141 
Host 142 
Host 143 
Host 144 
MyD88/TIRAP/TRIF/TRAM Lamina propria macrophges (low) 
130 
DCs 133 
Myofibroblasts 114 
Endothelial cells 145 
Circulating PMNs 115, 116, 131 
Cell surface 
TLR5 Flagellin Bacteria 146 MyD88 Myofibroblasts 114 
Endothelial cells 147 
Circulating PMNs 115, 131 
Cell surface 
TLR6 Diacyl lipopeptides 
Lipoteichoic acid  
Zymosan 
Mycoplasma 148 
Gram-positive bacteria 120 
Fungi 149 
MyD88/TIRAP Myofibroblasts 114 
Circulating PMNs 117 
Cell surface 
TLR7 Single-stranded RNA Imidazoquinoline 
Loxoribine  
Bropirimine 
Viruses 150,151 
Synthetic compound 152 
Synthetic compound 153 
Synthetic compound 153 
MyD88 Myofibroblasts 114 
Circulating PMNs 131 
Intracellular 
TLR8 Single-stranded RNA 
Imidazoquinoline 
Viruses 150 
Synthetic compound 154 
MyD88 Myofibroblasts 114 
Circulating PMNs 131 
Intracellular 
TLR9 Unmethylated CpG DNA Bacteria and viruses 155 MyD88 Myofibroblasts 114 
Circulating PMNs 131 
Intracellular 
TLR10 unknown  unknown Circulating PMNs 131 Cell surface 
 
TLR, Toll Like Receptor; MyD88, myeloid differentiation factor 88; TIRAP, Toll/IL-1R domain-containing adaptor protein (also called MAL); TRIF, Toll/IL-1 Receptor Domain-Containing Adaptor 
Inducing IFN-beta; TRAM, Toll-IL-1R domain-containing adaptor inducing IFN-beta-related adaptor molecule. *It is possible that these ligand preparations, particularly those of endogenous origin, were 
contaminated with lipopolysaccharide and/or other potent microbial components, so more-precise analysis is required to conclude that TLRs recognize these endogenous ligands. 
Adapted from S. Akira and K. Takeda 87 and MT. Abreu, M. Fukata, and M. Arditi 156
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3.2.1.1 Immunological aspects of IBD 
As briefly described above, the adaptive immune system can grossly be divided in Th1 type responses 
on the one hand, and Th2 type responses on the other. Immunologically, CD is found to be a Th1 
mediated disease, in which the inflamed area extends throughout the entire bowel wall, including the 
muscular and serosal layers of the intestine. Typical for Th1 type responses is the high expression of IL-
12 by APCs after antigen recognition, and indeed, high levels of IL-12 are produced by macrophages of 
CD patients 157, 158, and increased amounts of activated T cells are found in affected areas in CD 
patients, where they produce high levels of IFN-γ and TNF-α, and decreased amount of IL-4 159. Also, 
high expression levels of the IL-12β receptors and the typical Th1 transcription factor T-bet signal 
transducer and activator of transcription (STAT) 4 are found, all indicative of IL-12 signaling 160, 161. The 
most convincing evidence for the role of IL-12 has come from the observation that antibodies to IL-12 
could both prevent and cure disease in an animal model of colitis, and similarly, a clinical trial in CD 
involving anti-IL-12 antibodies has proven its clinical applicability 162. However, part of these effects may 
be attributable to the more recently identified cytokine IL-23, which is structurally related to IL-12 as it 
shares the p40 subunit, but has a p19 subunit instead of p35. Similar to IL-12, it has the ability to 
activate Th1-cells, but appears to function also more downstream in the Th1 response, sustaining the 
immune response rather than starting it, and inducing Th1 memory cells more effectively than IL-12163, 
164
. In addition, IL-23 activates a subset of T cells characterized by IL-17 production, the so called TH17 
T-cell subset, that has been found to mediate chronic inflammation and autoimmune disease in animal 
models 165. In a mouse model of mucosal inflammation (the IL-10-deficient mouse model for IBD) it was 
shown that inflammation was more dependent on IL-23 than IL-12, and administration of IL-23 could 
exacerbate colitis in these mice166. Administration of anti-IL-23p19 antibodies suppressed intestinal 
inflammation, and in two other murine models of IBD it was found that genetically inactivating the p19 
subunit inhibited production of several other pro-inflammatory cytokines, including TNF-α, IL-1, IL-6, and 
IL-17, specifically at mucosal sites, rather than influencing the systemic responses 167, 168. Elevated 
levels of IL-23 production by lamina propria APCs are also found in human CD, and administration of 
anti-IL-12p40 antibodies, specific for both IL-12 and IL-23 down-regulated IFN-γ, TNF-α, IL-6 and IL-17 
secretion162, 169. All this data combined, it appears now that IL-23 might have an even more important, or 
at least more mucosal specific function, in mucosal inflammation than IL-12. 
Yet another cytokine from this IL-12 family that is now being recognized to possibly play a part in the 
etiology of IBD is IL-27. IL-27 consists of Epstein-Barr-virus-induce gene 3 (EBI3) 170, which is related to 
IL-12p40, and IL-27p28, a protein with similarities to IL-12-p35, and secreted by APCs 171. On the one 
hand IL-27 has been shown to have pro-inflammatory Th1-activating properties, similar to IL-12. It 
induces rapid clonal expansion of naive CD4+ T cells and triggers IFN-γ secretion, and in fact sensitizes 
T cells for the Th1-cell polarizing effects of IL-12 171, 172, thereby directly inhibiting production of IL-4 by 
CD4+ T cells 173. Also, IL-27 can induce mast cells and monocytes to produce IL-1 and TNF-α 174. On the 
other hand IL-27 has been shown to have anti-inflammatory effects, negatively regulating mast cell and 
macrophage function 173, 175, 176. Mice deficient for a subunit of the IL-27 receptor, WSX-1 display 
elevated levels of IL-4, IL-6, TNF-α and IFN-γ 175, 177, also pointing towards immunosuppressive 
properties of IL-27. In investigating the role and expression of IL-27 in IBD, several groups have 
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identified an elevated expression of IL-27 in CD 178-180, but not in UC, in concordance with the possible 
Th1 role of IL-27. Although there is increasing evidence for the involvement of IL-27 in IBD, the exact 
contribution and mechanisms still need to be found. 
Although the above combinations of the related proteins IL-12p40, EBI3 and IL-12p35, IL-23p19, IL-
27p28 are all somehow implicated in CD, and are not found to be upregulated in UC, another novel 
cytokine that is formed by a combination of EBI3 and IL-12p35 181 is found to be upregulated in UC 178, 
182
. This cytokine is thought to have IL-12 antagonizing functions, thus inhibiting Th1 responses 183. The 
precise properties and role of this novel cytokine in IBD however are still under investigation (Figure 1). 
That exactly this cytokine is found in UC, and not CD, emphasizes the fact that CD and UC are two 
immunological distinct pathologies. Unlike CD, UC is characterized by contiguous superficial 
inflammation of the colonic lamina propria, and the immunological background of UC is of a more Th2 
type response. Th2 cells are more than Th1 cells equipped to promote B cell activation and antibody 
production. 
 
Figure 1 Overview of IL-12/23 family members and their receptors 
 
Four helix bundle cytokine 
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IL - 12R β 1  IL - 12R β 2 IL - 12R β 1  IL - 23R gp130  WSX1 
 
IL-12 is a covalently linked heterodimer composed of a light chain (IL-12p35) and a heavy chain (IL-12p40). The 
IL-12 receptor comprises IL-12Rβ1 and IL-12Rβ2, both of which have homology to gp130. The IL-12p40 
component of IL-12 can also dimerize with IL-23p19 to form IL-23. The receptor for this heterodimer is formed by 
the association of IL-12Rβ1 and IL-23R. The next member of this family of cytokines is IL-27, which is composed 
of EBI3 (Epstein–Barr-virus-induced molecule 3) and IL-27p28. IL-27 binds a receptor composed of gp130 and 
WSX1 (named after the WSXWS protein motif that is found in the carboxyl terminus of many type I cytokine 
receptors; also known as TCCR). The last member of this family is a cytokine composed of EBI3 and IL-12p35. 
Currently, it has not been assigned to a receptor, and its function remains elusive, but appears to antagonize the 
functioning of IL-12. 
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This is reflected in the production of various autoantibodies, like anti-neutrophil cytoplasmic (pANCAs) 
and anti-tropomyosin antibodies that are found in many UC patients 184, 185. This autoantibody 
production however, does not seem to play a central role in UC pathogenesis, but rather seems to 
reflect different disease subgroups within UC. The type of subclasses of antibodies produced are 
characteristic for Th2 type responses, as the antibodies found in UC are mostly of the IgG1 and IgG4 
subclass 186. Furthermore, although there are also elevated levels of TNF-α found, the key cytokines 
in this condition are IL-13 and IL-4 and IL-5 159, 187, 188.  
Of special interest here is IL-13. IL-13 is a Th2 type cytokine that enhances the expression of 
CD23/FcεRII and class II major histocompatibility complex (MHC) antigens on monocytes/ 
macrophages as well as on B cells; it stimulates B cell proliferation and it induces IgE and IgG4 class 
switching and production. Furthermore, it inhibits the production of proinflammatory and Th1 type 
cytokines including IL-1α, IL-6, and IL-12 by monocytes. Moreover, it synergizes with IL-2 in 
regulating IFN-γ synthesis in large granular lymphocytes 189-193. In a mouse model for intestinal 
inflammation, in which colitis is induced by intrarectal administration of oxazolone it was shown that 
this cytokine in particular is the driving force behind the intestinal inflammation seen in these animals. 
NK T cells and/or IL-13 were shown to be directly cytotoxic to the epithelial cells, providing an 
explanation for the lesions observed in UC 194. Even more, IL-13 is typically highly expressed in 
affected colonic tissue in UC 187. 
Together, these results emphasize the important role that various cytokines play in the induction and 
maintenance of the different forms of inflammatory bowel disease, and illustrate how the 
inflammations seen in CD and UC have clearly distinct cytokine profiles. This does not only reflect 
putative different etiologies but has also implications for the development and use of cytokine-based 
immunotherapy. 
 
3.2.1.2 Immunotherapy 
Clearly, there is an important role for Th1 and Th2 cytokines in CD and UC, respectively. Recently, 
cytokines are being recognized as promising therapeutic targets. The best-known example of cytokine 
modulating therapy in IBD is directed towards TNF-α. This typical pro-inflammatory cytokine is 
present in large amounts in CD patients, and is also found in elevated levels in UC patients 159. The 
main local effects of TNF-α comprise the induction of the classical signs of inflammation, heat, 
swelling, redness and pain. TNF-α induces other pro-inflammatory cytokines including IL-1 and IL-6 
and enhances leukocyte migration by inducing expression of adhesion molecules by endothelial cells 
and leukocytes 195. As said, TNF-α is found in elevated levels in the lamina propria of IBD patients, 
and has even been found in stools of pediatric CD patients 196, making this cytokine an interesting 
target for therapy based on biologicals. Indeed, during the past two decades, anti-TNF-α therapy has 
become one of the most effective and widespread used treatments for Crohn’s disease. 
Currently, there are two types of anti-TNF-α therapy, the one consisting of monoclonal antibodies directed 
against soluble TNF-α, and the other being a small recombinant human fusion protein consisting of the 
extracellular portion of the TNF receptor and IgG. After treatment, patients show a downmodulation of the 
activation normally attained by soluble TNF-α, reflected by a significant reduction in numbers of neutrophils 
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and activated T cells in the lamina propria 197. It had been shown that treatment with monoclonal antibodies 
induces lysis of inflammatory cells carrying membrane-bound TNF-α, and apoptosis in lamina propria T 
cells and PBMCs by activation of caspase-8, -9, and –3 198-201. The mechanism through which anti-TNF-α 
treatment attains its effects, is not purely through neutralizing soluble TNF-a however. This can be 
deducted from the differential effect of the two types of anti-TNF-α treatment, since the effects of the fusion 
protein, which basically can only bind free soluble TNF-α, are less outspoken than those seen after 
monoclonal antibody treatment, hence, neutralizing soluble TNF-α cannot be the only mode of action of 
the therapies 202, 203. 
At any rate, as with other anti-cytokine therapies such as anti-IL-12, or anti-IL-23 therapy, systemic 
administration of antibodies is a quite costly form of treatment, and can have some (severe) safety 
problems, mainly concerning immunogenicity directed towards the administered antibodies, leading to 
infusion reactions, loss of response, and serum sickness–like delayed infusion reactions. Also, more 
opportunistic infections are seen, mainly in patients concomitantly treated with immunosuppression 204, 205. 
 
3.2.2 Genetic aspects of IBD 
There are multiple lines of evidence that suggest a genetic contribution to the pathogenesis of IBD. These 
include epidemiologic data on racial and ethnic differences in disease prevalence, familial aggregation and 
twin studies as well as the association of IBD with recognized genetic syndromes, including psoriasis, 
eczema, and ankylosing spondylitis. The most striking support for the contribution of both genetics and 
environmental factors in the pathogenesis of IBD is provided by twin concordance studies, especially for CD. 
Should a disease be purely genetically determined, then the concordance between monozygotic twins should 
be close to 100%, whereas the concordance rates for dizygotic twins should not be different from that for all 
siblings. However, in IBD the concordance rates for monozygotic twins are significantly less than 100%, (42% 
to 58% for CD, 6% to 17% for UC 206, 207) indicating that there is a reduced penetrance for the IBD genotype, 
and that this is most likely due to non-genetic factors, such as environmental triggers. From these studies it 
has become evident that IBD is not inherited in a purely Mendelian fashion, but rather has a complex genetic 
etiology, with an intricate interaction with environmental factors (for reviews, see 208-210). In addition, based on 
these findings it is questionable whether IBD represents a spectrum of a variety of diseases with entirely 
different etiologies rather than the two currently known clinical disease entities (UC and CD). Due to this 
complexity, identifying the genes involved in IBD has proven to be difficult and time consuming, and so far, 
only a few genes have been irrefutably implicated in the etiology of IBD. 
Identifying genetic defects is only the first step in unraveling the genetic background of the pathogenic 
processes involved in IBD. Although our knowledge about mucosal immunology, genetics, and regulation of 
gene expression is growing rapidly, there are still quite a few questions about how the immunological balance 
in the GI tract is genetically orchestrated in the normal situation, let alone in the diseased situation. Therefore, 
the second step in understanding the genetic component of IBD etiology, determining the role of the found 
genetic defects, has proven to be very difficult. 
Here, I will first give an overview of the different approaches in finding IBD susceptibility genes, and then give 
an overview of the genes that are now thought to be involved in IBD, and how these could affect the immune 
system of IBD patients. 
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3.2.2.1 Approaches to identify genes involved in IBD 
Nowadays, quite a few different complementary approaches are being applied to identify genes 
involved in IBD susceptibility, both in humans and in animal models of IBD. I will first describe the 
types of studies that are performed in the human population, and then continue with the possibilities in 
animal models. 
At first, candidate gene studies have been performed, based on the suspicion of a role of the gene 
product in IBD, and involving genes associated with immune regulation or a role in epithelial barrier 
function. When polymorphisms are found, the frequency of these polymorphisms can then be 
determined in both affected and unaffected individuals. When the frequency is significantly different in 
the affected group, this could indicate a causative relation between the gene and the disease 
susceptibility or etiology. 
Later, with the development of more powerful methods of genomic screening, genetic linkage studies 
were used to genome-wide scan and type genetic microsatellite markers in families containing more 
than one affected member. If the actual disease-susceptibility gene is located close enough to the 
marker tested, it is less likely to be separated during meiosis due to crossing-over, and will therefore 
be coinherited. This principle of cosegregation, allows for the identification of chromosomal regions 
shared in affected individuals in excess of statistical expectation. Testing for many markers spread 
throughout the genome, broad genomic regions can be identified that are shared more often by 
affected pairs of relatives (e.g., affected sibling pairs). This way, the areas that are involved in IBD, the 
susceptibility loci, can be mapped on the genome. Thus far, six major susceptibility loci (IBD1-6), have 
been identified 
 
Table 3   Major Susceptibility Loci in Inflammatory Bowel Diseases 
IBD 
locus designation 
Chromosomal 
Location Study Diagnosis 
Candidate genes within 
or near locus 
IBD1 16q12 Hugot 211 CD NOD2 212 213 
IBD2 12q13 Satsangi 214 UC VDR, IFN-g 
IBD3 6p13 Hampe 215 CD, UC MHC I and II, TNF-a 
IBD4 14q11 Ma 216, Duerr 217 CD TCR alpha/beta complex 
IBD5 5q31–33 Rioux 218 CD IL-3, IL-4, IL-5, IL-13, CSF-2 OCTN, CD14 
IBD6 19p13 Rioux 218 CD, UC ICAM-1, C3, TBXA2R, LTB4H 
Other 1p36 Cho 219 CD, UC TNF-R family, CASP9 
Other 7q Satsangi 214 CD, UC MUC-3 
Other 3p Satsangi 214 CD, UC HGFR, EGFR, GNAI2 
Other 10q23 Hampe 215 CD DLG5 220 
Other 4q Vermeire 221 UC, CD NFKB1 222 
 
Adapted and updated from Bonen and Cho 2003 208 
NOD2, nucleotide binding oligomerization domain 2; VDR, vitamin D receptor; IFN-g, interferon-gamma; TCR, T-
cell receptor; IL, interleukin; CSF, cerebrospinal fluid; ICAM, intercellular adhesion molecule 1; TBXA2R, 
thromboxane A2 receptor; LTBH4H, leukotriene B4 hydroxylase; TNF-R, tumor necrosis factor-receptor; CASP, 
caspase; MUC3, mucin 3; HGFR, hepatocyte growth factor; EGFR, epidermal growth factor; GNAI2, inhibitory 
guanine nucleotide-binding protein; DLG5, discs, large homolog 5; NFKB1, nuclear factor of kappa light 
polypeptide gene enhancer in B-cells 1 (p105) 
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Yet another possible approach to identify genes that can be applied in the search for IBD susceptibility genes 
includes the use of microarray analysis in which differences in mRNA expression can be compared between 
patients and healthy controls, leading to the identification of genes that are differentially expressed in IBD 
patients (for a extensive description of the technique, see review 223). Differences in expression can indicate a 
difference in regulation of a certain gene, or gene family, or a pathway involved which could help pinpointing 
genes that are involved in the susceptibility 224, 225. Especially when this technique is combined with a classical 
genome screen, it can be a valuable tool in identifying possible candidate genes 226. 
Whenever a certain gene becomes suspect of being a susceptibility gene, either because it colocalizes to a 
linkage region, or because its product has been implicated in disease etiology because of its function or 
differences in mRNA expression levels, it can be sequenced to look for polymorphisms, and the classical 
candidate gene approach can then be applied to see if there truly is an association of this gene with the 
disease susceptibility. 
Recently, a new technique related to the mRNA expression microarray technique has been applied in the 
search for IBD susceptibility genes 227. In the so-called ‘genome-wide association study’, a microarray chip is 
used to simultaneously genotype over 300.000 known single nucleotide polymorphisms per sample, spread 
throughout the genome. The advantage of this technique over classical candidate gene approaches is that 
these studies do not have an a priori assumption about where the risk variants may reside, but have the 
disadvantage that they are limited in their coverage of rare genetic variants, that might also have a 
contribution to the genetic architecture of the disease. 
It has proven very difficult to identify susceptibility genes in IBD. Besides the technical difficulties of some 
methods, the main setbacks are the immense genetic variability within the human population, and the 
possibility that IBD in fact reflects a group of illnesses, instead of just two pathologies, with similar symptoms, 
but with possibly very different etiologies and genetic backgrounds. Also, many genes that have been 
implicated so far, have proven to have a very low penetrance. All this combined makes that very large 
sample sizes are needed to actually prove a relation with the disease susceptibility and a gene, and makes 
this process a very difficult and time consuming task. 
Another approach in finding IBD susceptibility genes can be sought in the use of animal models. Here, I will 
discuss the advantages and disadvantages of using animal models over human studies. 
In contrast to the human population where a large genetic heterogeneity exists, every mouse of the same 
inbred strain is in essence genetically identical. Interestingly, between strains there are many genetic 
differences, and these are responsible for differences in susceptibility to colitis, whether this colitis is induced 
by administering a chemical substance, or by genetically modifying the model. After generating F2 mice from 
a susceptible and a resistant strain these can be screened for colitis susceptibility and severity. From these 
crosses, the parts of the genome that cosegregate with disease susceptibility can be determined (Figure 2). 
With this straightforward technique, regions that cosegregate with the susceptibility or severity of the disease 
can be mapped on the mouse genome. These regions are called quantitative trait loci (QTLs), and typically 
span an area of a chromosome containing several genes. A number of studies have been performed like 
this, and from them, several QTLs have emerged (Table 4). 
Both the human and mouse QTLs can contain many genes. In the ideal situation, the QTL is fairly small, and 
only contains a few genes, with one of them being the obvious candidate gene because of its function. This 
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gene can be sequenced to see if it contains polymorphisms that could explain why this particular gene is 
involved in disease susceptibility. Usually, the areas spanned by the QTLs are quite large, and sequencing 
an entire QTL is practically not feasible. In this situation, searching for genes in mouse models has a great 
advantage over human studies, because of the possibility to generate congenic mouse strains. In a congenic 
strain, mice from one particular strain have a small part of their genome replaced with that same part of 
genome from another strain. The QTL from the susceptible strain can be transferred to the resistant strain. If 
this results in the resistant strain now becoming susceptible, this is proof of principle that the QTL in fact does 
harbor a susceptibility gene. The QTL can now be made smaller by consecutive crossing of mice, until it is 
small enough to be directly sequenced to search for functional polymorphisms between the strains, and 
identify the true susceptibility gene (Figure 2). The different approaches, with their advantages and 
disadvantages, are summarized in Table 5. 
 
3.2.2.2 Genes implicated in IBD susceptibility 
Taken together, many genes have been implicated in the etiology of IBD, all with different levels of 
significance. Interestingly, these genes are involved in a wide array of functions ranging from involvement in 
the barrier function of the gut epithelium, receptors involved in the recognition of bacteria, to specific cytokines 
that activate T lymphocytes. An overview of some of these genes, in particular those that have proven their 
role in the etiology and/or are of relevance for the research described in this thesis are given in the following 
sections. 
 
3.2.2.2.a NOD2 
In 2001, the groups of Hugot 212 and Ogura 213 described 3 different mutations in the NOD2 gene, that 
are associated with a highly increased susceptibility to CD. This gene maps to the locus on 
chromosome 16 previously identified as a susceptibility locus for IBD in a genome-wide scan. 
Individuals homozygous for these mutations, either as the consequence of the same mutation on 
each chromosome, or because of the combination of 2 different mutated alleles (so-called compound 
heterozygosity) leads to a 20-40 fold higher chance of developing CD, whereas the risk of developing 
the disease was found to be approximately four times higher in individuals that are heterozygous 208. 
So far, this is the only gene found that is so strongly associated with CD. 
NOD2 is a receptor for a PAMP, called muramyl dipeptide (MDP). MDP is a dipeptide that is part of 
peptidoglycans, which are part of the bacterial wall of both Gram-positive and Gram-negative bacteria. 
NOD2 has been shown to display NF-κB activating properties, after binding of its ligand MDP 234, 235. 
NOD2 is primarily expressed in monocytic cells, dendritic cells and granulocytes 236, 237.
 Chapter 1 
 26 
Figure 2 Principle of genome-wide linkage analysis and generating congenics 
 
Susceptible strain Resistant strain 
SS 
SR SR 
RR 
SS SR RR 
Susceptible Resistant 
F1: 
F2: 
x 
SR 
SS No  linkage: 
susceptible :
resist a nt : 
1:2:1 
SR SR RR 
L inkage 
susceptible :
resist a nt : 
RR SR SS SS 
SS 
SS SS SR 
SR SR SR 
SR 
RR RR RR RR 
X 
X 
X 
GCATGCATGCATG TATGCAT GCATGCATGCATG C ATGCAT 
X 
 
 Introduction 
 27 
Table 4   Quantitative Trait Loci found in animal models for Inflammatory Bowel Diseases 
 
Study 
 
 
QTL 
designation 
 
Chromosoma
l location 
 Human 
orthologous 
region 
Candidate genes within 
or near QTL 
Mahler ‘99 
3,5% DSS colitis, 
induced in C3H/HeJx 
C57BL/6J outcrosses 228 
Dssc1 Chr 5, 72 cM C57Bl/6J  Selpl, Pdgfa 
 
 Dssc2 Chr 2, 47 cM C57Bl/6J  Itga4, Il1α, Il1β 
Farmer ‘01 
IL-10 KO in 
C3H/HeJxC57BL/6J 229 
Cdcs1 3 C3H/HeJ 4q or 1p Fabpi, Egf, Nfkb1229  
Gbp1 226 
 Cdcs2  1  C3H/HeJ 2q Casp8, Cd28, Ctla4, 
Icos 
 Cdcs3 2 C3H/HeJ 
 
15q 2q Thbs1, B2m Il1, Pcna 
 Cdcs4 8  C57Bl/6J 8p Defb, Defcr 
 Cdcs5 17 C57Bl/6J 6p H2-Ea, C4/Slp, Tnfa 
 Cdcs6 18 C57Bl/6J 18q or 5q Apc, Mad2, Mad 229 
Cd14 226 
 Cdcs7,8     
 Cdcs 9 4   Pla2g2a 226 
 Cdcs10     
Bouma ‘02 230 Tnbs1 9 43-48 cM SJL/J  Il10rα, il18 231, claudin-18 
 Tnbs2 11 SJL/J 5q33-34 Il12p40, 
Kozaiwa ‘03 231 Ibdq1 9 SAMP1/YitFc SAMP1/YitFc Il 10ra, Il 18, 
Borm 05 232 Gpdc1 3 C3H/HeN  Nfkb1, Egf, Gbp1 
 Gpdc2 1 47 cM C3H/HeJ   
 Gpdc3 9 42 cM C3H/HeJ   
Sugawara ‘05233 Ibdq2 6 SAMP1/YitFc  Pparγ 
 
Selpl, P-selectin ligand; Pdgfa, platelet-derived growth factor A; Itga4, α -4 integrin; Il, interleukin; Fabpi, fatty acid-
binding protein, intestinal; Egf, epithelial growth factor; Nfkb1, nuclear factor of kappa light polypeptide gene enhancer 
in B-cells 1 (p105); Gbp1, guanylate binding protein 1; Casp8, caspase 8; Cd28, cluster of differentiation 28, 
(costimulatory T cell protein); Ctla4, cytotoxic T-lymphocyte-associated protein 4; Icos, inducible costimulator; Thbs1, 
thrombospondin 1; B2m, beta-2-microglobulin; Pcna, proliferating cell nuclear antigen; Defb, defensin B; Defcr, 
defensin-related cryptdin peptide; Fgfr1, the fibroblast growth factor receptor 1; H2-Ea, histocompatibility 2, class II 
antigen E alpha; C4/Slp, 4th component of complement/sex-limited protein; Tnfa tumor necrosis factor-alpha; Apc, 
adenomatosis polyposis coli; Mad2, MAD (mothers against decapentaplegic) homolog 2 (Madh2) encoding SMAD2; 
Mad4, MAD homolog 4 (Madh4) encoding SMAD4; Cd14, cluster of differentiation 14, lipopolysaccharide co-receptor; 
Pla2g2a, secretory phospholipase A2 group IIA; Pparγ, Peroxisome Proliferator-Activated Receptor-gamma. 
 
Figure 2 Principle of genome-wide linkage analysis and generating congenics 
a. Two mouse strains with different susceptibility for colitis are cross-bred to generate a F1 population that is 
heterozygous over their entire genome. The F2 generation resulting from brother-sister mating of the F1 
generation can display all possible different distributions of the parental genome, and they can develop all 
different grades of colitis. Because of these differences in genetic makeup and disease severity, it is possible to 
identify loci that are responsible for the susceptibility for colitis with linkage analysis. If at a certain point in the 
genome, there are no genes that are involved in the disease susceptibility, one will see a normal Mendelian ratio 
of parental alleles in both the susceptible and the resistant groups of mice of 1:2:1. If there is a gene in the 
vicinity of a marker, they will cosegregate together, and the ratio of parental genome in both groups will change. 
In the susceptible group, more mice will be homozygous for the susceptible allele and few for the resistant allele, 
and the other way around for the resistant group, more mice will be homozygous for the resistant allele and less 
for the susceptible allele. 
b. Once a QTL is identified, congenic mouse strains can be generated. In a congenic strain, mice from one 
particular strain have a small part of their genome replaced with that same part of genome from another strain. 
By cross-breeding the two strains, a F2 generation similar to that of the initial genome screen can be generated. 
The mice are genotyped, and mice that are homozygous for the desired region are used for backcrossing, 
generating mice that are partly homozygous for the original strain, and partly heterozygous. These F3 are 
intercrossed to generate mice that can be partly homozygous for the donor strain, and after genotyping, mice 
homozygous for the desired locus can be selected for further crossing. This procedure can be repeated until the 
congenic region is small enough to be sequenced, to search for polymorphisms that can explain the strain 
differences in susceptibility. 
,
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Table 5   Summary of advantages and disadvantages of different approaches to find susceptibility genes 
 
 
and to a lesser extent in intestinal epithelial cells, especially Paneth cells 238, 239. It is also expressed at 
low levels in T cells, in which expression can be upregulated after TNF-α or lipopolysaccharide (LPS) 
administration 237, 240. 
NOD2 is a member of the family of the nucleotide-binding oligomerization domain-leucine-rich repeat 
(NOD-LRR) protein family, which comprises of proteins that all consist of C-terminal ligand recognition 
domain(s), central NOD domain(s), and N-terminal protein-protein interaction domain(s) 241. The NOD2 
protein is composed of two N-terminal caspase recruitment domains (CARD), a NOD domain, and C-
terminal LRRs 236 (Figure 3). Members of the NOD-LRR protein family are known to be involved in 
regulation of apoptosis 242 and NF-κB activation 243. 
The three different mutations in the NOD2 gene that are responsible for the susceptibility for CD are 
found in, or close to the LRR region of NOD2. Two mutations lead to a amino acid substitution, 
(Arg702Trp and Gly908Arg) 212, and the third (3020insC) leads to a frameshift mutation that results in a 
truncated protein, lacking the last 33 amino acids 213 (Figure 3). The LRR is essentially important in 
bacterial recognition and the specific mutations found in CD have been shown to lead to a reduced 
capacity to induce NF-κB activation 213, 234. CD however, is characterized by an elevated NF-κB 
activation. So how can these contradictory findings be explained and why do mutations in NOD2 lead to CD? 
Approach Advantages Disadvantages 
Studies in humans  Genetical heterogeneity of population 
Heterogeneity of diseases 
Disturbing influence of environment 
factors 
Limited availability of sufficient patients, 
however, due to above 3 reasons, large 
sample size is needed to attain statistical 
significance 
Studies in murine models All mice within one strain are genetically 
identical 
Environmental factors are controllable 
Relatively easy access to large sample 
numbers 
Possibility to genetically engineer 
models to study relevance of found 
genes 
No models available truly representing 
all features of either CD or UC 
   
Candidate gene approach Technically relatively simple and 
straightforward 
A priori assumption needed, no 
investigation of ‘unexpected’ genes 
Genomic screening No a priori assumptions Very large sample sizes needed 
Read-out is genetic region, not a gene 
Microarray analysis No a priori assumptions 
Functional differences can be found 
Not all genetic variation lead to 
difference in mRNA expression, and 
expression difference does not 
necessarily be due to variation in the 
same gene 
Genome-wide association 
studies 
No a priori assumptions 
Direct read-out is gene 
Very large sample sizes needed 
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Figure 3 Structure of NOD2 
 
NOD2 has a tripartite structure, with two caspase recruitment domains (CARD), a central nucleotide binding and 
oligomerization domain (NOD), and a C-terminal set of ten leucine-rich repeats (LRRs). Depicted by arrows are 
the three major mutations that are associated with CD. 
 
 
There are currently several theories as to how these mutations are involved in disease pathogenesis. 
Grossly, they can be divided into two groups. The first theory is based on the proposition that CD 
develops as the consequence of a loss of functionality of the NOD2 protein whereas the other theory 
assumes that these mutations lead to a hyperactivated state of the mucosal immune system. The 
different possible routes how NOD2 mutations can lead to CD are discussed below. 
 
Defective epithelial defense 
In normal intestinal tissue, with functional NOD2, Paneth cells produce sufficient amounts of 
antibacterial substances, called α-defensins244. Normally, the production of these antimicrobial 
peptides is sufficient to keep the commensal bacteria in check. Paneth cells from individuals that are 
defective for NOD2 however, produce less α-defensins 240, 245. In mice, these antimicrobial peptides 
are called cryptdins, and mice that are NOD2 deficient produce less of these cryptdins, and are more 
susceptible to bacterial infection 246. Although there are many other bacterial sensing receptors in the 
intestine, it appears that without NOD2 function, there is a lack of sufficient antimicrobial peptides. 
This could lead to overgrowth of the commensal bacterial population, resulting in the colonization of 
the intestine by pathogenic bacteria and ultimately resulting in CD. Thus, the defects seen in epithelial 
defense would argue for the loss of function hypothesis. 
 
Altered Interleukin-1β processing 
IL-1β is a pro-inflammatory cytokine, which is primarily produced by activated macrophages and 
monocytes. It functions in the generation of systemic and local responses to infection, injury and 
immunological challenges by generating fever, activating lymphocytes and promoting infusion of 
leukocytes into the sites of injury or infection (for review see 247). IL-1β does not have a signal peptide, 
therefore, it cannot be excreted via the classical secretory pathway (i.e. via the endoplasmic reticulum to 
the Golgi). Instead, it is translated in the cytosol as an inactive precursor molecule, proIL-1β, that must 
be proteolytically processed to generate the active mature IL-1β. The enzyme involved in this 
conversion of proIL-1β to the active mature form of IL-1β is the IL-1β converting enzyme (ICE), also 
called caspase-1 248. 
1 
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NOD2 can have multiple roles in the production and excretion of IL-1β. Firstly, NOD2 can activate the 
serine/threonine kinase receptor-interacting protein (RIP)2/RICK/CARDIAK pathway, leading to NF-κB 
activation and subsequent transcription of IL-1β 249. Secondly, NOD2 can interact directly with ICE, and 
thereby promote conversion of the proIL-1β to functional IL-1β 250. 
Thus, NOD2 appears to be an activator of IL-1β production and excretion. Indeed, it has been shown in 
studies using human peripheral blood mononucleated cells (PBMCs) that NOD2 deficiency leads to a 
decreased IL-1β excretion in homozygous NOD2 deficient patients 251, 252. This effect appears to be 
mainly due to a defect in the processing of proIL-1β, since the transcription of mRNA in NOD2 
homozygous deficient PBMCs was shown to be upregulated after MDP stimulation, comparable to 
controls, but the excretion of functional IL-1β was diminished 251. These results would, like the defects in 
epithelial defense, argue for the loss-of-function hypothesis. 
On the other hand, in a study using knock in mice with NOD2 deficiencies, the opposite was found, with 
an enhanced IL-1β secretion in mice homozygous for the disease related mutations. In this study, it was 
shown that only the mutant form of NOD2 could activate the IL-1β converting enzyme ICE 253 thus 
arguing for a gain of function mutation. 
These contradictory results can be explained by the differences in experimental design in human and 
mouse models, but can also relate to the different cell types studied. In addition, the process of 
generating genetically modified mice could theoretically have induced another mutation that could be 
responsible for the observations. Also, the differential effects could be due to the fact that some 
defects are related to a knock-out versus a knock-in design. By the use of a knock-in design altering 
the LRR region of the gene, this leaves the capability of the NOD regions to oligo-dimerize with other 
NOD/NLR family member molecules. When the entire NOD2 is knocked-out, this process is 
completely ablated. Thus, in the first (knock-in murine model) functional ability to suppress through 
interaction of other NOD/NLR may be retained, and in fact gain of functionality of CARD-CARD 
interactions, resulting in an activation of the IL-1β pathway. In the NOD2 knock-out model, this will not 
occur. Also, the in vitro studies with human cells might not fully represent the in vivo situation, and one 
should be careful in translating these findings to general statements on pathogenic mechanisms. 
Finally, there is also the possibility that NOD2 does not function the same in humans and mice. 
 
Altered interactions with Toll-like Receptor signaling 
As mentioned above, NOD2 is an intracellular receptor for PAMPs. However, the most well known large 
family of PAMP receptors is probably the TLR family. These receptors recognize a wide variety of 
conserved microbial structures, and are thus essential in pathogen recognition by the innate immune 
system 86, 87. Binding of the appropriate ligand to a TLR triggers the host cells to elicit an immune response 
mediated through NF-κB dependent activation of inflammatory gene transcription (Figure 4). 
Thus, both TLR signaling and NOD2 signaling lead to NF-κB activation. Theoretically, simultaneous 
stimulation through TLRs and NOD2 should lead to an enhanced NF-κB activation, and loss of NOD2 
signaling would result in a diminished NF-κB response. Indeed, in human PBMCs, it has been shown that 
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NOD2 activation acts synergistically with TLR activation, leading to a stronger immune response, and this 
potentiating effect is lost in cells from CD patients with mutations in NOD2 234, 254-261. 
However, recently it has been implicated by Watanabe et al. that NOD2 activation leads to an inhibition of 
specifically TLR2 signaling in mice. In the absence of functional NOD2, these mice produce substantially 
larger amounts of specifically IL-12 after stimulation with the TLR2 ligand peptidoglycan (PGN) 262. As 
stated above, MDP is a derivative of PGN 263, so that both receptors intrinsically recognize the same 
bacterial substance, which could provide an explanation as to why NOD2 interacts with specifically this 
TLR. Nod2-/- mice adoptively transferred with OVA specific CD4+ T cells display a profoundly elevated IL-
12 production after infection with an OVA expressing E.Coli strain, and the colitis seen in these mice can 
be abrogated by anti-IL-12p40 monoclonal antibodies, or introducing a TLR2 deficiency in these mice 264. 
Extrapolating these findings to the human situation, it can be envisaged that when there is a lack of 
efficient dampening of the TLR2 response, followed by a subsequently high production of IL-12, this 
 
Figure 4 Toll-like receptor signaling 
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Figure 4 Toll-like receptor signaling 
Depicted are the various signaling pathways by which the Toll-like receptors (TLRs) lead to gene activation. 
TLR 1, 2, 4, 5, and 6 are located on the cellular plasma membrane, whereas TLR 3, 7, and 9 are situated intracellularly. 
IKK: Inhibitor of nuclear factor kappa-B kinase; MD-2: Myeloid Differentiation-2; MyD88: myeloid differentiation factor 
88; NEMO: NF-Kappa-B Essential Modulator; NF-κB: Nuclear factor kappa B Nuclear Factor of kappa light polypeptide 
gene; NOD: Nucleotide-binding Oligomerization Domain; RIP-2:Receptor-Interacting Protein-2; STAT: Signal 
Transducer and Activator of Transcription; TIRAP: Toll/IL-1R domain-containing adaptor protein; TLR: Toll Like 
Receptor; TRAF: TNF receptor-associated factor; TRAM: Toll-IL-1R domain-containing adaptor inducing IFN-beta-
related adaptor molecule; TRIF: Toll/IL-1 Receptor Domain-Containing Adaptor Inducing IFN-beta. 
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could conceivably lead to an unwanted strong immune response. This argues for the loss of function 
hypothesis, whether it is the loss of efficient TLR2 dampening, leading to a higher IL-12 production, or 
the lack of enhancing other TLR responses. As with the contradictory results seen in IL-1β processing, 
these discrepancies between human and mouse studies can be explained by the differences in 
experimental design in human and mouse models, the design of the genetic manipulations in the murine 
models, the different cell types studied, the differences in type of mutations, and the possibility that in 
vitro studies do not fully reflect the in vivo situation, or that NOD2 does not function the same in humans 
and mice. 
Since it is now well established that NOD2 signaling leads to NF-κB activation, it might seem contradictory 
that after abrogation of fully functional NOD2 signaling, the NF-κB activation is in fact found to be elevated 
in CD patients. One explanation could be derived from the data from Watanabe et al. 262, that NOD2 does 
not only have an activating effect, but more importantly, functions as a negative regulator of another 
immune activating process. Thus, cells lacking this dampening effect get hyperactivated, and show a 
heightened NF-κB activation. Another explanation could be that because of the NOD2 deficiency, the 
immune response is somewhat belated or less strong, giving pathogens an opportunity to infiltrate. Due to 
other signaling processes than through NOD2, the inflammation and the subsequent immune response 
are stronger, and thus higher levels of NF-κB activation are seen. 
The above-described theories on how mutations in NOD2 could be affecting the immune response in 
intestinal inflammation are summarized in Figure 5. 
 
3.2.2.2.b Genes involved in epithelial homeostasis 
In keeping intestinal homeostasis, the barrier function of the bowel wall is clearly of great importance. 
The permeability of the epithelial lining is normally tightly regulated, controlling what substances and 
cells are allowed to cross this barrier. 
Defects in epithelial barrier function have been found in both CD and UC 265-269 and particularly in 
patients with CD, an increased intestinal permeability has been postulated as an early predisposing 
factor for the pathogenesis 270. Here, I will discuss the genes that could have an effect on the 
intestinal homeostasis and that have so far been implicated in IBD susceptibility. 
 
Epithelial permeability 
Claudins 
The tight junctions are the main regulators of the epithelial permeability. They are the most apically 
located intercellular connections and are complexes of proteins that are linked to the actin 
cytoskeleton. The transmembrane proteins of the tight junctions include occludin 271, 272, junction 
adhesion molecule (JAM) 273, and members of the claudin-family 274. 
Recently, a significant amount of attention is drawn towards the claudin-family. These proteins are the 
most important proteins in the tight junction complexes contributing most to barrier function 275, 276, and 
alteration of claudin expression has been shown to directly influence the strength and functioning of 
the tight junctions 277. Indeed, accumulating data is provided that claudin expression is altered in CD. 
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For example, the expression of the pore-forming claudin-2 was found to be increased in CD, and 
expression of the sealing claudins, claudin-3, -5 and –8, was reduced and redistributed 278, 279. 
In our lab, we have recently gained additional evidence for the role of these proteins in an animal 
model of intestinal inflammation. In a search for genetic risk factors we performed a genome-wide 
screen in the trinitrobenzene sulfonic acid (TNBS) colitis model 230. In this screen, we identified a 
susceptibility locus on chromosome 9. In a subsequent microarray analysis in which we determined 
the expression of genes on this locus in diseased versus healthy mice we found that Claudin-18 maps 
to this locus and was significantly upregulated in inflamed colons. These findings point to a genetic 
difference between colitis susceptible and resistant mice in the upregulation of this tight junction 
molecule. The relevance for human disease is under current investigation. 
 
Myosin IXB 
Myosin IXB (MYO9B) is a gene that was first found to be of influence in the susceptibility to celiacs 
disease280, a disorder of the small bowel that is caused by an intolerance to gluten. Recently, this gene has 
also been implicated in IBD susceptibility, with a slightly stronger association found in UC 281. 
 
Figure 5 Schematic view of how NOD2 can be involved in intestinal inflammation 
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At present it is not known how the genetic variants that are found influence the cellular mechanisms 
involving MYO9B. MYO9B is expressed most abundantly in cells from the myeloid lineage, but, 
amongst others, also in intestinal and epithelial cell lines282. MYO9B is a member of the myosin 
superfamily. The gene encodes a single headed motor protein 283, belonging to the class of IX myosin 
molecules. These are unique compared to other classes, because they contain a Rho-GTPase-
activating domain within their tails. Rho-family GTPases are involved in remodeling of the 
cytoskeleton and tight junction assembly, both of which result in enhanced epithelial paracellular 
permeability 284, 285. Alterations in MYO9B could therefore, through altered Rho-dependent signaling, 
lead to a perturbation of the epithelial barrier function. Also, MYO9B is also shown to be involved in 
the control of bacterial invasion of epithelial cells 286, and activated Rho proteins are found to be 
involved in healing of human intestinal epithelial wounds 287. 
Further studies are necessary to determine how MYO9B variants influence the susceptibility to IBD, but he 
fact that this gene is found to be involved in both forms of IBD and celiacs disease, with typical different areas 
of involvement, points to the notion that certain genes can predispose to a shared general mechanisms 
underlying intestinal inflammatory disorders. Depending on the combination with other host specific genetic 
factors, this mechanism can then result in different disease outcome. 
 
Disc Large Homologue-5 
Disk large homologue 5 (DLG5) is recently implicated as a novel gene involved in IBD etiology 220. DLG5 is a 
member of the MAGUKs (Membrane Associated Gyanylate Kinase) family which mediates intracellular 
signaling, and is involved in maintaining epithelial integrity 288. A diminished functioning of DLG5 caused by 
variations in its gene could cause a less strong epithelial barrier, adding to the pathogenesis of IBD. The 
association found with these variations in the initial study however, was not always confirmed by other 
studies 289-291, rendering DLG5 involvement a topic of debate. Although the association with IBD is not always 
found, the risk variants of DLG5 do seem to be involved in the phenotypic expression of the disease, 
especially in perianal and penetrating CD 292, and being refractory to corticosteroid treatment 293. 
Although DLG5 does not seem to be associated with IBD in many studies, when combined with NOD2 
status, the frequency of the risk variations in DLG5 is higher in patients with NOD2 deficiencies 292. Also, 
recently it has been shown that the association with DLG5 variation and IBD is mainly found in the male 
gender 294. This gender dependence may explain the divergent association findings related to DLG5 and CD, 
as the gender composition of both the CD and the control cohort influences whether the risk variant is 
associated with IBD. 
 
IL-13 and Epithelial Growth Factor 
Next to differences in tight junctions, the increased permeability of the epithelium can also be caused 
by increased apoptosis of epithelial cells. Especially in UC, in which the number of apoptotic epithelial 
cells has been reported to be as high as 28% in fulminant disease, apoptosis of the epithelium could 
be a major factor increasing gut permeability 295. 
As said before, IL-13 is a cytokine that is typically highly expressed in affected colonic tissue in UC 
187
. Furthermore, it was recently shown that IL-13 impairs epithelial barrier function by increasing 
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epithelial apoptosis, increasing the expression of the pore-forming tight junction protein claudin-2, and 
decreasing rate of new cell formation in vitro as well as in vivo in UC patients 188. These functional 
properties of IL-13, combined with the notion that the gene for this cytokine resides in the IBD5 locus 
218
, indicates that alterations in this gene could contribute to the etiology of UC. 
Epithelial growth factor (EGF) and EGF receptor are genes that have been implicated in the etiology 
of IBD both by their location in human and murine susceptibility loci 214, 229, 232 and by their obvious role 
in maintaining gut integrity. Lack of sufficient properly functional EGF, or its receptor could 
conceivably aggravate this effect, by not providing enough stimulus for the epithelium to regenerate, 
as seen in mice lacking the EGF receptor which show an increased susceptibility to acute dextran 
sulfate-induced colitis 296. Although to date, no functional polymorphisms in the above genes have 
been found that could indicate a direct causative relation for these genes in the etiology of IBD, 
therapy directed against IL-13 or enhancing EGF could prove to be beneficial for some UC patients. 
Enhancing of EGF functioning has already been shown to be helpful in some UC patients 297. 
Although depleting IL-13 producing NK T cells has proven to block inflammation in a murine model for 
colitis 194, so far, no clinical data are available for anti-IL-13 treatment in UC patients. Still, anti-IL-13 
treatment has proven to be effective in asthma treatment, which is also a Th2 mediated disease with 
many immunological similarities to UC 298, 299. 
 
Bacteriocidal functions of the epithelium 
Defensins 
In addition to providing a solid boundary for pathogens, the cells of the epithelium also secrete 
antibacterial substances. The main cell type involved in this is the Paneth cell, a specialized epithelial 
cell located mainly in the crypts of the small intestine, in close proximity to epithelial stem cells 300. 
Among the antibacterial substances are lysozyme, an antimicrobial enzyme that dissolves the cell 
walls of many bacteria 301, type II phospholipase A2, an enzyme specialized in the lysis of bacterial 
phospholipids302, angiogenins, that exhibit microbicidal activity against both enteric and systemic 
bacterial and fungal pathogens 89, and α-defensins and β-defensins 303. Many of the genes encoding 
for these substances reside in mouse QTLs (see also Table 4), like defensin B (Defb), defensin-
related cryptdin peptide (Defcr), 229 and secretory phospholipase A2 group IIA (Pla2g2a) 226. 
Recently, it has been shown in mice that NOD2 deficiency results in a reduced production of 
cryptdins, the mouse orthologue of human α-defensins. These mice show a profound susceptibility to 
bacterial infection via the oral route, but not through intravenous or peritoneal delivery, indicating the 
importance of the cryptdins, especially in mucosal immunity 246. Also, in normal human intestinal 
tissue, with functional NOD2, Paneth cells produce a sufficient amount of α-defensins, which keep the 
commensal bacteria in check, but Paneth cells from individuals that are defective for NOD2, produce 
less α-defensins 240, 244. Also, in humans, the copy number of β-defensins is highly polymorphic within 
the healthy population, and recently, it has been shown that people with 3 copies or less have a 
significantly higher risk of developing colonic CD 304. Thus, defective defensins functioning could lead 
to an overgrowth of the commensal-bacterial population, resulting in an uncontrolled inflammation. 
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Solute Carrier Family 22A4/22A5 gene cluster 
Within the IBD5 locus on chromosome 5q two related genes of the solute carrier family, SLC22A4 and 
SLC22A5 are positioned that code for the carnitine/organic cation transporters OCTN1 and OCTN2, 
respectively. These cation transporters are involved in maintaining a physiological cation 
concentration in the intestine. Recently two novel functional single nucleotide polymorphisms (SNPs) 
have been reported to be associated with CD. The first, Leu503Phe in SLC22A4 leads to decreased 
activity of OCTN1, and the second, a G->C transversion in the promoter of SLC22A5, leads to a 
decreased expression of OCTN2 in the intestine 305. These genes were also found to be implicated in 
the susceptibility to UC 306, 307. Not all studies on these genes were able to replicate the associations 
found. Some studies show an association with perianal disease 292, where others report a 
predominant association with ileal involvement 308 or fibrostenosing disease behavior 309. 
Although there is genetic data available pointing towards SLC22A4 and SLC22A5 as susceptibility 
genes for IBD, at this time, there are no confirmatory studies demonstrating the altered expression 
and activity in primary human cells stratified on the IBD5 locus, or studies in murine models that give 
more insight in the functioning of these genes in IBD pathogenesis. These studies are warranted to 
further establish the presence or absence of involvement of these genes, and to provide a 
physiological explanation of the genetic association. 
 
Multi Drug Resistance 1 
Within a region of suggestive linkage on chromosome 7 lays the gene Multi Drug Resistance 1 
(MDR1). The MDR1 protein is a member of the ATP-binding cassette of membrane transporters, and 
functions as a drug efflux pump P-glycoprotein 170 (Pgp-170) and is expressed on the surface of 
lymphocytes and intestinal epithelial cells. It has been found that IBD patients with high expression of 
MDR1 are more refractory to corticosteroid therapy, providing a possible mechanism for involvement 
of this gene 310, 311. However, mice in which the Mdr1 gene has been deleted spontaneously develop 
colitis 312.  
Clearly, alterations in the expression of this gene appear to be very important in IBD susceptibility. 
Indeed, an Ala893Ser/Thr polymorphism was found in MDR1, and this appeared to be involved in 
especially UC susceptibility 313, 314 and corticosteroid refractory CD 315, although the association with 
CD was not generally confirmed 316. 
 
3.2.2.2.c Genes involved in mucosal immunity 
Antigen recognition 
In order to have a proper mucosal immune response, the immune system needs to be able to detect 
when a potentially dangerous pathogen is trying to invade the host. After the recognition of a 
pathogen by a receptor, the signal needs to be transported to the nucleus of the cell to elicit the 
proper immune response. Many genes that are involved in this process have been implicated in the 
etiology of IBD, and some of the most prominent ones will be discussed here. 
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TLR4, CD14 and MD-2 
Probably one of the most well known Gram-negative bacterial endotoxic products is LPS. LPS is 
recognized by TLR4, in close physical combination with myeloid differentiation-2 (MD-2) 317, and this 
recognition is greatly enhanced by either membrane bound or soluble CD14 318-320. Because of their 
obvious function in innate pathogen recognition, the genes involved in LPS recognition are interesting 
candidate genes in IBD pathogenesis. Even more, CD14 lays within the IBD5 locus on chromosome 
5q, and mice deficient for TLR4 are extremely susceptible for colitis 321, 322. Quite some studies have 
been performed using the candidate gene approach for CD14 and TLR4. Indeed, an Asp299Gly 
variant within the TLR4 gene has been found that is associated with LPS hyporesponsiveness 323. 
This variant has been associated with CD and UC 324 reproducibly, or at least a trend towards 
association was found in most studies 210. 
A promoter polymorphism (-159C/T) in CD14 has been implicated in IBD in a number of studies 325, 
326
, especially after stratification for NOD2 mutations 327, however this association was not generally 
reproduced 328. A possible explanation for this could be that the populations studies were stratified 
differently, or that the CD14 polymorphisms is in fact in linkage with other yet to be discovered 
disease-causing variant(s), or with other genes, like SLC22A4/5, that reside relatively close to CD14. 
 
TLR5 
Recently, the bacterial substance flagellin has been identified as a dominant antigen in CD 329. 
Flagellin is recognized by TLR5. Carriage of a relatively common polymorphisms that causes a 
premature stopcodon in the TLR5 gene has been found to induce decreased serum anti-flagellin 
antibody levels in controls, and this appears to protect from developing CD in Ashkenazi Jews 330, 331. 
 
The Human Leukocyte Antigen gene complex 
One of the most consistently replicated IBD linkage regions is the IBD3 locus on chromosome 6 332. 
Within this locus lays the MHC region, in man called Human Leukocyte Antigen complex (HLA). The 
MHC region is divided into three subgroups called MHC class I, MHC class II, and MHC class III. The 
main function of MHC class I and II molecules is to recognize antigens and present them to T cells. 
Class I molecules are expressed on almost every nucleated cell and present peptides that are derived 
from cytosolic proteins that have been endogenously processed to CD8+ T cells. Class II molecules 
on the other hand, present peptides that are derived from exogenous proteins, that have been 
endocytosed and digested in lysosomes, to CD4+ T cells and are expressed only on specialized 
professional APCs, like DCs and macrophages, and on activated T cells and B cells. The MHC class 
III region harbors genes that encode for other immune components, such as complement components 
(e.g., C2, C4, factor B) and cytokines (e.g. TNF-α). 
Within the complete MHC region over 200 different MHC genes are found, that are all highly 
polymorphic 333. Certainly, there must reside susceptibility alleles in this genomic region, however, the 
immense genetic complexity makes it extremely challenging to find them. Because of the diversity, 
extremely large sample groups are needed to definitely show linkage with disease susceptibility. A 
meta-analysis combining results from 29 studies showed significant association of HLA-DR2, HLA-
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DR9 and HLA-DR*0103 for UC, and a protective association for HLA-DR4 with UC. In CD, HLA-DR7, 
HLA-DRB3*0301 and HA-DQ4 were found to be associated with disease susceptibility, whereas HLA-
DR2 and HLA-DR3 were found to be protective 334. 
 
Signal transduction 
Next to the ability to recognize pathogens, one of the most important processes in regulating the 
immune response is the signal transduction from the receptor downstream to the nucleus, to activate 
transcription of either pro- or anti-inflammatory genes. Typically, a receptor activates a cascade of 
kinases that subsequentially activate each other by processes like phosphorylation or ubiquitination, 
ultimately resulting in the release of transcription factors. Normally, when in rest, these transcription 
factors are kept in the cytosol, but upon activation they migrate to the nucleus, where they can 
activate gene transcription. Evidently, because of the importance of a fine tuned, well regulated 
signaling in immune responses, any gene involved in this cascade is a likely candidate gene in a 
disease that is characterized by an imbalanced immune activation, as seen in IBD. 
 
Nuclear Factor κB 
The nuclear factor (NF)-κB family is a group of critical transcription factors involved in a variety of 
regulatory processes, including innate and adaptive immune responses, cell growth, apoptosis, and tissue 
differentiation 335, 336. One of the NF-κB family members, the gene coding for the NF-κB subunit p50, 
NFKB1 is found on chromosome 4q24. This region was originally implicated in UC susceptibility in North 
American populations with UC, especially in Ashkenazi Jews, and appeared to epistatically interact with 
the IBD1 region 219, and this was later confirmed in European and Canadian studies 215, 218, 221. In addition, 
in two separate spontaneous colitis models, the Gnai2-/- mouse model 232, and the IL10-/- mouse model 229, 
a locus on chromosome 3 was found to significantly contribute to colitis susceptibility and severity (called 
Gpdc1 and Cdcs1 respectively). This region is the mouse orthologue for the human 4q region and harbors 
mouse Nfkb1. Interestingly, an elevated susceptibility to bacterial infections and intestinal inflammation is 
demonstrated in Nfkb1 deficient mice 337, 338 but on the other hand, mice with enhanced NF-κB p50 
expression show enhanced inducible NF-κB activation, chronic inflammations and elevated susceptibility 
to bacterial infections 339. These findings are further corroborated by studies in human IBD, where elevated 
levels of NF-κB activation are found in the intestinal mucosa of both CD and UC patients 340, 341. These 
observations designate NFKB1 to be an interesting candidate gene for IBD. 
Indeed, a promoter polymorphism, conferring a ATTG deletion 94 bp upstream of the transcription start 
of the NFKB1 gene was found to be associated with UC susceptibility 222. These results were confirmed 
in our study in an Amsterdam based IBD patient group 342, but other studies failed to reproduce the 
association 343-345. 
Nevertheless, it is clear that any alteration in NF-κB signaling can have profound effects on the immune 
state of the host. Should the promoter polymorphism in NFKB1 be a true susceptibility allele, the exact 
mechanism underlying the NFKB1 related disease susceptibility would remain difficult to explain. One 
can think of several explanations. To exert its effect, p50 binds to p65 to form biologically active 
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heterodimers, which translocate from the cytoplasm of the cell to the nucleus. Here, they bind to NF-κB 
binding sites in promoter sequences of inflammatory proteins, including IL-12, TNF-α and IFN-γ and 
regulate their transcription. Alternatively, p50 is able to form homodimers which block transcription by 
binding to NF-κB sites in the nucleus 346. The polymorphisms in the promoter region leads to a less 
strong activation of NF-κB1 transcription, which seems contraintuitive to the fact that especially in UC, 
high levels of NF-κB activation are seen. However, if the diminished NFKB1 transcription would lead to 
less available p50, fewer inhibitory p50/p50 homodimers can be formed. Fewer blocking homodimers 
could then lead to a stronger activation of transcription of inflammatory genes, leading to the strong NF-
κB induced immune response, as seen in UC. Another potential explanation is that low levels of p50 
lead to a poor innate immune response. Bacteria that would have normally been handled by this first line 
of defense are then able to provide for ongoing antigenic signals and subsequently cause an ongoing 
inflammation. 
The importance of the NF-κB signaling route in intestinal inflammation is also shown by the effects of 
IKKβ deficiency on the gut epithelium. This Inhibitor of nuclear factor Kappa-B Kinase β (IKKβ) is 
essentially important for the activation of NF-κB. Lack of proper IKKβ functioning in itself does not 
lead to increased epithelium apoptosis and gut permeability, but after challenge with intestinal 
ischemia-reperfusion, radiation therapy, or toxin A derived from Clostridium difficile, these animals are 
far more susceptible to colitis 347-349. 
Clearly, any change in the delicate balance of NF-κB signaling can lead to an alteration in immune 
response which can be associated with enhanced susceptibility to colitis, however larger studies with 
well defined patient groups are warranted to discern whether or not the NFKB1 promoter polymorphism 
is a true susceptibility allele. 
 
Cytokines and cytokine receptors 
Because of their important role in the immune response, in initiating, regulating, and perpetuating it, the 
genes that code for cytokines and their receptors are an obvious group of candidate genes for IBD. 
 
Tumor Necrosis Factor locus 
The gene coding for TNF-α is one of the genes residing in the MHC class III region on chromosome 6, 
within the IBD3 susceptibility locus. In close proximity of TNFA, lays the gene formerly known as TNFB, 
now named lymphotoxin-α (LTA). Both genes are interesting candidate genes, not only because of their 
location, but especially because of their function as some of the most potent pro-inflammatory cytokines. 
Even more, elevated levels of serum TNF-α have previously been demonstrated in IBD patients, 350 and 
anti-TNF-α therapies are effective for patients with active CD and UC 351-353 (See also section 3.2.1.2). 
Many studies have been performed looking for polymorphisms in both genes. Especially for TNFA, 
several polymorphisms have been found, that are associated with enhanced susceptibility to, or severity 
of a variety of infectious diseases like mucocutaneous Leishmaniasis 354, 355 and death from cerebral 
malaria 356, 357, neoplastic disorders like colorectal cancer 358, 359, and autoimmune like disorders, such as 
asthma 360, 361. 
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These polymorphisms have been found to be associated with IBD in several studies 362-365 and appear 
to occur in only five conserved combinations, or haplotypes (TNF-C, -E, -H, -I and –P). Some studies 
have found that they seem to be more involved in the severity of disease than susceptibility itself 366, 367. 
 
The Interleukin 1 cluster 
A cluster of cytokines that has been implicated in the susceptibility to IBD is the IL-1 cluster. This 
cluster comprises of three genes, IL1A, IL1B and IL-1 receptor antagonist (IL1RA). IL-1α and IL-1β 
are both pro-inflammatory cytokines, mainly expressed in cells of the myeloid lineage and epithelial 
cells, that have many pro-inflammatory properties, as described before 247. IL-1RA on the other hand 
is a substance that is closely related to IL-1α and IL-1β, and binds to the IL-1 receptor but does not 
trigger it. Thus, IL-1RA can function as a buffer, keeping the IL-1 receptor occupied, preventing 
binding of the activating ligands IL-1α and IL-β, thus limiting the activation. An imbalance in the 
expression of IL-1RA and IL-1 has been shown to influence the susceptibility and clinical course of 
several inflammatory diseases, like rheumatoid arthritis and inflammatory myopathies, and 
intravenous administration of IL-1RA has shown to be promising in many of them 368-370. 
In IBD as well, many studies have been performed showing that an imbalance in the IL-1 system is 
found in IBD patients 371, 372. Indeed, polymorphisms in the IL-1RA and IL-1B genes have been found 
to be involved in the susceptibility to IBD 373-375, and even more the severity of UC 376. However, as 
with many of the above discussed genes, the results found were not always reproduced when 
different populations were studied 377-379. 
 
Interleukin-12 
Another cytokine that would be an interesting candidate gene, especially in Crohn’s disease, is IL-12, 
being a key cytokine for the induction of Th1 immune responses and elevated IL-12 levels being one 
of the hallmark features of the disease. Polymorphisms causative of an elevated IL-12 production in 
CD would provide a plausible explanation for the disease susceptibility. 
Biologically functional IL-12 is a heterodimer formed by an IL-12α chain (IL-12p35) and IL-12β chain 
(IL-12p40) encoded by IL12A and IL12B respectively. The latter subunit, IL-12p40, was shown to be 
linked to susceptibility to chemically induced colitis in mice 230. A logical step would be to try to identify 
polymorphisms in the human form of the gene. Indeed, there are functional polymorphisms found in 
human IL12B, that were shown to be associated with susceptibility to several autoimmune diseases, 
or with high secretion levels of IL-12. However so far, no association of IL12A or IL12B 
polymorphisms with CD, or IBD in general has been proven 380, 381. 
 
Interleukin-23 receptor 
Very recently, a highly significant association between Crohn’s disease and the Interleukin-23 
receptor (IL23R) gene on chromosome 1p31, which encodes a subunit of the receptor for IL-23 was 
found using a genome-wide association study 227. The uncommon coding variants of the gene found 
in this study confer protection against CD. These finding were further substantiated in a study in 
pediatric IBD patients, showing that especially in non-Jewish CD patients with ileal disease, the rare 
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IL-23R allele is protective for the development of IBD 382. At this point, very few data is available on 
the genetic involvement of IL-23, however, combining the two above studies with previous studies on 
the proinflammatory role of IL-23 in CD, point out the importance of the IL-23 signaling pathway in CD 
etiology, and make this pathway a very promising therapeutic target in IBD. 
 
Many genes have been investigated in IBD susceptibility. So far only NOD2, based on its strong 
association, is irrefutably connected to CD. The inconsistent findings with the other above described 
genes and several other genes that were not discussed here may reflect underpowered cohorts to 
dissect out the effects of for instance differences in tobacco use, disease behavior, location, and 
duration. False-positive, or negative results can also occur when the frequencies of the various alleles 
vary in different racial and ethnic groups, for example the difference of frequency of the NOD2 
polymorphisms in Caucasian and Asian populations, or when the studied groups are not recruited 
from the same genetic homogeneous population. Furthermore, differences in phenotype definitions 
can trouble the genetic view. 
 
Concluding remarks 
Although Crohn’s disease and ulcerative colitis are the best defined pathologies within IBD it is clear 
that IBD is in fact a plethora of diseases, all characterized by chronic inflammation of the 
gastrointestinal tract, but with differences in the development, localization, histological and 
immunological features, as well as complications of the disease. Complicating factors in defining 
possible subtypes within either CD or UC can be found in the immense diversity in the human 
population, and differences in environmental factors, life style, and gut flora. Also, the extent to which 
these factors have an effect on the susceptibility and development of the diseases remains largely 
elusive, and is most probably not the same for all the sub- pathologies within IBD. In addition, the 
underlying genetic defects can be different for the different subtypes of IBD. Although in the past 
decade much progress is made in our knowledge about the genetic background of IBD, the larger part 
of the puzzle still remains to be solved. Meta-analyses combining the results of many studies and 
studies with sufficiently large cohorts of strictly defined patients are warranted to dissect the complex 
polygenic background of IBD. 
Understanding this background, and most probably being able to divide IBD patients in genetically 
distinct subgroups will be of great aid in understanding the physiology and immunology of the disease 
and will ultimately lead to the development of specific treatments for all subgroups of the diseases. 
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Abstract 
Crohn’s disease and ulcerative colitis are chronic idiopathic inflammatory disorders of the gastro-
intestinal tract. While the exact etiology of these inflammatory bowel diseases remains elusive, both 
immunological and genetic determinants have been identified that are involved in disease 
pathogenesis. Murine models of mucosal inflammation have provided a detailed insight in the 
immunological processes underlying chronic mucosal inflammation. Here, we highlight some recent 
findings that have contributed to our understanding of human IBD. 
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Introduction 
Crohn’s disease (CD) and ulcerative colitis (UC) are two related but distinct chronic inflammatory 
disorders of the gastrointestinal tract, commonly denoted as inflammatory bowel diseases (IBD). 
The exact causes remain elusive, but thus far, IBD is thought to be the result of an inappropriate and 
ongoing activation of the mucosal immune system driven by the presence of normal luminal flora in a 
genetically susceptible host 1. This paradigm has emerged, to a great extent, from studies in animal 
models of mucosal inflammation. The large variety of animal models that has been identified so far is 
consonant with the view that many types of imbalance in the gastrointestinal immune system can lead 
to mucosal inflammation, and by extension, that human IBD is likely to be a common denominator for 
a group of clinically related disorders with multiple etiologies and distinct clinical characteristics. Even 
more, there is now convincing evidence that the immunological abnormalities underlying both forms of 
IBD are entirely different (Box 1). 
In Europe and North America, there are an estimated 3.6 million IBD patients. Disease incidence 
appears to be lower in developing countries; however, as societies become more “Westernized”, with 
attendant changes in life-style, diet and other environmental exposures, the incidence rates rise, and 
approximate those of the industrialized areas 2. 
Thus, while environmental factors play an important role in disease pathogenesis, there is substantial 
epidemiological evidence that genetic factors have a decisive role in the susceptibility to IBD as well. 
The most convincing epidemiological evidence for this thesis comes from twin concordance studies, 
particularly in CD. These epidemiologic observations are supported by genetic linkage studies in 
which families containing more than one affected member are analyzed using genome-wide 
genotyping technology. These studies identified several chromosomal regions harboring IBD 
susceptibility genes 3. The most prominent and first discovered region is located on chromosome 16 
(denoted IBD1) and is involved in susceptibility to CD but not UC 4. More recently, it was found that 
polymorphisms in the NOD2 gene (NM_022162) are responsible for the linkage with this region (see 
further discussion below) 5, 6. Importantly, these mutations are found only in a small proportion of CD 
patients. Therefore, other, as yet unknown gene-defects must exist that are responsible for disease 
susceptibility in the remainder group of patients. 
The broad variety of factors involved in the etiology, the genetic heterogeneity of the human 
population and complex gene-gene and gene-environment interactions significantly complicate further 
unraveling the causes of IBD. Therefore, much of our current understanding of IBD comes from the 
systematic study of well-defined animal models. The scope of the current review will not be to provide 
a detailed overview of all models, but rather to summarize some general concepts and to highlight 
some recent advances in our understanding of IBD, that have emerged from these models, with a 
special emphasis on recent advances in the field of (murine) genetics. 
 
In vitro models 
The gastro-intestinal tract involves many different cell types that are not only involved in digestion and 
nutrient absorption, but also provide an essential physical and immunological barrier to the milieu 
exterieur. Deficiencies involving any of these cells could lead to an exaggerated mucosal 
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inflammation. It follows that such a complex system can not be easily mimicked in vitro . However, by 
studying just one cell type at a time, specific aspects of the cellular mechanism involving IBD can be 
explored. In addition, in vitro models for the gut wall function can be safely used in toxicity and 
efficacy tests for novel drug therapies. 
 
 
Box 1 Characteristics of human inflammatory bowel diseases 
• General definition 
Inflammatory Bowel Disease (IBD) is a chronic relapsing idiopathic inflammation of the gastrointestinal 
tract. The two main clinical forms of IBD are Crohn’s disease (CD) and ulcerative colitis (UC) 
• Epidemiology 
Disease prevalence is highest in industrialized countries for both CD and UC, ranging from 10-200 cases 
per 100,000 individuals in North-America and Europe 
• Areas of involvement 
o CD: Most commonly the terminal ileum, cecum, peri-anal area and colon, but any part of the 
gastrointestinal tract can be affected. Characterized by segments of normal bowel between 
affected regions, known as ‘skip lesions’. 
o UC: Involves the rectum and extends proximally in a continuous fashion, and always remains 
restricted to the colon. Is sometimes restricted to the rectum as ‘ulcerative proctitis’ 
• Histology and characterization of inflammation type 
o CD: A transmural inflammation (affecting all layers of the bowel wall), dense infiltration of 
lymphocytes and macrophages; granulomas in up to 60% of the patients; fissuring ulceration 
and submucosal fibrosis 
The inflammation is characterized by a Th1 type response, with high levels of IL-12, IFN-γ and 
TNF-α. 
o UC: An inflammation affecting the superficial (mucosal) layers of the bowel wall, infiltration of 
lymphocytes and granulocytes and loss of Goblet cells, accompagnied by ulcerations and crypt 
abcesses 
The inflammation is characterized by a more Th2 type response, with high levels of IL-5 and IL-
13 (but not IL-4), and high levels of autoantibodies, such as anti-neutrophil cytoplasmic 
antibodies (pANCA), indicative of B-cell activation 
• Clinical features and complications 
Both CD and UC involve diarrhea and pain, and can show extra-intestinal inflammatory manifestations in 
joints, eyes, skin, mouth and liver. Longstanding IBD leads to an increased risk for colon carcinoma, in 
particular in UC. 
o CD: narrowing of the gut lumen can lead to strictures and bowel obstruction, abcess formation, 
and fistulization to skin and internal organs.  
o UC: severe diarrhea, blood loss and progressive loss of peristaltic function leading to rigid 
colonic tube, in severe cases, this can lead to ‘toxic megacolon’ and perforations.  
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Primary cultures 
Primary cultures can be obtained from colorectal tissue specimen or biopsies derived from endoscopy. 
These cultures have the advantage of containing the same combination of cell populations present in the 
intestine, and thus represent the in vivo situation, however, they are difficult to maintain and generally 
survive for only a few days 7. 
 
Cell lines 
Several cell lines resembling the gut epithelium, mostly derived from carcinomas, are commercially 
available (Table 1). The cell line used most often in IBD research is the CaCo2 cell line, which is 
derived from colorectal carcinoma cells and resembles the columnar epithelium of the small bowel 8. 
Also, cell lines derived from human fetal cells, like the H4 cell line derived from human fetal 
enterocytes have been used 9. Epithelial cell lines can be applied for pharmacokinetic and toxicity 
studies of drug therapies. A drawback for using them is the loss of tissue characteristics with the 
passaging of the cells, and the lack of interaction with other cell types involved in mucosal immunity. 
 
Table 1. Comparison summary table 
 In Vitro Models In Vivo Models 
Pros Relatively cheap 
Reduced complexity of the system 
Incorporate multiple cell types, histologies 
and processes 
Similar complexity to human system 
Cons Difficult to model complex aspects of 
disease, incomplete congruence between 
cultured cells and parental in vivo cells 
Loss of tissue characteristics due to 
continued passaging 
Relatively expensive and time-intensive 
Ethical considerations 
Best use of model Characterization of specific cell types 
from susceptible donor 
Pharmacokinetic, toxicity and efficacy 
testen of (novel) drugs 
Identification of susceptibility genes 
Preclinical studies 
How to get access to the 
model 
Literature 
Directly from scientist 
American Type Cell Culture (ATCC) 
www.atcc.org 
 
Literature 
Directly from scientist 
Jackson Labs, www.jax.org 
Taconic M&B www.taconic.com 
Charles River Laboratories 
www.criver.com 
References 
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In vivo models 
During the course of the last fifty years, an amazingly large number of different models of mucosal 
inflammation has been described all showing some of the characteristics of either CD or UC. A recent 
excellent and detailed overview of the various animal models of IBD has been provided by Strober 
and colleagues 10. Several species have been studied, including mice, rats, rabbits, guinea-pigs and 
tamarins. Here we will give a brief overview of the different categories of models, with some examples 
in each category. 
 
1. Induced models 
The models studied in greatest detail so far involve induction of colitis by administration of an exogenous 
colitogenic substance. In general, these models require the co-administration of a substance that 
temporarily disrupts the mucosal integrity, allowing the colitogenic components to gain access to the 
mucosal immune system (for examples, Box 2). 
In one of the early models of IBD, rabbits were sensitized with ovalbumin. Then, the colonic 
epithelial barrier was disrupted by rectal administration of formalin, followed by re-administration of 
the antigen, leading to a transient inflammation with many similarities to UC (the ‘Auer procedure’) 
11
. An important conclusion from these and subsequent studies was that the perpetuating 
inflammation in IBD results from a break in ‘tolerance’ to antigens in the normal mucosal microflora. 
The presence of this nonpathogenic luminal flora is a prerequisite for developing inflammation, 
since in virtually all models known today, there is no inflammation when animals are kept under 
germfree conditions. Indeed, early studies in guinea-pigs demonstrated that the inducing agent 
carrageenan did not provoke ulcerations in germfree animals, while restoration of animals with 
Bacteroides vulgatus resulted in the development of cecal ulcerations upon carrageenan feeding 12. 
In addition, disease may ameliorate when animals are treated with antibiotics. For example, HLA-
B27 transgenic rats develop a spontaneous gut, joint and skin inflammation when housed under 
conventional conditions. If these animals are kept under germfree conditions however, no intestinal 
inflammation is seen. Treatment of these animals with antibiotics significantly reduces the severity 
of the inflammation 13, 14. While there is evidence that these findings can be extrapolated to human 
IBD, it must be noted that despite exhaustive research, to date no specific pathogenic microbes 
have been associated with susceptibility to human IBD. 
 
2. Defective T-cell mediated colitis 
Generally, encounters with mucosal antigens do not result in inflammatory responses, but instead in 
negative regulatory T cell responses, induction of anergy or deletion of antigen-specific T cells, a 
phenomenon known as “oral tolerance”. This phenomenon was already noticed in the late sixties by 
Halpern et al., who showed that feeding rats E.coli before immunizing them with dead or live E.coli in 
Freund’s adjuvant could prevent the development of colitis 15. Recently, several different regulatory 
cells, involved in dampening immune responses to harmless antigens, have been identified 39. It 
follows that defects in development or function of these regulatory cells may lead to mucosal 
inflammation. Indeed, a surprising number of murine models of IBD can be traced to a regulatory T 
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cell defect (Box 2). A notable example is mucosal inflammation that is induced in severe combined 
immunodeficient (SCID) mice by the adoptive transfer of naïve (CD45RBhi) T cells lacking regulatory 
cells, which is prevented by the co-transfer of mature (CD45RBlo) cells containing regulatory T cell 
subpopulations 40. So far it has been very difficult to trace abnormalities in regulatory T cell function in 
human IBD. Thus, further work will be necessary to assess the meaning and validity of this finding. 
 
 
Box 2 Examples of animal models in differently induced colitis models for IBD 
a.    Induction of colitis by administration of an exogenous colitogenic substances: 
Trinitrobenzene sulfonic acid (TNBS): mouse, rat, rabbit, guinea-pig 26, 29, 
Dextran sulfate sodium (DSS): mouse, rat, guinea-pig 30-32, 
Oxazolone: mouse, rat 33, 34 
 
b.    Induction of colitis caused by defective T-cell mediated regulation: 
Adoptive transfer model in severe combined immunodeficient (SCID) mice 16, 
IL-10 deficient mice 35, 
Transforming growth factor-β (TGF-β) deficient mice 36, 
Tgε26 mice (defects in thymic development of regulatory cells) 37 
 
c.    Induction of colitis by introduction of a gene-defect or a transgene 1: 
Gi2α-/- mice 38, 
IL-10-/- mice 35, 
TCR-α chain deficient mice 27, 
STAT4 transgenic mice 28 
 
 
3. Spontaneous models 
A third category involves spontaneous models of mucosal inflammation. This category can be divided 
into two related subcategories; animals that spontaneously develop mucosal inflammation, and 
models in which a gene-defect or a transgene causes an inappropriate mucosal immune response. 
 
3a. Spontaneous models: 
The most notable example of this kind are cotton-top tamarins, who develop a colitis similar to UC 20. 
Since these animals are relatively closely related to humans, they are theoretically excellent models 
for efficacy testing of novel drug therapies 41. The ethical and practical drawbacks are however 
apparent. 
Another model is the recently recognized SAMP1/YitFc mouse strain that develops a chronic intestinal 
inflammation localized in the terminal ileum. The resulting ileitis bears a remarkable resemblance to 
human Crohn's disease with discontinuous, transmural inflammatory lesions in the terminal ileum 21. 
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3b. Spontaneous colitis in genetically modified animals: 
With the introduction of large scale genetic engineering during the early nineties of the last century, it 
became apparent that inactivating or overexpressing entirely different genes frequently leads to 
mucosal inflammation (Box 2). This category now represents the largest group of models of mucosal 
inflammation. An important conclusion relevant to human IBD is that entirely different genetic defects 
can lead to mucosal inflammation and a more or less similar clinical picture. In other words, it is very 
unlikely that there is only one gene or a limited group of genes involved in IBD susceptibility.  
 
Recent novel insights in the etiology of IBD derived from animal models; 
The Nod2-/- mouse 
As alluded to above, mutations in the NOD2 gene were identified in 2001 as the first genetic risk factor for 
CD 4-6. Until very recently, the mechanism by which this leads to mucosal inflammation remained 
enigmatic. NOD2 is an intracellular receptor for muramyl dipeptide (MDP), a part of bacterial peptidoglycan 
(PGN), and is expressed in a variety of cell types, including monocytes and monocyte-derived cells. 
MDP recognition by NOD2 leads to NF-κB activation, which leads to production of pro-inflammatory 
cytokines 40. The polymorphisms in the NOD2 gene lead to abrogated NOD2-signaling and, as one would 
think, should lead to diminished NF-κB activation. This is contrary to the inflammatory response seen in 
CD patients, which is associated with a notably elevated NF-κB activation. 
These seemingly contradicting findings were recently partially clarified. Watanabe et al. 20 stimulated 
splenocytes from Nod2-/- mice with ligands for different types of Toll Like Receptors (TLR’s). They found 
that splenocytes from Nod2-/- mice showed an increased NF-κB activation and consequently IL-12 
mediated Th1 responses following stimulation with PGN. This effect was specific for PGN, and did not 
apply to other TLR ligands. PGN can bind to both TLR2 and, through its MDP component, to NOD2. This 
indicates that under normal conditions, TLR2 activation by PGN is inhibited by NOD2. Thus, simultaneous 
signaling through NOD2 leads to a dampening of the NF-κB activating effect of TLR2 signaling. The exact 
mechanism by which NOD2 signaling inhibits the TLR2-mediated NF-κB activation and Th1 response and 
why this leads to gut-specific inflammation remains enigmatic. 
 
Genetic Analysis of IBD using Murine Models  
Identifying NOD2 as a susceptibility gene for CD is a major scientific breakthrough. However, mutations in 
this gene are found in only a subgroup of CD patients. Identification of the remainder set of susceptibility 
genes may be problematic since it seems likely that their contribution to the disease will be more limited 
than that of NOD2. 
Linkage strategies in humans usually encounter significant difficulties in the final stages of gene 
identification. Some of these difficulties can be overcome by identification of genetic factors underlying 
experimental models of mucosal inflammation, followed by a candidate gene approach in humans testing 
the relevance of the identified mouse gene to human IBD (Table 2). This approach has been successfully 
applied to several complex immune-mediated diseases, but has only recently received attention in IBD 
research 41. In an initial study of this kind, genetic factors underlying susceptibility to dextran sulphate-
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induced colitis (DSS colitis) were examined 21. The approach taken here, and in other genetic studies, was 
to cross susceptible mice (in this case C3H/HeJ mice) with relatively resistant mice (C57BL/6J mice) and 
then correlate co-segregation of microsatellite polymorphisms associated with each strain with 
susceptibility to disease in the F2 progeny. In this study, a number of susceptibility loci (called quantitative 
trait loci, QTL) were identified indicating the complexity of the genetic factors operating in DSS colitis. So 
far, the nature of the underlying genes remains unknown. 
Other models of inflammation that were analyzed in this fashion are two gene-knockout models; colitis in 
IL-10 deficient mice, and in G-protein Giα2 deficient mice. The IL-10-/- F2 progeny was analyzed as 
indicated above and yielded a remarkably strong association with a region on chromosome 3, called 
Cdcs1 22. Surprisingly, the exact same region was identified in the Giα2 deficient model 23. This indicates 
that even a severe primary genetic defect (either IL-10 or Giα2) may depend on the presence of a 
secondary factor (encoded by one or more genes within the locus on chromosome 3). It is likely that the 
latter gene(s) is of major importance in maintaining the balance in the mucosal immune response, and that 
this balance is disrupted when a key homeostatic gene is inactivated. Exactly what gene(s) is responsible 
for the disease susceptibility associated with this QTL remains to be established. 
Yet another model that has been studied and one that has so far yielded the most information, is the TNBS 
colitis model. This colitis in SJL/J mice is a Th1 type inflammation and is completely prevented or reversed 
by treatment with anti-IL-12. In the genetic study performed, comparing susceptible SJL/J mice and 
resistant C57BL/6 mice, two QTLs were identified 24. Interestingly, the first QTL, on chromosome 9 has 
also been found in a preliminary study of the SAMP1/YitFc mice described previously 25. The occurrence 
of this locus in two very different models, one of which spontaneously mimics a form of human IBD, 
suggests that this locus bears further examination. 
The second QTL, on chromosome 11, is particularly of interest because it is syntenic to human 
chromosome 5q33-34 that has been linked to human Crohn’s disease 3, and is associated with 
susceptibility to other Th1-mediated disease models, i.e., experimental allergic encephalitis (Eae6) and 
experimental insulin-dependent diabetes (Iddm18) 42, 43. Peak linkage in this QTL was found near the gene 
encoding the IL-12 p40 subunit, (Il12b, NM_008352). This gene makes a logic candidate gene, since CD 
is characterized by elevated IL-12 production, and anti-IL-12 therapy proved very effective, both in mice 
and in humans 44. Indeed, we found that Il12b is polymorphic between SJL/J and C57BL/6 24. Taken 
together, these data strongly suggest that the high IL-12 responses and susceptibility to TNBS colitis are 
related, and the polymorphism in Il12b is the most likely genetic abnormality causing TNBS colitis. 
Whether a similar polymorphism exists in human CD remains to be seen 45. 
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Table 2 Advantages of genetic research in animal models and humans 
 Animal models Human 
Genetic 
composition 
+ Inbred population, greatly reduced 
complexity 
- Outbred population 
Environment + constant control of environment and diet, 
the same for all animals 
- multiple  factors in environment,  diet and 
life-style, differing from patient to patient 
Systematical 
analysis 
+ Possibility to generate genetically 
engineered models varying in only one 
specific gene, without variations in 
environmental factors 
- lack of possibility to look at one factor at a 
time  
Numbers + Relatively simple generation of large 
sample sizes 
- limited numbers of patient available for 
research 
   
Genetical 
engineering 
+ Offers possibility to analyse role of specific 
gene, making use of congenic, transgenic 
or knock-out mice 
- legally and ethically not possible 
Summary of advantages of genetic research in animal models compared to human studies 
 
Concluding remarks 
The study on the causes of IBD, both in animal models as well as in humans, have revealed important 
new insights in the immunological processes and genetic abnormalities leading to mucosal 
inflammation. These findings have already, and will further lead to new therapeutic approaches aimed 
at interfering with these processes. The most notable example includes different strategies to block 
key inflammatory cytokines such as TNF-α, which has already proven to be a highly effective 
treatment in CD, achieving positive effects in some 60% of patients. Similar effects have recently 
been shown for anti-IL-12 therapy in CD, and the list of therapeutic targets is rapidly growing. 
A next step will be to tailor therapeutic regimens to the individual patients, i.e., based on correcting 
the immunological abnormality or genetic defect operative in a particular patient. The feasibility of this 
possibility is quite obvious with respect to the NOD2 mutation since in this case the lesion is most 
likely to involve an hematopoietic cell that can be substituted with normal genes. 
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Abstract 
Background & Aims: Mice with a disrupted gene for the G-protein alpha inhibitory 2 chain (Gnai2-/-) 
develop a spontaneous colitis resembling human inflammatory bowel disease (IBD). Disease 
expression differs markedly between inbred strains of mice, indicating genetic control of disease 
susceptibility. We performed a genome-wide screen to localize the chromosomal regions regulating 
disease expression. Methods: 284 F2 mice derived from resistant C57BL/6J Gnai2-/- mice and 
susceptible C3H/HeN Gnai2-/- mice were analyzed in a genome-wide screen for colitis susceptibility 
and severity. Results: A highly significant locus on chromosome 3 (Gpdc1) contributed to colitis 
susceptibility and severity (Likelihood ratio statistics (LRS) = 32.4; LOD score = 7, P < 1.0 x 10-5). The 
peak linkage of this locus at 62 cM co-localizes exactly with a previously identified locus controlling 
colitis susceptibility in IL-10 deficient mice. In addition, evidence for linkage with a locus on 
chromosome 1 (Gpdc2; LRS = 19.7; LOD = 4.3) was found, and the two loci interacted epistatically 
(combined LRS = 68.2). A third locus (Gpdc3) was found on chromosome 9 and this locus interacted 
epistatically with a locus on chromosome 7 which by itself did not have an effect on the trait. 
Conclusion: The identification of a major locus on chromosome 3 that controls susceptibility to 
spontaneous colitis in two different gene-knockout models indicates that this locus harbors a gene(s) 
that plays a key role in maintaining mucosal homeostasis. Identification of this gene(s) may contribute 
to the further understanding of the mechanisms underlying human IBD. 
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Introduction 
While the exact etiology of the two major forms of inflammatory bowel disease, Crohn’s disease (CD) 
and ulcerative colitis (UC) is still unclear, there is a growing agreement that they occur as the 
consequence of a genetically determined dysregulated immune response to one or more antigens 
from the mucosal microflora 1. 
That this abnormality has strong genetic underpinnings has long been recognized and in recent years 
a number of IBD susceptibility loci have been established by linkage studies 2. Moreover, the 
susceptibility conferred by one of these loci, (IBD1) has been shown to be due to mutations in the 
NOD2 (CARD15) gene, which when present on both chromosomes, causes CD in 8-17% of 
Caucasian CD patients 3, 4. It is now known that NOD2 is an intracellular sensor of a component of 
bacterial peptidoglycan (muramyl dipeptide) that regulates NF-κB activation 5; nevertheless, it is not 
yet known how this abnormality leads to CD and/or a dysregulated immune response. In addition, the 
fact that NOD2 mutations occurs in only a minority of CD patients underscores the fact that it 
accounts for only small part of the genetic factors underlying CD as a whole and suggests that the 
mucosal immune dysregulation causing this disease can have many causes. 
An important step forward in the understanding of IBD has come from the identification of animal 
models of mucosal inflammation that more or less resemble human IBD 6. One of the key findings to 
emerge from the study of these models is that susceptibility to colitis in most, if not all, of the 
experimental models is influenced by the strain of the mouse in which the model is expressed. These 
strain differences in disease susceptibility offer the opportunity to identify genes that are involved in 
determining susceptibility/resistance to mucosal inflammation and as such may contribute to the 
identification of the genes involved in human IBD. 
One mouse model that displays such strain differences in susceptibility is the spontaneous colitis 
model occurring in mice deficient in the G-protein alpha inhibitory chain 2 (Gαi2) 7-10. Such mice most 
likely develop mucosal inflammation because signaling through Gαi2 normally inhibits IL-12 
production and thus in the absence of this molecule, IL-12 production and the Th1 response is greatly 
exaggerated. The strain-specific variation in inflammation observed in this model is exemplified by the 
fact that the C3H/HeN strain is highly susceptible to disease, whereas the C57BL/6J strain maintained 
under identical circumstances, is highly resistant. As implied above, this introduces the possibility that 
a genetic analysis of these strains of Gnai2-/- mice might lead to the identification of modifying genes 
critical to the expression of colitis in these mice. 
On this basis, we performed such a genetic analysis of Gnai2-/- mice using genome-wide microsatellite 
methodology to identify genetic susceptibility loci in Gnai2-/- (C3H/HeNxC57BL/6J) F2 generation 
intercrosses. This genetic screening procedure allowed identification of a highly significant 
susceptibility locus on chromosome (Chr.) 3 as well as additional loci on Chr. 1, 9 and the X-
chromosome. The importance of the Chr. 3 locus is emphasized by the fact that this locus also is 
likely to be involved in the strain variation in disease susceptibility found in IL-10 KO mice 11. 
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Materials and Methods 
Mice 
Specific pathogen-free, 5–6-week-old C3H/HeN mice were obtained from The Jackson Laboratory 
(Bar Harbor, ME). Gαi2 knock-out mice on the C57BL/6J background were bred from homozygous 
C57BL/6J breeding pairs as described before 10 12, and were originally a kind gift of Baylor University 
School of Medicine. The Gnai2 deficiency was backcrossed from the C57BL/6J background onto the 
C3H/HeN strain for >6 generations. Since Gnai2 deficiency causes severe inflammation in C3H/HeN 
mice, causing early death and loss of desire to breed, these mice were maintained in the 
heterozygous state (Gnai2+/-). 
(C57BL/6JxC3H/HeN) Gnai2-/- F1 hybrids were derived from the reciprocal mating of C57BL/6J Gnai2-/- 
mice with C3H/HeN Gnai2+/- mice, and subsequent genotypic selection for the Gnai2-/- deficiency. 
These mice were used to generate a first group of 147 F2 mice by brother-sister mating of F1 Gnai2-/- 
mice and this group of mice was analyzed using a genome-wide screen. Meanwhile, an additional 
group of 137 F2 mice was generated making a total of 284 F2 mice (146 female and 138 male). 
Mice were maintained in the National Institute of Allergy and Infectious Diseases animal holding 
facilities and all breeding pairs were set up randomly. Animal use adhered to National Institutes of 
Health Laboratory Animal Care Guidelines. 
 
Clinical Evaluation and Definition of Disease 
Susceptibility to and severity of colitis in F2 mice was determined by weekly monitoring of clinical 
signs of colitis, diarrhea and weight loss. Mice were sacrificed when they showed profound weight 
loss and/or signs of colitis. Mice that showed no signs of disease and no weight loss at the age of 5 
months were considered resistant to colitis and sacrificed as well. Blood was drawn from all mice for 
serological studies and colons were removed for histopathological analysis. 
 
Histologic Assessment of Tissues 
Colonic tissue specimens were obtained from all euthanized mice, and fixed in 10% buffered formalin 
phosphate (Sigma-Aldrich, Zwijndrecht, The Netherlands). The specimens were embedded in 
paraffin, cut into sections, and stained with H&E. The degree of inflammation on microscopic 
horizontal sections of the entire colon was graded semiquantitatively from 0 to 4 as described 
previously 13, in short: 0, no evidence of inflammation; 1, low level of lymphocyte infiltration with 
infiltration seen in 10% high power fields and no structural changes observed; 2, moderate 
lymphocyte infiltration with infiltration seen in 10%–25% high-power fields, crypt elongation, bowel 
wall thickening that does not extend beyond the mucosal layer, and no evidence of ulceration; 3, high 
level of lymphocyte infiltration with infiltration seen in 25%–50% high-power fields, high vascular 
density, and thickening of the bowel wall that extends beyond the mucosal layer; 4, marked degree of 
lymphocyte infiltration with infiltration seen in 50% high-power fields, high vascular density, crypt 
elongation with distortion, and transmural bowel wall thickening with ulceration. 
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Definition of Groups 
To define a semi-quantitative and gradual division of the disease expression in F2 mice, we created a 
total score of disease severity, combining the percentage of weight loss, the age of sacrifice and the 
histological score by assigning a score from zero to four for each grade of the corresponding trait 
(Table 1). If mice were found dead (due to rapid disease progression), an extra point was added to 
the total score. Theoretically, this would result in a maximum score of 13. Animals were considered 
resistant when they had a total disease score of 3 or less, implicating they displayed no or only 
minimal clinical or histological signs of disease upon sacrifice aged 20 weeks or older, whereas mice 
with a total score of 4 or higher were considered susceptible. We had previously established that mice 
that had not developed any signs of disease by the age of 20 weeks, would not do so if they were 
followed for a longer period of time (up to 1 year; data not shown). Therefore, mice that did not 
develop any signs of disease were sacrificed at the age of 20 weeks 
In part of the analysis, the phenotypic extremes were analyzed. These included on the one hand most 
resistant mice with a disease score of 0 to 2, and on the other hand most susceptible mice with a 
score of 8 or higher. 
 
Table 1. Definition of Disease Severity in Gnai2 Deficient F2 Mice 
Score Histology % Weight loss Age of death (wks) 
0 0 0 – 4 26+ 
1 1 5 – 9 20 – 25 
2 2 10 - 19 15 – 19 
3 3 20 - 29 10 – 14 
4 4 30+ 0 - 9 
 
Total score of colitis was determined by the sum of the score for each  
trait (histology, weight loss, age of death) and adding an extra point if an 
animal was found dead. 
 
 
Genotyping 
Spleens were taken from all mice and frozen at -70°C. DNA was isolated using a commercial kit as 
described by the manufacturer (Gentra Systems, Biozym, Landgraaf, The Netherlands). Primers for 
microsatellite markers that differ at least 6 base pairs in size between susceptible C3H/HeN mice and 
resistant C57BL/6J mice were selected from online available databases 
(CIDR; http://www.cidr.jhmi.edu/mouse/mouse.html) and The Jackson Laboratory 
(http://www.informatics.jax.org/) and purchased from Invitrogen Life Technologies (Breda, The 
Netherlands). A total of 134 microsatellite markers equally dispersed along the mouse autosomes and 
the X-chromosome were selected for genotypic analysis. Using these markers, a genetic map was 
generated with an average locus distances of 12 cM, with the largest distance (28 cM) on proximal 
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Chr. 2 between markers D2Mit1 and D2Mit242. The markers used in this study will be published 
online (http://www.immunogenetics.nl). 
To evaluate which markers cosegregate with disease phenotype, a first group of 147 mice were 
selected for a genome-wide screen: 56 resistant F2 mice (30 females and 26 males) with a disease 
score of 3 or less and 91 F2 susceptible mice (47 females and 44 males) with a disease score of 4 or 
higher. From this group, 76 mice were selected with the most distinct phenotypes (47 resistant, 29 
with severe colitis). Genetic regions that showed suggestive or significant linkage, either from the 
group with the extreme phenotypes or the total first group, were then further investigated by 
genotyping the remainder of the eligible mice. 
Polymerase chain reaction (PCR) amplification was performed in GeneAmp PCR System 9600 and 
GeneAmp PCR System 9700 (both PE Applied Biosystems, Nieuwekerk aan de Ijssel, The 
Netherlands) in 96-well plates in 10µL volumes using a protocol provided by the manufacturer 
(Research Genetics, Invitrogen). Thirty cycles of 94°C for 45 seconds, 55°C for 45 seconds, and 72°C 
for 60 seconds followed by an extension period at 72°C for 7 minutes were generally used, although 
some primers required a slightly different annealing temperature for optimum amplification. After PCR 
amplification, PCR products were run on 4% agarose gels (in a mixture of 2% ultra pure agarose 
(NuSieveGTGAgarose; Cambrex Bio Science Rockland, Rockland ME, USA), and 2% low melting 
(Invitrogen)) and visualized by ethidium bromide (Invitrogen) staining. 
 
Statistical Analysis 
The MapManager software package was used to construct linkage maps with microsatellite markers 
that experimentally showed polymorphism between the C3H/HeN and C57BL/6J strain 
(http://mapmgr.roswellpark.org/mmQTX.html). Likelihood ratio statistics (LRS) values for colitis 
severity were calculated with MapManager QTXb18 version 0.27 in populations of females and males, 
females alone and males alone. Logarithm of the odds (LOD) scores were determined by LRS/2ln10. 
Empirical thresholds for suggestive and significant linkage were determined by permutation analysis 
using the MapManager software package with 1000 permutations. Gene-gene interactions between 
the different genetic loci were identified using the same statistical program. 
For nonparametric linkage analysis of resistant and susceptible mice, χ2 analysis was performed 
using GraphPad InStat version 3.05 for Windows 95 (GraphPad Software, San Diego, CA; 
http://www.graphpad.com). A χ2 test statistic for each marker locus was derived using 2x3 
contingency tables to test for linkage. 
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Results 
Distribution of colitis susceptibility in parental strains and their offspring 
Parental strains 
We generated homozygous C3H/HeN Gnai2-deficient mice by crossing C57BL/6J Gnai2-deficient 
mice with C3H/HeN mice, backcrossing F1 mice carrying the gene defect to C3H/HeN mice for >6 
generations and then intercrossing to obtain homozygous mice. Such homozygous Gnai2 deficient 
(Gnai2-/-) C3H/HeN mice, when reared under specific-pathogen-free conditions, were highly 
susceptible to colitis (Fig. 1). 
 
Figure 1. Distribution of Colitis Scores in Different Groups of Mice As previously described, 
colitis in C3H/HeN Gnai2-/- 
mice is characterized by 
severe diarrhea and weight 
loss, frequently accompanied 
by rectal prolapse and 
dilation of the colon 10. In 
general, only the distal half of 
the colon is involved, with a 
sharp demarcation between 
the involved and non-involved 
areas. 
Microscopically, massive  
One illustrative experiment out of several, each including 10 mice   infiltrations of lymphocytic  
per group are shown. Each dot represents a single mouse.   cells are seen, accompanied 
 by depletion of goblet cells, 
crypt elongation, high vascular density and transmural bowel wall thickening with ulceration (Fig. 2). 
C3H/HeN Gnai2-/- mice display a greatly reduced survival rate and in general breed poorly, probably 
because most mice develop disease before the reproductive age. Colitis develops in these mice as 
early as week 6 and even before full onset of gastrointestinal disease, the animals exhibit decreased 
body weight as compared to their wildtype littermates (data not shown). Therefore, for breeding 
purposes, the C3H/HeN mice were maintained in a heterozygous state for the Gnai2 deficiency 
(Gnai2+/-). Based on genotyping the offspring of Gnai2+/- x Gnai2+/- mice, the frequency of 
homozygous Gnai2 deficient mice was markedly below the expected 25%, indicating intrauterine 
death in a significant number of Gnai2-/- mice (results not shown). Interestingly, heterozygous Gnai2 
C3H/HeN deficient mice did not develop any signs of disease, indicating that colitis only occurs if no 
functional Gnai2 is present (Fig. 1). 
Whereas C3H/HeN Gnai2-/- mice are highly susceptible to colitis, C57BL/6J Gnai2-/- mice are highly 
resistant and disease did not occur in these mice even when the latter were followed for as long as 6 
months (Fig. 1), and in addition, upon necropsy, colons of these mice were normal, both 
macroscopically and microscopically (Figure 2c, d). 
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F1 generation 
The F1 generation was generated by crossing C3H/HeN Gnai2+/- mice with C57BL/6J Gnai2-/- mice. As 
expected, 50% of the offspring was homozygous for the Gnai2 deficiency, and these mice were used for 
further analysis and breeding purposes. The Gnai2-/- F1 offspring was relatively resistant to colitis. Thus, in 
general, these animals did not develop weight loss, diarrhea or macroscopic signs of colitis, although 
occasionally some histological abnormalities were found (Fig. 2e). 
 
F2 generation 
A total of 284 F2 mice (138 males; 146 females) was generated by interbreeding the Gnai2-/- F1 generation. 
As can be seen from Figures 2 and 3, the F2 population displayed a broad spectrum of disease, varying from 
highly resistant with no clinical and histological signs of illness, to highly susceptible, with severe colitis. The 
severity of colitis was determined using a semi-quantitative classification as described in detail in Materials 
and Methods. However, as can also be seen from Figure 3, the trait followed an essentially bimodal 
distribution. Thus, in part of the analysis, the trait was analyzed as a qualitative trait: mice with a disease 
score of 3 or less (n = 145; 79 males, 66 females) were considered resistant to colitis since they did not 
exhibit any clinical signs of disease, and, in addition, displayed no or only minimal weight loss and histological 
abnormalities (Table 1). In contrast, a total of 139 mice (59 males, 80 females) displayed clinical signs of 
disease accompanied by significant weight loss and histological disease (i.e., a disease score of 4 or higher) 
and were considered susceptible. Overall, females were somewhat more susceptible to colitis than males. 
This was reflected in the mean colitis score, which was higher in females than in males (4.9 vs. 4.2; P < 0.05). 
Occasionally, histological signs indicative of colon carcinoma were found in F2 mice. This occurred 
exclusively in mice with severe inflammation. However, there was no clear correlation between occurrence of 
carcinonoma and the duration of the disease, since, in some instances, neoplastic lesions were found in mice 
as young as 9 weeks. 
 
Figure 3 Distribution of Colitis in Gnai2 Deficient F2 Mice 
 
Distribution of colitis in F2 mice. Dotted line indicates cut-off for resistant/susceptible mice. The colitis severity 
follows a bimodal distribution. Also, females are more severely affected as male mice. 
 
Figure 2. Microscopic Views of Normal and Diseased Colons 
Representative H&E stained longitudinal sections (x100) of colons of: a: Wild-type C3H/HeN; b: GNAI2-/- 
C3H/HeN; c: Wild-type C57BL/6J; d: GNAI2-/- C57BL/6J; e: GNAI2-/- C3H/HeNxC57BL/6J F1; f-j: GNAI2-/- F2 
mice, with increasing histological scores 
total colitis score 
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Strategies for Analysis and Distribution of Traits 
In order to identify the genetic regions determining the differences in susceptibility between 
susceptible C3H/HeN and resistant C57BL/6J mice, we genotyped the initial group of 147 F2 mice of 
our cohort with a panel of 134 microsatellite markers equally dispersed among the genome. 
We first analyzed disease in the F2 population as a qualitative (binary) trait, i.e. susceptible versus 
resistant mice. Among the 147 mice, 56 (30 females; 26 males) were relatively resistant, with a 
disease score of 3 or less, whereas 91 (47 females; 44 males) were susceptible (with a disease score 
of 4 or higher). Contrasting genotype and allele frequencies of these groups led to the identification of 
4 chromosomal regions that exhibited an association suggestive for linkage (P < 1.6x10-3 or stronger) 14. 
These loci reside on Chrs. 1, 3, 13 and the X-chromosome. 
Subsequently, the subgroup of mice with the most extreme phenotypes were analyzed. This analysis 
has the advantage that the phenotypes of these groups are clearly distinct and non-overlapping, and 
the disadvantage of lower statistical power due to the lower sample number. Contrasting mice with a 
disease score of 2 or less with mice with a disease score of 8 or higher resulted in essentially the 
same associations. In addition, this analysis allowed identification of an association with a locus on 
Chr. 9, which was not found in the entire group of mice. 
Finally, disease was considered as a quantitative trait in which the genes contribute to the trait in a 
continuous fashion rather than in a discrete way. This was accomplished by a total disease score 
which takes into account histological score, weight loss and age of sacrifice (Table 1). Due to the 
semi-quantitative nature of our phenotypes we established an empirical genome-wide significance 
level for our dataset by performing a permutation analysis. The observed genotypes of the F2 animals 
were kept constant while the phenotypes were randomly shuffled over the genotype data, thereby 
efficiently disrupting any genotype–phenotype correlation. Linkage analysis was performed and the 
strongest association (expressed as the likelihood ratio statistics-LRS) in each experiment was 
recorded. This procedure was repeated 1000 times and through this method the LRS threshold for 
95% significance was calculated to be 16.5. Suggestive linkage was calculated to be found above a 
threshold LRS value of 10.0. 
All chromosomes with regions identified with the above strategies that showed at least suggestive 
linkage were genotyped in the entire cohort of 284 F2 mice, to confirm or discard the linkage. 
 
Identification of major susceptibility locus on chromosome 3 
Analysis of the entire F2 population as a qualitative trait confirmed the presence of a region on the 
distal part of Chr. 3 that is strongly associated with colitis susceptibility. As can be seen from Table 2, 
the strongest association was found with microsatellite markers D3Mit316 at 59 cM (χ2 = 29.7; P < 
1.0x10-5) and D3Mit348 at 61 cM, (χ2 = 29.6; P < 1.0x10-5). Analysis of phenotypic extremes led to a 
similarly significant association with these markers (χ2 = 32; P < 1.0x10-5, data not shown). When 
mice were subdivided according to sex, the same significant associations were found in both males 
and females. 
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Table 2. Distribution of Genotypes Surrounding the Locus on Chromosome 3 Regulating 
Susceptibility to Colitis in Gnai2 Deficient F2 Mice 
Marker Position (cM) Genotype Resistant (n) Susceptible (n) P value χ2 
D3Mit307 22 BB 44 32 2.5x10-3 11.9 
  BC 60 77   
  CC 21 50   
       
D3Mit137 35 BB 41 34 1.0x10-4 18.1 
  BC 65 65   
  CC 19 60   
       
D3Mit310 38 BB 40 34 <1.0x10-5 21.7 
  BC 68 64   
  CC 17 61   
       
D3Mit189 49 BB 43 30 <1.0x10-5 24.3 
  BC 65 67   
  CC 17 62   
       
D3Mit78 55 BB 42 32 <1.0x10-5 24.8 
  BC 67 65   
  CC 16 62   
       
D3Mit316 59 BB 39 33 <1.0x10-5 29.7 
  BC 72 62   
  CC 14 64   
       
D3Mit348 61.2 BB 42 37 <1.0x10-5 29.6 
  BC 69 58   
  CC 14 64   
       
D3Mit147 79.4 BB 39 38 5.0x10-4 15.2 
  BC 68 64   
  CC 18 57   
       
D3Mit19 87.6 BB 39 37 0.02 8.0 
  BC 64 71   
  CC 22 51   
 
Microsatellite analysis of chromosome 3. Numbers of different genotypes were compared between susceptible 
and resistant mice in a contingency table using the χ2 test for independence. Markers at peak association are 
indicated in Bold. cM, centi Morgan; n, number of mice; BB indicates homozygous for the C57BL/6J strain; BC 
indicates heterozygous; CC indicates homozygous for the C3H/HeN strain. 
 
 
We then analyzed the F2 population as a quantitative trait. As shown in Figure 5, this analysis confirmed 
the highly significant association with this region. The strongest association was again with the 
chromosomal region surrounding D3Mit348 at 61 cM. A peak LRS of 32.4, corresponding to a LOD 
score of 7 was found for this locus. The strength of the association markedly exceeded the threshold for 
significant linkage (LRS = 16.5) that was determined empirically by permutation analysis. We have 
provisionally designated this QTL Gpdc1, for G protein deficiency-induced colitis. 
To study the mode of inheritance of this locus, we stratified mice according to their genotype at position 
D3Mit348, and determined the severity of colitis in these groups. As can be seen from Figure 4, F2 mice 
that were homozygous for the C75BL/6 allele at this position had a mean (± SEM) colitis score of 4.01 (± 
0.31) and this was not significantly different from mice heterozygous for the C57BL/6J allele at this 
position, who had a mean score of 4.16 (± 0.27). This was in sharp contrast with the colitis score in mice 
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homozygous for the C3H/HeN allele at this position 6.40 (± 0.32; P < 0.001). These findings are 
consistent with the view that two copies of the C3H allele at this position are required to develop colitis, 
and help to explain the resistance in the F1 population of mice. 
 
Figure 4. Quantitative Trait Analysis of Chromosomes 1, 3, and 9 
 
 
 
 
 
Genetic linkage analysis: other QTLs 
Since the association with the region on Chr. 3 was remarkably strong, this locus might theoretically 
overshadow associations with other genetic loci that otherwise might have an important effect on the 
trait. We therefore performed sequential regression analyses in which we stratified for marker 
D3Mit348. This analysis continued to show evidence suggestive of linkage to colitis susceptibility on 
Chrs. 1, 9, and X identified in the initial screen. (Table 3), but did not reveal additional loci. The locus 
on Chr. 13 that was previously mentioned to be a locus of suggestive linkage in the first group did not 
retain any association in the total group of mice, and was thus discarded as being a locus of interest. 
 
Chromosome 1 
A locus on Chr. 1, denoted by D1Mit215 at 47 cM showed suggestive linkage to disease susceptibility 
in the first group of 147 mice. As can be seen in Table 4, analysis of the entire group of 284 mice as a 
On Chr. 1, after stratification by 
Gpdc1, a broad peak is found, 
spanning a region of approximately 
30 cM, from 39 cM to 70 cM 
(Gpdc2). The peak has a LRS of 
19.7. On Chr. 3, a very broad 
region shows linkage to colitis 
susceptibility, with the 95% 
confidence interval of 22 cM around 
the peak marker D3Mit348, which 
had a LRS of 32,4 (Gpdc1). After 
stratification by Gpdc1, on Chr. 9 a 
peak at 42 cM with marker 
D9Mit123 just reaches the 
significance cut-off LRS of 16.5 
(Gpdc3). All susceptibility loci are 
C3H/HeN-derived 
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qualitative trait confirmed this finding, but did not markedly increase the strength of the association  
(P = 1.5x10-3; χ2 = 13.0). 
QTL analysis essentially confirmed the qualitative trait data, revealing a broad peak of approximately 
30 cM surrounding the marker D1Mit308 (Fig. 4), with a maximum LRS of 19.7 (17.8 without 
stratification for D3M348) which corresponds with a LOD score of 4.3. According to the results 
obtained in the permutation test, this LRS value exceeds the threshold for significance in a genome-
wide screen, and we have therefore provisionally designated this locus Gpdc2. 
Similar to Gpdc1, only mice that were homozygous for the C3H/HeN allele showed a significant rise in 
colitis score, as can be seen in Figure 5. Mice that were homozygous for the C57BL/6J allele and 
mice that were heterozygous at this locus had a mean (± SEM) colitis score of 4.34 (± 0.36) and 4.31 
(± 0.27) respectively, whereas mice that were homozygous for the C3H/HeN allele had a mean score 
of 5.77 (± 0.33; P < 0.01), indicating that this locus also acts in a recessive manner. 
 
Chromosome 9 
An association suggestive of linkage with Chr. 9 was found in the phenotypic extremes in the first 
group of mice. Although analysis of the entire group of mice as a qualitative trait did not confirm this 
finding, a significant deviation from the normal genotype distribution was found in the phenotypic 
extremes of the entire group (P = 8.0x10-4). QTL analysis of the entire group of mice revealed 
suggestive linkage with marker D9Mit123 at 42 cM, with a LRS of 14.2. After controlling for D3Mit348, 
the LRS increased to 16.5, and thus reached borderline genome-wide significance (Fig. 4; Table 3). 
We have provisionally named this C3H/HeN-derived locus Gpdc3. 
 
 
Table 3. Single-Point QTL Analysis for Colitis Susceptibility in Gnai2 Deficient F2 Mice 
Locus LRS  Locus LRS 
Primary linkage analysis  Stratified by D3Mit348 
D1Mit380 11.5  D1Mit380 11.2 
D1Mit215 12.8  D1Mit215 10.6 
D1Mit308 17.8  D1Mit308 19.7 
D1Mit102 9.7  D1Mit102 9.4 
     
D3Mit137 18.4  D3Mit137 - 
D3Mit310 20.4  D3Mit310 - 
D3Mit189 24.1  D3Mit189 - 
D3Mit78 26.0  D3Mit78 7.9 
D3Mit316 30.0  D3Mit316 8.2 
D3Mit348 32.4  D3Mit348 Not informative 
D3Mit147 10.1  D3Mit147 7.8 
     
D9Mit336 7.4  D9Mit336 9.6 
D9Mit123 14.2  D9Mit123 16.5 
D9Mit355 5.3  D9Mit355 6.8 
     
DXMit223 12.9  DXMit223 14.4 
 
Likelihood Ratio Statistics (LRS) were calculated using marker regression analysis after control for the major QTL 
on Chr. 3 (right columns) or without control for this QTL (left columns). Suggestive Linkage: LRS > 10.0 (italic); 
Significant Linkage: LRS > 16.5 (bold). All susceptibility loci are C3H/HeN-derived. 
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Table 4. Distribution of Genotypes Surrounding the Locus on Chromosome 1 Regulating 
Susceptibility to Colitis in Gnai2 Deficient F2 Mice 
Marker Position (cM) Genotype Resistant (n) Susceptible (n) P value χ2 
D1Mit64 5 BB 15 25 0.86 0.3 
  BC 25 52   
  CC 10 20   
       
D1Mit430 10 BB 15 22 0.58 1.1 
  BC 24 54   
  CC 11 21   
       
D1Mit236 25.7 BB 12 25 0.24 2.8 
  BC 29 43   
  CC 9 28   
       
D1Mit380 36.9 BB 32 35 0.074 5.2 
  BC 68 73   
  CC 25 51   
       
D1Mit215 47 BB 34 37 1.5x10-3 13.0 
  BC 68 62   
  CC 23 60   
       
D1Mit308 62.1 BB 37 33 0.018 8.0 
  BC 63 71   
  CC 25 55   
       
D1Mit102 73 BB 37 29 0.074 5.2 
  BC 63 90   
  CC 25 40   
       
D1Mit206 95.8 BB 17 24 0.48 1.5 
  BC 20 46   
  CC 13 27   
       
D1Mit155 112 BB 14 26 0.79 0.5 
  BC 22 48   
  CC 14 23   
 
Microsatellite analysis of chromosome 1. Numbers of different genotypes were compared between the 
susceptible and resistant mice in a contingency table using the χ2 test for independence. Markers at peak 
association are indicated in Bold. cM, centi Morgan; n, number of mice; BB indicates homozygous for the 
C57BL/6J strain; BC indicates heterozygous; CC indicates homozygous for the C3H/HeN strain 
 
 
X-Chromosome 
Since male mice are hemizygous for the X-chromosome, we performed nonparametric analysis for 
the allele rather than the genotype frequencies in the qualitative trait analysis (Table 5). This resulted 
in a P value suggestive of linkage (P = 3.0 x 10-3) in the total group of mice for marker DXMit223 
located distally (at 73.3 cM) on the X-chromosome. Separate analysis of male and female mice 
revealed a stronger association of this locus in female mice than in male mice, although the 
association in female mice was weaker than in the group as a whole, probably because of the lower 
statistical power arising from the smaller size of the female subgroup. After stratification for D3Mit348, 
QTL analysis again revealed a statistical association suggestive of linkage for the total group of mice, 
with a LRS of 14.1 (Table 3). Again, this susceptibility locus was derived from the C3H/HeN strain. 
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Figure 5. Distribution of Colitis Score for Different Genotypes at D3Mit348 and D1Mit308 in Gnai2 
Deficient F2 Mice  
 
A significant difference between the C57BL/6J homozygous and C3H/HeN homozygous groups of mice for 
markers D3Mit348 and D1Mit308 was found. BB indicates homozygous for the C57BL/6J strain; BC indicates 
heterozygous; CC indicates homozygous for the C3H/HeN strain 
 
 
Epistatic and additive interactions with the identified locus on chromosome 3 
Separately, the QTLs on Chr. 1 and 3, and to a lesser extent the loci on Chr. 9 and X contributed 
significant main effects to both the qualitative and quantitative disease trait. The MapManager 
software package was then used to asses epistatic and additive interactions between Gpdc1 and 
other chromosomal regions. Only mice that are genotyped for their complete genome are informative 
for identification of interactions between chromosomal regions; therefore, in this analysis, we used the 
data from the initially screened 147 mice. 
When marker alleles for Gpdc1 were paired with those of Gpdc2, a strong interaction was observed 
between the two loci. Thus, the combined LRS for both loci was higher than the sum of the LRS of 
both QTLs individually (Table 6; combined LRS = 68.2). In addition, a C3H/HeN derived locus on Chr. 7 
which did not have an effect on the trait individually (LRS = 4.4), showed significant epistatic effects 
when paired with Gpdc3 (Table 6). 
 
 
Table 5. Allele Frequencies on the X-Chromosome in Gnai2 Deficient F2 Mice 
Marker Position (cM) Allele Resistant (n) Susceptible (n) P value χ2 
DXMit68 17.2 B 84(43) 99 (77) 0.06 (0.27) 3.5 (1.1) 
  C 90(59) 154 (121)   
       
DXMit64 45 B 82 (43) 100 (66) 0.1 (0.2) 2.4 (1.4) 
  C 92 (59) 153 (122)   
       
DXMit223 73.3 B 91 (49) 88 (55) 3.0x10-4 13.0 
  C 83 (53) 165 (133) (1.4x10-3) (10.1) 
 
Microsatellite analysis of the X-chromosome. Allele frequencies were compared between susceptible and 
resistant mice in a contingency table using the χ2 test for independence. Markers at peak association are 
indicated in bold. Numbers between brackets represent female mice. cM, centi Morgan; n, number of alleles; B 
indicates C57BL/6J alleles; C indicates C3H/HeN alleles 
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Table 6. Summmary of Epistatic Effects 
Locus A Position 
(cM) 
Individual Effect 
(LRS) 
Locus B Position 
(cM) 
Individual Effect 
(LRS) 
Combined 
Effect (LRS) 
Chr. 3 
 Gpdc1 
62.1 32.4 Chr. 1 
 Gpdc2  
61.2 17.8 68.2 
Chr. 7 
(D7Mit350) 
41 4.4 Chr. 9 
 Gpdc3 
42 14.2 37.8 
 
Interactions between individual markers were calculated using the MapManager QTX software package. The 
interacting region of Gpdc1 conferred D3Mit316 and D3Mit348, and Gpdc2 conferred D1Mit308 and D1Mit215. 
Only the highly significant results are tabulated (P < 1.0 x 10-5). cM, centi Morgan. All susceptibility regions were 
C3H/HeN-derived. 
 
 
Distribution of C3H/HeN and C57BL/6J Alleles in the F2 Study Population 
The Gnai2 deficiency of C57BL/6J mice was transferred to C3H/HeN mice by serial backcrossing for 
six generations (see Methods); this plus the fact that parental C3H/HeN Gnai2-/- mice exhibited a 
reduced survival rate introduced the possibility that the C3H/HeN Gnai2 KO mice carry some excess 
C57BL/6J DNA that skewed the allele distribution in the F2 generation and thus decreased the 
number of fully informative mice in this generation. 
To determine if this was in fact the case, we first tested the genome-wide allele distribution by 
comparing the found allele distribution with the expected distribution in a 2x2 contingency table. The 
genome-wide distribution of C57BL/6J:C3H/HeN alleles did not differ from the expected 1:1 
distribution. We then examined the allele distribution in individual chromosomes. For chromosomes 2 
and 6, B6 alleles were slightly more expressed, whereas for chromosomes 4, 8, 14 and X C3H alleles 
were slightly more expressed (p ≤ 0.05); however the over-expression of C57BL/6J alleles was 
strongly significant only on chromosome six (p = 0,0006) (data not shown). Thus, the possibility exists 
that Chr. 6 could harbor a susceptibility region that was inaccessible to discovery in this study. 
 
Discussion 
During the last decade, numerous animal models have been identified that have provided key insights 
into the mechanisms underlying both experimental mucosal inflammation and human inflammatory 
bowel disease 6. One of the most important of these insights is that the development of colitis in mice 
with a severe primary immunological defect (such IL-10 deficiency 11) or in mice with colitis induced by a 
haptenating agent (such as trinitrobenzene sulphonic acid (TNBS)-colitis 15) manifest varying levels of 
colitis depending on their genetic background. This indicates that even a severe (genetically 
determined) primary defect may depend on the presence of genetically determined secondary factors to 
produce disease. This is borne out in the present study of colitis development in Gnai2-/- mice wherein 
we show that disease expression is dependent on a secondary factor(s) encoded by one or more genes 
within susceptibility loci on chromosome 3 and other chromosomes. 
A second important insight derived from the animal models is that despite the fact that the cause of 
inflammation differ widely among the various models, they are almost always due to either an 
exaggerated Th1 response characterized by high expression of IL-12 and IFNγ, or, less frequently, by a 
Th2 response mediated by IL-4/IL-13 and that both types of responses are dependent on cell stimulation 
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by antigens in the mucosal microflora 6. In the Gnai2-/- mice studied here the inflammation falls into the 
Th1 category in that the colitis is characterized by a marked increase in Th1-type cytokine production 16. 
In this case the Th1 orientation is best explained by the studies of He et. al., who have shown that 
treatment of normal mice with pertussis toxin (PT), a substance that inhibits Gi protein-signaling, 
enhanced the capacity of splenocytes to produce IL-12 in response to both microbial and non-microbial 
stimuli 12. Thus, the genetically-determined absence of Gi signaling in these mice could result in a 
resetting of the Th1/Th2 “immunostat” in a way that leads to an excess Th1 in response to microbial 
antigens in the gut. This formulation is consonant with our previous study that provided strong 
circumstantial evidence that in the TNBS-colitis model, a strain-specific dysregulation in IL-12 secretion 
is present which results in over-production of IL-12 in response to TLR4 stimulation15. In addition, it is 
consonant with the Th1 colitides occurring in both IL-10 deficient mice and Stat3 deficient mice (the latter 
characterized by an IL-10 signaling abnormality) although in these cases Th1 overproduction is likely 
due to deficient down-regulation of the mucosal Th1 responses elicited by mucosal microflora17, 18. If we 
now combine the concept of a reset immunostat with the fact noted above that in most cases models of 
colitis exhibit marked strain specificity and thus evidence for the existence of secondary genetic factors, 
we can say that the latter is in some manner directly or indirectly influencing the increase Th1 response 
to induce disease. Alternatively, it is creating conditions under which an augmented Th1 response leads 
to colitis. 
As a first step to identify the genetic factors operating in Gnai2-/- mice, we performed a genome-wide 
linkage analysis for colitis susceptibility. We analyzed F2 intercross mice derived form segregating 
crosses between relatively resistant C57BL/6J and susceptible C3H/HeN mice. This allowed the 
identification of several chromosomal loci that are involved in colitis susceptibility and/or severity. The 
locus that most strongly associated with colitis susceptibility, provisionally named Gpdc1, resides on the 
distal end of mouse Chr. 3 and represents the major determinant of colitis susceptibility in this intercross 
population. Remarkably, this locus was previously found to control colitis susceptibility in a different 
model of spontaneous colitis, the IL-10 deficient mouse model 11. By using virtually the same mouse 
stocks (the C57BL/6J strain and in this case the C3H/HeJBir strain (which carries the lps mutation in the 
Toll-like receptor 4 (TLR4), and therefore lacks the capacity to respond to lipopolysaccharide (LPS) 19), 
rather than the C3H/HeN strain, Farmer and coworkers identified a major colitogenic locus (designated 
Cdcs1) at precisely the same position on Chr. 3 as Gpdc1. This finding strongly suggest that this region 
on Chr. 3 harbors a gene that has a strong modulating effect on the exaggerated Th1 responses seen in 
both models, which is independent of the primary genetic abnormality that gave rise to these responses. 
Thus, identification of this gene may provide new fundamental insights in the regulation of pathological 
Th1 mucosal immune responses. 
Whether the modifying gene on Chr. 3 described here and previously in IL-10 KO mice is acting in 
relation to two very different primary abnormalities, operative in each type of mice, or a single 
abnormality operative in both type of mice, is an open question. The first possibility is supported by the 
findings of He et al., already alluded to above which locates the defect in the capacity of dendritic cells in 
Gnai2-/- mice to produce IL-12 and not in the regulation of a normal capacity to produce IL-12, as in 
IL-10 KO mice. Thus, these data suggest that Gnai2-/- mice and IL-10 KO mice have two basically 
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different immunoregulatory abnormalities. The second possibility is favored by data recently reported by 
Dalwadi et. al. who showed that Gnai2-/- mice are characterized by a reduction in marginal zone (MZ), 
transitional type 2 (T2) and B-1a splenic B cells (that have the capacity to produce IL-10) as well as 
decreased in vitro (LPS-induced) B cell IL-10 responses 20. Thus, these data suggest that Gnai2-/- mice 
also have an IL-10 defect and that the modifying gene can be affecting the IL-10 production defect in 
both mouse strains. In view of these somewhat disparate findings it is too soon to decide on whether the 
modifying gene on Chr. 3 is modifying a single abnormality or two separate abnormalities. 
As previously discussed by Farmer et al., there are several genes present in the identified locus on Chr. 
3 that would make attractive candidate secondary disease genes 11. One of these is the gene encoding 
the NF-κB p105 transcription factor (Nfkb1). NF-κB designates a group of critical transcription factors 
controlling various promotors of pro-inflammatory cytokines, cell-surface receptors, transcription factors, 
and adhesion molecules 21. Thus, any mutation affecting the Nfkb1 gene would clearly have major 
implications for a great variety of immunological and/or inflammatory processes. The fact that IL-12 is a 
cytokine that is under transcriptional regulation of NF-κB makes this gene even more of interest, since in 
the Gnai2-/- model, the IL-12 expression is clearly altered/elevated 12. Indirect evidence that this gene 
might be important in IBD comes from a recent study by Karban et. al., who found an elevated 
frequency for the –94delATTG allele in the promotor region of Nfkb1 in UC patients 22, a finding since 
confirmed by studies our own IBD patient group (data not shown). Nevertheless, we did not find a 
polymorphism in the coding region of murine Nfkb1 so that if this gene is a disease gene, the 
abnormality would have to consist of a subtle change in the way it is activated and thus in the way it 
functions under different circumstances. This multifaceted question is currently under investigation. 
The gene encoding epidermal growth factor (the Egf gene) is a second candidate gene of interest 
present in the Chr.3 locus. Since EGF induces epithelial cell proliferation polymorphisms or mutations in 
the Egf gene could conceivably affect the repair mechanisms of the mucosa and thus the susceptibility 
to mucosal injury due to inflammatory processes. Indeed, treatment of UC patients with EGF has proven 
useful in some cases 23. Yet a third candidate in the Chr. 3 locus is the gene encoding guanylate binding 
protein-1 (GBP1), a member of a family of proteins induced by IFN-γ during macrophage induction that 
shares the ability to bind to guanine nucleotides 24. GBP1 is a GTPase that converts GTP to GMP. GBP 
expression is abundant in IFN-exposed cells, but little is known about its function 25. Interestingly, type I 
and II IFNs are capable of inducing the synthesis of GBP1 in some strains of mice, including the colitis 
susceptible C3H/HeN strain, whereas cells of other strains, including C57BL/6J, fail to synthesize GBP1 
in response to both types of IFNs and therefore could comprise an important candidate gene 26. 
While the association of disease in Gnai2-/- mice with Chr. 3 was quite strong, this locus explained only 
part of the phenotypic variance. Thus, it is not surprising that we identified other disease susceptibility 
loci as well. One such locus (designated Gpdc2) was found on Chr. 1 at 47 cM and provided strong 
evidence of interaction with Gpdc1. That is to say that the strength of the association of the two loci 
taken together was markedly higher than the sum of association of the individual loci. This indicates that 
the two loci may act in a combined fashion in determining disease susceptibility. Interestingly, evidence 
for the presence of a disease gene on Chr. 1 associated with the gene on Chr. 3 (Cdcs 1) was also 
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found in IL-10-deficient mice 11. It should be noted however that in this case, peak linkage was more 
proximal and it thus cannot be excluded that the two identified Chr. 1 regions represent different loci. 
A third susceptibility locus, Gpdc3, was identified on Chr. 9 with peak linkage at 42 cM. At this junction it 
is important to note that Gnai2 also resides on Chr. 9. However this gene is located at 59 cM, clearly 
separated from the region of peak linkage, strongly diminishing the possibility that this locus is caused 
by artificial interference in the knock-out backcross protocol. Furthermore, D9Mit355, located at 53 cM, 
right in between Gpdc3 and Gnai2, is polymorphic for C57BL/6J, C3H/HeN and 129/SvJ, the strain on 
which the Gnai2 knock-out model was originally created 10. Using this marker, no residual 129/SvJ DNA 
was found at this position, adding further evidence that Gpdc3 is a true QTL (data not shown), and that it 
is unlikely that this QTL is caused by artificial interference with the Gnai2 congenic segment. Although 
Gpdc3 had only borderline significance for linkage with disease, it is of interest because it’s location 
corresponds to a locus we previously identified in the TNBS-colitis mouse model, Tnbs1 15. In addition, a 
similar locus (designated Ibdq1) has recently been found by Kozaiwa et al., in SAMP1/YitFc mice who 
spontaneously develop an ileitis similar to that in human Crohn’s disease 27. Finally, in the DSS model of 
induced colitis, evidence for the involvement of Chr. 9 has also been obtained 28. As has been outlined 
in the study by Kozaiwa, precise localization of genes controlling complex traits using F2 and first 
backcross animals is generally not possible because of the limited number of informative 
recombinations produced in cohorts of manageable size and the substantial variability of phenotypic 
expression in mice with random segregations of other disease-associated alleles. However, it is at least 
striking that several models have disclosed linkage in overlapping regions on mid-Chr. 9, which might 
indicate that this region does in fact harbor a susceptibility gene that mediates overall susceptibility to 
intestinal inflammation, and is not caused by artificial interference or expression differences induced by 
the mutation. 
Studies in congenic mouse stocks will be able to shed light on the question as to whether the same 
gene(s) are involved in the different colitis models. That genome-wide analysis of experimental models 
has the power to eventually identify disease causing gene(s) was recently demonstrated by McIntire and 
colleagues 29. In their study, they used congenic stocks for a genetic region on mouse chromosome 11 
initially identified in a genome-wide screen and were able to identify a gene involving asthma 
susceptibility using positional cloning. 
In conclusion, we have identified a major susceptibility locus on mouse Chr. 3 that exerts is effect in 
conjunction with a locus on Chr. 1. The identification of similar if not identical loci in different models of 
spontaneous mucosal inflammation indicates that these regions harbor genes that play an important role 
in maintaining overall mucosal homeostasis. Identification of these genes, using the approach described 
above involving congenic mice, will provide detailed understanding of the factors that facilitate the 
development of colitis in individuals prone to mount increased Th1 responses. This will thus be relevant 
to the further understanding of human IBD. 
 
This study was supported by the Crohn’s and Colitis Foundation of America. G.B. is a Fellow of the 
Royal Dutch Academy of Arts and Sciences. 
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Introduction 
In our studies to locate quantitative trait loci (QTLs) involved in colitis susceptibility in a Gnai2 deficient 
mouse model, we compared the genome of F2 mice derived from the resistant C57BL6/J strain and 
the susceptible C3H/HeJ mouse strain. We found a major C3H/HeJ derived QTL on distal 
chromosome 3. Within this locus lay a number of interesting candidate genes, amongst which Nfkb1 
and Egf. 
Mice with altered NF-κB signaling have proven to have a higher susceptibility to opportunistic 
infections and show an inflammatory phenotype 1. Furthermore, it is known from human studies that 
both ulcerative colitis (UC) and Crohn’s disease (CD) patients show elevated levels of NF-κB 
activation 2, 3. Also, linkage was found previously with chromosome 4q 4, were the human ortholoque 
for Nfkb1 resides. This chromosomal region appeared to epistatically interact with the IBD1 region on 
16p where the first gene identified as a true susceptibility gene for CD, NOD2 is located 5, 6. This 
linkage of chromosome 4q with IBD susceptibility was confirmed by several studies 7,8, and found to 
be mainly associated with UC. 
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NF-κB signaling route 
NF-κB stands for Nuclear Factor of kappa light polypeptide gene enhancer in B-cells. The NF-κB 
family comprises of a group of critical transcription factors, involved in enhancing gene expression of 
genes involved in a variety of regulatory processes, including innate and adaptive immune responses, 
cell growth, apoptosis, and tissue differentiation 9, 10. The NF-κB signaling route and its family 
members are highly conserved throughout the animal kingdom. Here I will focus on the murine forms. 
Amongst the family members are p50/105 (encoded by Nfkb1), p52/p100 (encoded by Nfkb2), p65 or 
RelA, RelB and c-Rel (encoded by Rela, Relb and Rel respectively). In short, they exert their effects 
by forming complexes with each other, both homo-dimers and heterodimers, resulting in a multitude of 
possible complexes, all with specific target genes and differential effects in activating their specific 
genes transcription. 
 
Activation and Regulation 
In resting state, the NF-κB complexes are kept in the cytosol by their sequestering proteins, the IκB 
protein family, and upon activation they are released and translocate to the nucleus, where they exert 
their effect on gene expression. Recently, activation of the NF-κB signaling pathways has been 
categorized into the canonical (classical) pathway and the noncanonical (alternative) pathway 11 
(Figure 1). The former is characterized by nuclear translocation of complexes containing p50/105, the 
latter by the formation and translocation of complexes containing p52/p100. The canonical pathway 
typically involves activation through cell surface receptors like Toll-like Receptors (TLRs) or Tumor 
Necrosis Factor-Receptor (TNF-R). 
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Figure 1 Canonical (classical) and non-canonical (alternative) NF-kB pathway 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The canonical pathway is characterized by nuclear translocation of complexes containing p50/105. It typically 
involves activation through cell surface receptors like Toll Like Receptors (TLRs) or Tumor Necrosis Factor-
Receptor (TNF-R). Adapter proteins (e.g. TNF receptor-associated factors (TRAFs) and Receptor-Interacting 
Protein (RIP)) are recruited, that in turn recruit inhibitor of nuclear factor kappa-B kinase (IKK) complexes 
containing NF-Kappa-B Essential Modulator (NEMO). This complex induces degradation of the sequestering 
protein IκB, releasing the NF-κB complex that can then migrate to the nucleus. The canonical pathway has an 
auto-regulatory mechanism, in that NF-κB activates expression of the IκB gene, leading to resequestering of the 
NF-κB complex. 
The noncanonical pathway can be activated by other receptors, (e.g., Lymphotoxin-β (LT-β), B-cell activating 
factor (BAFF), and CD40). In the noncanonical pathway, receptor binding leads to activation of the NF-κB-
inducing kinase (NIK), which phosphorylates and activates an IKKα complex, which in turn phosphorylates the 
IκB domain of p100, leading to its partial proteolysis and liberation of the p52/RelB complex, that can in turn 
migrate to the nucleus. 
 
 
Adapter proteins (e.g. TNF receptor-associated factors (TRAFs) and Receptor-Interacting Protein (RIP)) are 
recruited, that in turn recruit inhibitor of nuclear factor kappa-B kinase (IKK) complexes containing NF-Kappa-
B Essential Modulator (NEMO). Activation of this complex leads to degradation of the sequestering protein 
IκB, and finally results in translocation of the NF-κB complex to the nucleus. The canonical pathway has an 
auto-regulatory mechanism, in that NF-κB activates expression of the IκB gene, leading to resequestering of 
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the NF-κB complex. The noncanonical pathway can be activated by certain receptors, (e.g., Lymphotoxin-β 
(LT-β), B-cell activating factor (BAFF), CD40). In the noncanonical pathway, receptor binding leads to 
activation of the NF-κB-inducing kinase (NIK), which phosphorylates and activates an IKKα complex, without 
NEMO, which in turn phosphorylates two serine residues adjacent to the ankyrin repeat C-terminal IκB 
domain of p100, leading to its partial proteolysis and liberation of the p52/RelB complex (Figure 1) 12. 
NF-κB p50 mediated gene transcription can be regulated in several ways (Figure 1). 
To exert its effect, p50 binds to p65 to form a biologically active heterodimer, which can translocate from the 
cytoplasm of the cell to the nucleus. Here, it binds to a NF-κB binding site in promoter sequences of 
inflammatory genes, to enhance gene expression. In resting state, the p50/p65 complex is kept in the cytosol 
by IκB. Activation of kinases that ubiquitinate IκB (IKKs) leads to degradation of these IκBs, resulting in the 
release of the NF-κB complex. Alternatively, next to binding of ‘regular’ IκBs to NF-κB complexes, dimer 
formation with an active protein (e.g. p65) and p105 precursor proteins can take place. The IκBγ part of the 
p105 keeps the complex inactive and in the cytoplasm. Removal of the inhibitory IκBγ C-terminal half of the 
precursor leads to activation of the NF-κB complex. 
Next to sequestering potentially active complexes in the cytosol by IκB, NF-κB mediated gene transcription 
can be inhibited by blocking the NF-κB binding sites in the promoter region of the genes. The subunit p50 is 
able to form homodimers, that can also translocate and bind to the NF-κB binding sites, but do not have the 
gene transcription enhancing properties. This way, p50 can function as it’s own inhibitor, by preventing the 
binding of activating complexes 13. 
 
Nfkb1 gene structure and functioning 
As alluded to earlier, Nfkb1 encodes for NF-κB p50/105 (Figure 2). It is a large gene, residing on the distal 
part of mouse chromosome 3, coding for 971 amino acids (aa’s) encoded by 24 exons (GeneID: 18033). The 
protein product of Nfkb1 is synthesized as an inactive cytoplasmic precursor protein, p105, which upon 
processing generates the active subunit p50 of the Rel/NF-κB complex. This p50 protein is formed from the 
N-terminal side of the precursor. From the C-terminal side of the p105 precursor, an IκBγ protein can be 
formed. This IκBγ protein is a sequestering protein, involved in retaining the NF-κB complex in the cytosol, 
thus inhibiting NF-κB activation. Both gene products will be discussed here. 
 
p50 
The p50 part of the protein harbors a Rel homology domain (RHD), which mediates DNA-binding, 
dimerization and association with the IκB family of inhibitory proteins. The C-terminal domain within 
the RHD has an immunoglobulin-like fold that binds to DNA. This RHD is shared with the other 
members of the Rel/NF-κB transcription factor family members. The C-terminal end of p50 harbors a 
nuclear localization signal (NLS). This sequence does not seem to influence the dimerization and 
DNA-binding properties, but is involved in binding IκB inhibitors. The IκB proteins bind preferably to 
the RHD of their specific subunit (e.g. IκBα to p65/RelA, IκBγ to p50) and thus block the NLS of their 
specific subunit, keeping the complex sequestered in the cytoplasm. 
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Figure 2 Gene structure of Nfkb1 
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IκBγ 
As mentioned above, next to p50, Nfkb1 also encodes a p70 IκB protein, IκBγ, which is identical to 
the C-terminal 607 amino acids (aa’s) of p105. IκBγ contains 7 ankyrin–like repeated sequences, that 
are responsible for association with the RHD of the NF-κB subunits. At the C-terminal side, the IκBγ 
protein contains a death domain and destruction box. The death domain is necessary for cytoplasmic 
retention of NF-κB, but is by itself not sufficient for retention in the cytoplasm. It does not participate in 
IκBγ binding to NF-κB. 
Alternative RNA splicing generates two IκBγ isoforms with properties different from those of p70. One 
63-kDa isoform, termed IκBγ1 lacks 59 amino acids C-terminal to ankyrin repeat 7, but has a novel 
35-aa C terminus, encoded by an alternative reading frame. The second, a 55-kDa isoform, IκBγ2, 
lacks the 190 C-terminal aa’s of p70IκBγ. In contrast to p70IκBγ, which is a cytoplasmic protein, IκBγ1 
is found in both the cytoplasm and nucleus, whereas IκBγ2 is predominantly nuclear. Both IκBγ1 and 
IκBγ2 are specific for p50 and have different affinities for this subunit, suggesting that alternative RNA 
splicing may be used to generate IκBγ isoforms that respond differently to intracellular signals. 
 
Taken together, NF-κB mediated activation of gene transcription shows very complex regulation 
mechanism. Any change in gene transcription or gene function of any of the family members can 
have significant consequences for the regulation of the immune status of the host. In summary, there 
is substantial evidence for altered NF-κB activation in both human IBD and in animal models of colitis. 
In addition, at least one gene of this pathway, Nfkb1, maps to linkage regions in both animal models 
as well as in human IBD. Taking this into consideration, we decided to compare the sequences of the 
Nfkb1 gene from the two mouse strains described in the previous chapter to see if we could identify 
polymorphisms in the coding region of the gene that could help to explain the differences in 
susceptibility between the two strains. 
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Materials and Methods 
For sequencing the transcribed part of Nfkb1 (aa’s 1 until 3601), mRNA was isolated from colons from 
both C57BL/6J and C3H/HeN mice, using Trizol (Invitrogen, Breda, The Netherlands), according to 
manufacturers recommendations. cDNA products were generated from the mRNA using the 
RevertAid First Strand cDNA Synthesis Kit (Fermentas, St.Leon-Rot, Germany). For sequencing the 
5’UTR promoter region, genomic DNA was isolated from spleens from both C57BL/6J and C3H/HeN 
mice, using a commercial kit as described by the manufacturer (Biozym, Landgraaf, The 
Netherlands). Overlapping fragments were amplified by PCR using Nfkb1 specific primers designed 
on the basis of the published genomic DNA sequences (accession NM 008689.1 GI: 6679043). 
Amplified DNA and cDNA fragments were purified by gel purification (QIAEX® II Gel Extraction Kit, 
QIAGEN, Westburg, The Netherlands) cloned into a plasmid vector for sequencing (TOPO TA 
Cloning® Kit for Sequencing, version H, Invitrogen). Plasmids with the gene fragments were isolated 
(QIAprep® Spin Miniprep Kit, QIAGEN) and commercially sequenced by BaseClear (Leiden, The 
Netherlands). Sequences of amplified fragments were compared with each other and with the 
published Nfkb1 DNA sequences. 
 
Results and Discussion 
We found 5 single nucleotide polymorphisms (SNPs) of which one lays in the ‘3-UTR of the gene 
(Table 1 and Figure 3). These polymorphisms were found by aligning the sequences of the two 
strains to each other, and comparing them to the published sequences from GenBank. 
The first SNP, at position 903 after the translation start, was also found by Bleich et al. (AY 521463, 
GI: 41350656), and was C57BL6/J derived. All the other polymorphisms found in this study were 
C3H/HeN derived. We did not find the other (C57BL6/J derived) SNP found by Bleich (at position 
1119, C->T transition). All the SNPs identified in the coding region of the gene are silent mutations, 
i.e. mutations that do not cause a change in amino acid composition of the protein. 
 
 
 
Table 1 Single nucleotide polymorphisms between C3H/HeN and C57BL6/J mice 
 Nucleotide  
Location C3H/HeN C57BL6/J Amino acid 
903 G A T = T 
1860 C T K = K 
2028 A G Q = Q 
2796 A G V = V 
3255 (UTR) T A N/A 
 
Locations given are numbers of basepairs from the transcription start. Amino Acids are; T = Threonine, K = 
Lysine, Q = Glutamine, V= Valine, N/A not applicable. 
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Figure 3 Polymorphisms between C3H/HeN and C57BL6/J strains in Nfkb1 
 
Single nucleotide polymorphisms are indicated in bold. Top sequences are C3H/HeN derived, bottom sequences 
are C57BL6/J derived. The nucleotides that differed from the published sequences for that same strain are 
underlined. 
 
 
The fact that we did not identify any functional polymorphisms in Nfkb1 does not necessarily mean 
that this gene is not involved in the difference in susceptibility to colitis as seen in C57BL6/J and 
C3H/HeN mice. We only sequenced the cDNA, so the translated part of the gene, omitting all the 24 
introns. Also, it is still not exactly known what part of the sequence before the known transcribed part 
comprises the promoter of this gene. Mutations in both the promoter, the introns, and the 3’UTR could 
have a profound effect on the expression of the gene, or cause so far unknown splice variants to 
occur. Ongoing studies in congenic mouse strains in which the QTL found on chromosome 3 is 
transferred from the susceptible strain to the resistant strain and vice versa will be helpful to further 
discern whether Nfkb1 is involved in colitis susceptibility in the Gnai2-/- model. 
      871 gtttgggaag gatttgggga cttttccccc acggatgttc atagacagtt tgccattgtc 
      871 gtttgggaag gatttgggga cttttccccc acagatgttc atagacagtt tgccattgtc 
       aa  V  W  E   G  F  G  D   F  S  P   T  D  V   H  R  Q  F   A  I  V  
 
     1831 ggcaactctg tcctgcacct agctgccaac gaaggacacg acagaatcct cagcatcctg 
     1831 ggcaactctg tcctgcacct agctgccaat gaaggacacg acagaatcct cagcatcctg 
       aa  G  N  S   V  L  H  L   A  A  K    E  G  H   D  R  I  L   S  I  L  
 
     2011 gcagaagtca atgctcaaga gcagaagtct gggcgcacag cgctgcacct ggccgtggag 
     2011 gcagaagtca atgctcagga gcagaagtct gggcgcacag cgctgcacct ggccgtggag 
       aa  A  E  V   N  A  Q  E   Q  K  S   G  R   T   A  L  H  L  A  V  E  
 
     2761 ctccgggata gtgacagcgt ctgtgacagt ggtgtaaaga catccttccg caaactcagc 
     2761 ctccgggata gtgacagcgt ctgtgacagt ggtgtggaga catccttccg caaactcagc 
       aa  L  R  D   S  D  S  V   C  D  S   G  V  E   T  S  F  R   K  L  S  
 
     3241 cctgctgtca ttaataggtg tcgctgtccc cacccggtgt cctttctagc catctactgt 
     3241 cctgctgtca ttaaaaggtg tcgctgtccc cacccggtgt cctttctagc catctactgt 
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Summary 
Nuclear factor κB (NF-κB) designates a group of critical transcription factors involved in a variety of 
immunologic and/or inflammatory processes. Conceivably, genes involved in the NF-κB pathway 
make interesting candidate genes for chronic inflammatory disorders, including the Inflammatory 
Bowel Diseases (IBD), Crohn’s disease (CD), and Ulcerative colitis (UC). In two mouse models of 
colitis strong linkage has been observed with a locus on chromosome 3 that harbors the Nfkb1 gene. 
In addition, a polymorphism in the promoter region of the human NFKB1 gene was found to be 
associated with susceptibility to UC. In this study, we searched to confirm this previously found 
association in IBD in a different population. 
Allele and genotype frequencies of the –94ins/delATTG polymorphism were determined in 266 
unrelated Dutch Caucasian IBD patients (127 UC, 139 CD), and 155 matched healthy controls. 
The allele frequency of the deletion was significantly higher in UC patients (P=0,019), but not in CD 
patients, compared to healthy controls, and the UC patients homozygous for the –94 ATTG deletion 
had a younger age of onset. 
Our findings confirm the previously found association between this polymorphism and susceptibility to 
UC in an independent study population and adds further evidence for the role of this gene in disease 
susceptibility. 
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Introduction 
Crohn’s disease (CD) and ulcerative colitis (UC) are two related but distinct chronic inflammatory 
disorders of the gastrointestinal tract, commonly denoted as inflammatory bowel diseases (IBD) 1. The 
exact cause remains elusive, but thus far, IBD is thought to be the result of an inappropriate and 
ongoing activation of the mucosal immune system driven by the presence of normal luminal flora in a 
genetically susceptible host 2. 
Epidemiological linkage studies indicate that genetic factors play a key role in the etiology of IBD 3, 4. 
Indeed, mutations in NOD2 have been identified in a subgroup of CD patients. However, IBD is 
clearly not inherited as a simple Mendelian trait but rather has a complex genetic basis with multiple 
genes involved. This is further substantiated by various linkage studies in which a large number of 
chromosomal regions have been identified that are linked to disease susceptibility. One of these is 
found on chromosome 4q24 and harbors, among others, a member of the nuclear factor B (NF-κB) 
family, NFKB1. This gene is an attractive candidate gene since its gene product is involved in 
regulating a large variety of inflammatory responses. NFKB1 encodes two isoforms, the cytoplasmic 
non DNA-binding p105, and the 50 kDa DNA-binding p50 5. As stated above, NF-κB p50/105 is a 
member of the NF-κB family, a group of critical transcription factors involved in a variety of regulatory 
processes, including innate and adaptive immune responses, cell growth, apoptotis, and tissue 
differentiation  6, 7. To exert its effect, p50 binds to p65 to form biologically active heterodimers which 
translocate from the cytoplasm of the cell to the nucleus. Here, they bind to NF-κB binding sites in 
promoter sequences of inflammatory proteins, including IL-12, TNF-α and IFN-γ and regulate their 
transcription. Alternatively, p50 is able to form homodimers which block transcription by binding to NF-
κB sites in the nucleus 8. Interestingly, mice with enhanced p50 expression show enhanced inducible 
NF-κB activation, chronic inflammations and elevated susceptibility to bacterial infections 9. 
Additionally, NFKB1 has been identified as a strong candidate gene in two different mouse models for 
colitis (the IL-10 deficient 10 and Gnai2 deficient 11 mouse models), since in both models strong 
linkage is observed with the chromosomal region in which the mouse homologue for NFKB1 resides. 
These findings are further corroborated by studies in human IBD. Thus, elevated levels of NF-B 
activation are found in the intestinal mucosa of both CD and UC patients 12, 13. In addition, in North 
American populations with UC, especially in Ashkenazim Jews, linkage was found previously with 
chromosome 4q 14. This chromosomal region appeared to epistatically interact with the IBD1 region 
on 16p where the first gene identified as a true susceptibility gene for CD, NOD2 resides 15, 16. The 
linkage of chromosome 4q with IBD susceptibility was confirmed by studies in Europe, combining 
patients from England, Germany and Holland 17, 18, and found to be mainly associated with UC. 
Recently, Karban et al. described a promoter polymorphism 94 bp upstream of the transcription start 
of the NFKB1 gene. This polymorphism consists of an ATTG-deletion, at a putative NF-κB binding 
site. The authors found an elevated frequency of the deletion in UC patients in a non-Jewish North 
American population. Also, oligonucleotides containing the deletion showed strongly diminished 
binding to nuclear proteins isolated from normal human colonic tissue and cell lines but not to nuclear 
proteins isolated from normal human ileal tissue 19. This functional polymorphism potentially leads to 
altered expression of NFKB1 and altered NF-κB activation patterns, which, at least in part, could 
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induce elevated IBD susceptibility. In this study we describe the frequency of the previously described 
promoter polymorphism in our Dutch Caucasian patient population. We found an elevated frequency 
of the ATTG-deletion in UC patients, but not in CD patients. 
 
Materials and Methods 
Patients 
DNA was isolated previously from whole blood using standard isolation procedures. Patients were 
recruited from the department of Gastroenterology of the Vrije Universiteit Medical Center, 
Amsterdam. Informed consent was obtained from all participants after approval of the VUmc Medical 
Ethical Committee. For UC, 127 patients were available, 63 females, 64 males, and for CD 139 
patients were available, 102 females, 37 males. The mean age at first diagnosis of IBD was 31,9 +/- 
12,3 years for UC and 27,0 +/- 12,0 years for CD. 
Severity of disease was defined by means of the localization/extent of inflamed area for UC, e.g. 
involvement of only the rectum (proctitis), the rectum and the sigmoid or descending colon (left-sided 
colitis), or the entire colon (pancolitis). Severity of disease in CD patients was defined using the 
Vienna classification, using codes to indicate age of onset, behavior and localization of the disease. 
Vienna-A, age at diagnosis, A1= <40years, A2= >40 years, Vienna-B disease behavior, B1 = 
inflammatory, B2 = structuring, B3 = perforating, Vienna-L, localization, L1 = terminal ileum, L2 = 
colon, L3 = ileo-colonic, L4 = upper GI-tract. 
 
Genotyping the –94delATTG human Nfkb1 promoter polymorphism 
A restriction enzyme digestion assay was used to genotype a –94ins/delATTG polymorphism as 
described before 19. In short, DNA samples were used to amplify a 289 bp PCR fragment from 
genomic DNA (Forward primer TTT AAT CTG TGA AGA GAT GTG AAT G, reverse primer CTC TGG 
CTT CCT AGC AGG G [Invitrogen Life Technologies, Breda, The Netherlands]). Products were 
digested with the enzyme PflM1 (New England Biolabs, Beverly, MA, USA) and analyzed on a 4% 
agarose gel (in a mixture of 2% ultra pure agarose [NuSieve GTG Agarose; Cambrex Bio Science 
Rockland, Rockland, ME, USA] and 2% low melting agarose [Invitrogen]) 
 
Statistical analysis 
For case-control test for genetic association, a χ2 test for independence statistic was derived using 
2x3 contingency tables. Odds ratios with 95% confidence intervals were calculated using Fisher’s 
Exact Test and the approximation of Woolf. One-way ANOVA was used to compare mean age of 
onset for patients from different genotypes. For all analyses, GraphPad InStat version 3.05 for 
Windows 95 was used (GraphPad Software, San Diego, CA; http://www.graphpad.com). All groups 
were checked for Hardy-Weinberg equilibrium. 
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Results 
We genotyped our 266 Dutch Caucasian IBD patients (127 UC, 139 CD), and matched healthy 
controls (n = 155) for the –94 ATTG deletion promoter polymorphism (Table 1). All populations were 
in Hardy-Weinberg equilibrium. 
When comparing UC patients with the controls, we found that allele and genotype frequencies of the 
–94 ATTG deletion were significantly higher in UC patients (p=0,019). No differences in allele or 
genotype frequencies were found between CD patients and healthy controls (p = 0,39 respectively; 
Table 1). 
Comparing the UC population with the control population revealed a significant risk for developing UC 
in the subjects homozygous for the –94 ATTG deletion (25% versus 16%; odds ratio = 2,51; 95% 
confidence interval = 1,28-4,92; p = 0,011) The heterozygote genotype revealed an elevated, but not 
quite significant risk (48% versus 43%, odds ratio = 1,71; 95% confidence interval = 1,00-2,07; p = 
0,058) Comparing the CD population to the controls did not reveal any elevated risk (data not shown). 
Subsequently, we investigated whether this polymorphism could be linked to a particular clinical 
phenotype. First, patients were stratified according to gender. In UC patients, the association with this 
polymorphism was particularly strong in men, and not in women. Stratification according to gender did 
not reveal any significant sex differences for CD (Table 1).  
 
Table 1 Genotypes of patients and healthy controls and -94 delATTG allele frequency 
Genotype -94 delATTG  Fenotype (n) 
del/del del/ins ins/ins allele frequency p value 
UC female (63) 11 (17%) 37 (59%) 15 (24%) 0,47 0,15 
UC male (64) 21 (33%) 24 (37%) 19 (30%) 0,52 0,04 
UC (127) 32 (25%) 61 (48%) 34 (27%) 0,49 0,019 
CD female (102) 12 (12%) 52 (51%) 38 (37%) 0,37 0,60 
CD male (37) 4 (11%) 18 (49%) 15 (40%) 0,35 0,72 
CD (139) 16 (12%) 70 (50%) 53 (38%) 0,37 0,39 
Total IBD (266) 48 (18%) 131 (49%) 87 (33%) 0,42 0,21 
Controls female (80) 13 (16%) 36 (45%) 31 (39%) 0,39 N/A 
Controls male (75) 11 (15%) 31 (41%) 33 (44%) 0,35 N/A 
Controls (155) 24 (16%) 67 (43%) 64 (41%) 0,37 N/A 
 
del/del represents individuals homozygous for the –94 delATTG allele, del/ins represents heterozygous 
individuals and ins/ins represents individuals homozygous for the wild-type allele. P values are patient groups 
compared to controls, either as a whole group, or gender matched. N/A not applicable 
 
The mean age of onset was significantly lower in patients homozygous for the –94 delATTG allele (27 
years vs. 33 or 34 years, p=0,03, Table 2), indicating that homozygosity for this allele could be a risk 
factor for early onset of the disease. Stratifying UC patients according to localization of disease led to 
very small populations, too small to provide valid evidence for relevant observations for all groups 
(Table 2). Neither did we find an association of the polymorphism with the severity of disease, as 
defined by the need of colectomy or cyclosporin (CSA) treatment (data not shown). 
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Table 2 Genotypes of UC patients 
Fenotype (n) Genotype   p-value 
 del/del del/ins ins/ins 
-94 delATTG allele 
frequency  
Proctitis (10) 4 (40%) 4 (40%) 2 (20%) 0,6 0,11 
Left sided (54) 13 (24,1%) 26 (48,1%) 15 (27,8%) 0,48 0,15 
Pan colitis (63) 15 (23,8%) 31 (49,2%) 17 (27,0%) 0,48 0,035 
Controls (155) 24 (16%) 67 (43%) 64 (41%) 0,37 N/A 
Age of onset 27 33 34 N/A 0,03 
 
del/del represents individuals homozygous for the –94 delATTG allele, del/ins represents heterozygous 
individuals and ins/ins represents individuals homozygous for the wild-type allele. P values are patient groups 
compared to controls. N/A not applicable 
 
 
Next, we subdivided the CD patient group according to the Vienna classification 20. Although the –94 
delATTG allele frequency appeared to be higher in patients with perforations (Vienna B3, data not 
shown), subdividing the CD patients led to very small populations and these groups were too small to 
provide valid observations. 
 
Discussion 
The NFKB1 gene encodes for two isoforms, the cytoplasmic non DNA-binding 105 kDa p105 protein, 
and the 50 kDa DNA-binding p50 protein, and is one of the most prominent members of the NF-B 
family. The NF-B family consists of transcription factors involved in a variety of immune responses, 
and it has been implicated in many inflammatory pathologies, such as asthma, arthritis, 
atherosclerosis, and IBD. There is linkage evidence that the region where NFKB1 resides, 4q24, is 
involved in IBD susceptibility. 
The region of the mouse genome where Nfkb1 is located has been implicated in two separate 
spontaneous colitis models, in which F2 backcrosses derived from resistant C57BL/6J Gnai2-/- and 
susceptible C3H/HeN Gnai2-/- mice 11, or C57BL/6J Il-10-/- and susceptible C3H/HeJ IL-10-/- mice 10, 
were analyzed in a genome-wide screen for colitis susceptibility and severity, identifying a highly 
significant locus on chromosome 3 contributed to colitis susceptibility and severity (called Gpdc1 and 
Cdcs1 respectively). In addition mouse Nfkb1 is involved in chronic inflammations and an elevated 
susceptibility to bacterial infections and intestinal inflammation is demonstrated in Nfkb1 deficient 
mice 21, 22. These observations designate NFKB1 to be an interesting candidate gene for IBD. 
In this study we describe the frequency of the previously described –94 ATTG-deletion polymorphism 
of the Nfkb1 promoter in a Dutch Caucasian IBD patient population. Similar to findings in a mixed 
Northern American population 19, the allele frequency was elevated in UC patients, providing further 
evidence that this polymorphism is associated with disease susceptibility for this subtype of IBD. Such 
elevated frequency of the –94 ATTG-deletion was not observed in CD. The association found in UC 
appeared to be a little stronger in men. Interestingly, patients (men and women together) homozygous 
for the –94 ATTG-deletion allele had a significantly younger age of onset of disease. 
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It has to be noted that the studied population is relatively small, and the results have not been 
corrected for multiple testing. Furthermore the phenotypical description of the patients is exploratory, 
because it is impossible to predict the development of disease. Although this could lead to an 
underestimation of patients with the more severe forms of disease, we find significant association with 
the –94 delATTG polymorphism in our UC patient group, in concordance with the results from Karban 
et al. On the other hand, a recently published study by Oliver et al. did not find evidence for 
association of this polymorphism in a white Spanish population (Oliver et al. (2005). The 
discrepancies between these studies could be explained by differences in environmental factors for 
the different populations, but a more likely explanation could be that the haplotypic context of the 
Spanish population is different from the North European and North American populations. Indeed, the 
white North American populations studied in genome screens identifying the 4q region (Cho et al. 
(1998); Rioux et al. (2000) descend largely from the North European Caucasian populations, in which 
the same region was also identified 17, 18. Of note, part of the population described by Hampe was 
recruited from the Academic Medical Center in Amsterdam, and thus virtually from the same 
population as ours, and the population described by Vermeire was recruited from the Flemish Belgian 
population, which is relatively closely related to our Amsterdam population. 
The exact mechanism underlying the NFKB1 related disease susceptibility remains unknown, but one 
can think of several explanations. The deletion of the –94 ATTG leads to a less strong activation of 
NF-κB1 transcription, which seems contra intuitive to the fact that especially in UC, high levels of NF-κB 
activation are seen. However, if the diminished NFKB1 transcription would lead to less available p50, 
fewer inhibitory p50/p50 homodimers can be formed. Fewer blocking homodimers could then lead to 
a stronger activation of transcription of inflammatory genes, leading to the strong NF-κB induced 
immune response, as seen in UC. 
Another potential explanation is that low levels of p50 lead to a poor innate immune response. 
Bacteria that would have normally been handled by this first line of defense are then able to provide 
for ongoing antigenic signals and subsequently cause an on-going inflammation, as is seen in mice 
lacking Nfkb1 21-23. On the other hand, mice that express enhanced levels of p50 also show chronic 
inflammation and higher susceptibility to bacterial infections 9. Clearly, any change in the delicate 
balance of NF-κB signalling can lead to an alteration in immune response which in is associated with 
enhanced susceptibility to colitis. 
 
In summary, we found that the allele frequency of the –94 ATTG deletion was significantly higher in 
UC patients compared to healthy controls, but not in CD patients, and patients homozygous for the –
94 ATTG deletion had a younger age of onset. Our findings confirm the previously found association 
between this polymorphism and susceptibility to UC in an independent study population. Studies to 
determine the physiological effect of this polymorphism are warranted. 
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Summary 
Celiac disease (CeD) is a common gastrointestinal disorder resulting from permanent intolerance to 
wheat gliadins and related proteins in rye and barley. In addition to the strong genetic association with 
HLA-DQ2 and HLADQ8, a genetic region on chromosomes 5 (CELIAC2) has been identified that 
harbors a ablesusceptibility gene for CeD. The gene(s) responsible for this association, however, 
remains to be identified. In the present study we evaluated polymorphisms in the genes encoding 
interleukin-12 p40 (IL12B) and interferon regulatory factor 1 (IRF1). Both genes are located in the 
CELIAC2 region, and have key roles in inducing interferon (IFN)-γ secreting T helper 1 (Th1) cells, 
one of the immunological hallmarks of CeD. The frequencies of a TaqI gene polymorphism in the 3′ 
UTR of IL12B and a HinfI gene polymorphism in the 3′ UTR of IRF1 were studied in 258 Dutch CeD 
patients and 237 ethnically matched healthy controls. The transmission of the polymorphic variants 
from parents to affected child was determined in 123 families with at least one affected child. The 
frequencies of the IL12B TaqI gene polymorphism and the IRF1 HinfI gene polymorphism did not 
differ significantly between patients and controls. In addition, in the family study, no deviation from the 
expected transmission from parents to affected child of any of the polymorphic variants was found. 
The IL12B TaqI and the IRF1 HinfI gene polymorphisms do not appear to be involved in susceptibility 
to CeD. Further studies on the factors that drive the Th1 immunopathology in CeD are required. 
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Introduction 
Celiac disease (CeD) is an immune-mediated disorder of the small intestine caused by permanent 
intolerance to gluten, a dietary protein found in wheat, rye and oats. CeD affects up to 1 in 150–300 
people in western European and Northern American populations 1-4. Genetic factors play a key role in 
CeD susceptibility 5, 6. This genetic component can in part be attributed to a strong association with 
the HLA genes. The primary HLA association in most cases of celiac disease is with DQ2, and in a 
minority of patients the association is with DQ8 6. However, since DQ2 occurs at a high prevalence in 
the general Caucasian population, it is anticipated that other, as yet unknown genes are involved in 
disease susceptibility. Indeed, linkage studies have provided evidence for the existence of additional 
genetic risk factors 7-14. Two chromosomal regions have been identified in more than 1 genome-wide 
screen, and there is general agreement that these regions harbor CeD susceptibility genes. They are 
located on chromosome5q31-33 (designated CELIAC2) and on 2q33 (designated CELIAC3) 
(http://www.gene.ucl.ac.uk/nomenclature). 
Immunologically, CeD appears to be a T helper 1 (Th1) mediated disorder, characterized by high 
expression of interferon-gamma (IFN-γ) mRNA and increased numbers of IFN-γ positive cells at 
lesional sites 15. What drives these high IFN-γ responses during the inflammatory response in the 
small intestine is unknown. Accumulating evidence from in vivo and in vitro experimental test systems 
supports the notion that interleukin-12 (IL-12) is required for optimal in vivo Th1 responses 16, 17. Active 
IL-12 exists as a disulfide-linked heterodimer of 35-kDa (p35) and 40-kDa (p40) subunits, each 
encoded by separate genes. Given its strong capacity to induce IFN-γ secretion, IL-12 is a potential 
candidate gene for CeD. In addition, the gene encoding the p40 chain (IL12B) resides within 
CELIAC2 on chromosome 5q31-33 10, 18. IL12B is highly conserved among human subjects. However, 
an A→C polymorphic site is found in the 3′ untranslated region (UTR) at position 1188, which creates 
a TaqI cutting site. This polymorphism has recently been the focus of considerable interest since it 
was found to be associated with susceptibility to both multiple sclerosis and type I diabetes mellitus 19, 20, 
and has an effect on IL-12 secretion in vitro 21. It must be noted, however, that the genetic association 
data have been inconclusive thus far for both diseases, emphasizing the importance of replicating 
genetic association studies in independent data sets 22, 23. 
Interferon regulatory factor (IRF)-1 is a member of the IRF family of transcription factors that are 
involved in the regulation of genes that control cell growth, differentiation, and death. In addition, IRF-
1 is involved in several steps of the immune response that may be pertinent to CeD, including the 
polarization of the cytokine response in CD4+ T cells. Thus, Irf1 deficient mice (–/–) fail to mountTh1 
responses, which can be attributed to impaired IL-12 production in these mice 24. Indeed, IRF-1 
binding sites are present in the IL12B promoter 25. The gene for IRF1 is located on chromosome5q31. 
A G→A polymorphism at position 1688in the 3′-untranslated region of the gene was recently 
described by 26. In the present study we investigated the involvement of both gene polymorphisms in 
CeD susceptibility in the Dutch population. This was accomplished by studying these polymorphisms 
in a case–control study as well by studying the transmission of alleles from parents to affected 
children. 
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Materials and methods 
Patients and controls 
A total of 258 Dutch celiac patients (70 males and 188 females) and 237 Dutch controls (113 males 
and 124 females) were included in the study. The mean age at presentation of disease was 39 years 
(range 1–75 years), and did not differ from the mean age of the control group (38 years; range 6–87 
years). For the transmission disequilibrium test (TDT), a total of 123 trios (parents and affected child) 
were available. The affected children from the trios were included in the case–control group. All 
patients and controls were unrelated and Caucasian. Histological analysis of patients was performed 
at the time of diagnosis prior to initiating a gluten-free diet. The histological features were classified 
according to the modified Marsh classification 27, with a slight modification of Marsh III. Marsh III is 
characterized by subtotal villous atrophy (VA) and significant intraepithelial lymphocytosis (> 30 
lymphocytes per 100 epithelial cells). In order to define the severity of the histological features of 
subtotal villous atrophy more precisely, we have further classified the Marsh III type lesion into three 
subgroups based on architectural changes: Marsh IIIa (partial VA), characterized by a villous-crypt 
ratio of less than 1/1; Marsh IIIb (subtotal VA), character characterized by recognizable villi in an 
otherwise flat mucosa, and Marsh IIIc (total VA), characterized by a nearly total absence of villi. 
 
TaqI RFLP analysis 
Genotyping for the TaqI polymorphism in the 3′ UTR of IL12B was performed as previously described 28. 
In short, 50 ng of genomic DNA was PCR amplified using primers that cover the TaqI restriction site. 
After PCR amplification, the 233-bp product was cut with the TaqI restriction enzyme for 16 h at 65 °C. 
The products were visualized on an ethidium bromide-stained 2% agarose gel. 
 
Hinf I SNP analysis 
Genotyping for the HinfI polymorphism in the 3′ UTR of IRF1 was performed as previously described 
26
. In short, PCR amplification of 50 ng of genomic DNA was performed using primers that cover the G 
to A transition at position 1688. This transition, however, does not confer the restriction enzyme 
recognition site. A HinfI site was introduced by altering the 3′ end of the primer to generate the 
enzyme recognition site, as shown in bold script (forward primer: 5′TCTCGTTCCCAAAGAACTACC3′; 
reverse primer: 5′CTCTGAGGCTGAGGGAGAAT3′). In the presence of the G allele at position 1688, 
this results in the HinfI cutting site, whereas this site is lost when the A allele is present. After PCR 
amplification, the 114-bpproduct was digested with the HinfI restriction enzyme for10 h at 37 °C, 
resulting in an uncut product for IRF-1*A and 94- and 20-bp products for IRF-1*G, which were 
visualized on an ethidium bromide-stained 4.5% agarose gel. 
 
Statistical analysis 
Data are presented as genotype and allele frequencies for each gene polymorphism. For the 
comparison of genotype and allele frequencies, the χ2 test was performed using the GraphPad 
Instat® software package (Graphpad Software, San Diego, CA). A p-value < 0.05 was considered 
statistically significant. 
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Associations with the two gene polymorphisms were subsequently determined using the transmission 
disequilibrium test. This test scores the transmission of alleles from heterozygous parents to affected 
children by comparing the transmitted alleles vs. the untransmitted alleles. Because both gene 
polymorphisms under investigation are biallelic, this test assumes a 50% transmission of each allele if 
the polymorphism is not associated with the disease. 
 
 
Results 
Case–control study 
IL12B 
The A→C base pair substitution at position 1188 in the3′ UTR of IL12B results in the creation of a 
TaqI cutting site. All genotypes were in Hardy–Weinberg equilibrium. As can be seen from Table 1, no 
significant differences were seen in the genotype distributions between patients and healthy controls. 
We subsequently stratified patients according to the modified Marsh III classification. This resulted in 
75 patients with Marsh IIIA, 119 with Marsh IIIB and 64 with Marsh IIIC. No association with the TaqI 
gene polymorphism was found either when patients were subdivided according to this classification. 
Finally, no differences between genotype and allele frequencies were found when males and females 
were analyzed separately (results not shown). 
 
 
Table 1. Genotypes of the IL12B TaqI RFLP in 258 Dutch celiac patients and 237 healthy controls 
 Total Genotype 
AA 
Genotype 
AC 
Genotype 
CC 
Allele frequencies 
 N n (%) n (%) n (%) A  C 
Patients  
 
258  173 (67.0)  76 (29.5)  9 (3.5)  0.82  0.18 
Controls  
 
237  157 (66.3)  70 (29.5)  10 (4.2)  0.81  0.19 
 
AA indicates absence of the Taq I restriction site; CC indicates homozygous for the presence of the Taq I 
restriction site, and AC indicates heterozygous. 
 
 
IRF1 
The single base pair mismatch reverse primer used for the determination of the genotype frequencies 
of the IRF1 polymorphism introduces a HinfI restriction enzyme cutting site in the IRF1*G genotype. 
Table 2 shows the genotype distribution in 252 Dutch patients and 237 controls. The populations were 
in Hardy–Weinberg equilibrium, and the genotype and allele frequencies were similar between males 
and females. No association was found with this polymorphism when patients were compared with 
controls. When patients were classified according to the modified Marsh III classification, no 
association with the IRF1 polymorphism was found either (results not shown). 
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Table 2. Genotype of the IRF1 HinfI RFLP in 252 Dutch celiac patients and 237 healthy controls 
 Total Genotype 
AA 
Genotype 
AG 
Genotype 
GG 
Allele frequencies 
 N n (%) n (%) n (%) A  G 
Patients  
 
252  24 (9.5) 120 (47.6) 108 (42.9) 0.33 0.67 
Controls  
 
237  31 (13.0) 96 (40.5) 110 (46.5) 0.33 0.67 
 
AA indicates absence of the HinfI restriction site; GG indicates homozygous for the presence of the Hinf I 
restriction site, and AG indicates heterozygous. 
 
 
Family study 
From 123 CeD families, the parents were genotyped for the polymorphisms in IL12B and IRF1. From 
these 123 trios, there were 66 informative transmissions of heterozygous parents to affected children 
for the IL12B polymorphism, and 114 informative transmissions for the IRF1 polymorphism. For both 
polymorphisms, no significant deviation from the expected transmission rate of 50% was observed, as 
is shown in Table 3. 
 
Table 3. Transmission of the infrequent allele vs. transmission of the frequent alleles from  
heterozygous parents to affected children 
 IL12B*C 
(%) 
IL12B*A (%) P 
IL12B 66 informative transmissions 31 (47) 35 (53) ns 
 
 
 
 
IRF1*A (%) 
 
IRF1*G (%) 
 
IRF1 114 informative transmissions 53 (46.5) 61 (53.5) ns 
 
IRF1*A and IL12B*C represent the infrequent alleles, whereas IRF1*G and IL12B*A represent the common 
alleles. 
 
 
Discussion 
Genetic factors play an important role in the susceptibility to CeD. In particular, the role of the HLA-
DQ genes in CeD is well established, contributing an estimated 40% of the genetic risk of CeD 29. In 
order to identify non-HLA genetic factors related to CeD, several genome-wide mapping studies have 
been conducted 7-14. Several independent studies identified linkage with a region on chromosome 
5q31-33 and it is now generally accepted that this region, designated CELIAC2, harbors a gene 
involved in CeD susceptibility 8, 10, 18. Among the many genes that are located in this region, the gene 
encoding the IL-12 p40chain is of particular interest given its role in priming T cells to IFN-γ producing 
T helper 1 cells. It is now well established that CeD is associated with increased IFN-γ secretion at 
lesional sites. Thus, in a study by 15, it was shown that IFN-γ mRNA in mucosal biopsies was 
 IL12B and IRF1 gene polymorphisms and susceptibility to celiac disease 
 113 
increased more than 1000-fold in cases of untreated disease. Interestingly, however, in the same 
study, only minute amounts of IL-12 p40 mRNA expression were found in the same biopsies. A 
possible explanation for the discrepancy between IL-12 p40 and IFN-γ expression may be that T cells 
primed with a soluble protein in the presence of IL-12 are rendered capable of secreting IFN-γ 
independently of IL-12 on subsequent antigen stimulation. Therefore, the discrepancy between IFN-γ 
mRNA levels and IL-12 p40 mRNA does not exclude a role for a dysregulated IL-12 response in the 
susceptibility to CeD. In the present study, however, we found no significant association between IL-
12B genotypes and susceptibility to celiac disease. Also, no significant associations were found when 
patients were classified according to the severity of the disease. Our findings are in accordance with 
those of a previous study, where no association with this polymorphism was found in a group of celiac 
patients from Norway and Italy 30. Based on the results of these two studies involving three European 
populations, the role of this polymorphism in susceptibility to CeD can be excluded. It must be noted, 
however, that it cannot be entirely excluded that other IL12B variants may contribute to the cause of 
this immune-mediated Th1 disease. Given its potent and pluripotent role in the immuneresponse, IRF1 
is another positional and functional candidate gene for CeD. IRF1 is induced by several exogenous 
and endogenous factors, including cytokines, and in turn induces the induction of a large variety of 
genes. Of particular relevance for CeD, IRF-1 is a potent inducer of IFN-α, which in turn has been 
shown to be capable of inducing enhanced Th1 responses and crypt cell hyperplasia in explant 
cultures of human fetal gut 31. Another target of interest is the IL12B gene¸ since IRF-1 directly affects 
IL-12 production by macrophages 25, whereas IL-12 in turn can induce IRF-1 through STAT4 32. Thus, 
IRF-1 has a significant role in Th1 differentiation. Since IRF1 has not been studied previously in CeD, 
we determined whether a HinfI RFLP in the 3′ UTR of IRF1 is involved in CeD susceptibility. Based on 
the results of the present study, it can be concluded that it is very unlikely that this gene is involved in 
susceptibility to CeD. Having found no association with IL12B and IRF1in the pathogenesis of CeD, 
we need to consider other cytokines that are involved in Th1 differentiation. In this regard, the Th1-
inducing cytokine IL-23 (which consists of the IL-12 p40 chain linked to a p19 chain, not to the IL-12 
p35 chain) has been shown, at least in murine systems, to stimulate Th1 responses in memory cells 
more effectively than does IL-12. Thus, it is possible that it is more important than IL-12 in sustaining 
Th1 inflammation 33. Whether IL-23 plays a role in CeD, however, remains to be seen, and this is 
currently under investigation. 
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Abstract 
The mechanism by which mutations in Nucleotide-binding Oligomerization Domain (NOD2), 
predispose to Crohn’s disease (CD) is still poorly understood. Previous studies in mice have shown 
that NOD2 signaling inhibits Toll-Like Receptor (TLR)-2 responses. So far, this effect could not be 
reproduced in humans. Making use of monocytes isolated from normal NOD2 expressing subjects as 
well as NOD2 deficient CD patients, we tested the effect of NOD2 signaling on TLR responses after 
stimulation with different doses of the NOD2 ligand MDP, together with suboptimal doses of TLR 
ligands. Culture supernatants and nuclear extracts were isolated, and NF-κB activation and 
production of the pro-inflammatory cytokines TNF-α, IL-6, IL-12p40 and IL-12p70 were measured. 
Monocytes from individuals without NOD2 mutations or heterozygous for any of the NOD2 mutations 
respond to stimulation with MDP in a dose dependent fashion, although this response is weak 
compared to TLR stimulation. Simultaneous addition of TLR ligand and low doses of MDP to the 
culture medium resulted in a significant increase in the NF-κB activation as well as cytokine 
production, as compared to TLR stimulation alone. However, addition of higher doses of MDP in 
combination with TLR2 signaling led to a striking downregulation of the responses, whereby cytokine 
levels returned to baseline production. These results were reflected in the NF-κB activation. 
Importantly, this downregulation of TLR responses by high dose MDP was not seen in monocytes 
from NOD2-/- patients. 
The results show for the first time that human monocytes respond to combined TLR2/NOD2 signaling 
in a biphasic fashion. This mechanism is likely a safety mechanism to prevent exaggerated anti-
bacterial immune responses in the gut to high or perpetuating bacterial load. This regulatory 
mechanism is absent in NOD2-/- deficient patients and may therefore underlie the onset of IBD in this 
group of patients. 
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Introduction 
The innate immune system forms the first line of defense against microbial pathogens. Essential in 
the detection of pathogens is the family of Toll Like Receptors (TLRs) which recognize conserved 
microbial structures, such as bacterial cell wall components like lipopolysaccharide (LPS, recognized 
by TLR4, lipoproteins and lipoteichoic acid (LTA, recognized by TLR2), double stranded RNA 
(dsRNA, recognized by TLR3) or single stranded viral RNA (recognized by TLR7) 1, 2. Although the 
various TLRs signal via a range of adaptor molecules and different downstream kinases, the signaling 
ultimately result in an NF-κB dependent activation of inflammatory genes 1. Next to TLRs, which are 
all membrane bound receptors (whether or not on the cell surface or in intracellular vesicles), there 
are also various cytosolic receptors involved in the innate immune response. One of those is 
nucleotide-binding oligomerization domain 2 (NOD2). NOD2 is a sensor of bacteria-derived muramyl 
dipeptide (MDP) 3 4. It is a member of the NOD-leucine-rich repeat (LRR) protein family, which 
comprises of proteins that all consist of a C-terminal ligand recognition domain, a central NOD 
domain, and an N-terminal protein-protein interaction domain(s) 5 6. Members of the NOD-LRR protein 
family are known to be involved in regulation of apoptosis 7 and NF-κB activation 8. NOD2 has also 
been shown to display NF-κB activating properties, after binding of its ligand, MDP 3. NOD2 has been 
shown to be primary expressed in monocytic cells, dendritic cells and granulocytes 6, 9, and to a lesser 
extent in intestinal epithelial cells, especially Paneth cells, 10, 11, and T cells, in which it can be 
upregulated after TNF-α or LPS administration 9, 12. 
 
Mutations in the LRR of NOD2 are implicated in an increased risk of developing Crohn’s disease 
(CD), 13, 14 a chronic inflammatory disorder of the gastrointestinal tract. From epidemiological studies 
throughout the Western world, homozygosity for NOD2 mutations leads to a 20-40 times higher 
chance of developing CD, where the risk of developing the disease is approximately four times higher 
in individuals that are heterozygotic 15. 
It is shown that NOD2 activation can act synergistically with TLR activation, leading to a stronger 
immune response, but this potentiating effect is lost in cells from CD patients with mutations in NOD2 
3, 16-23
. This effect is seen at the level of immune cells, whereas in the intestinal Paneth cells the NOD2 
mutation leads to impaired production of α-defensins, which could lead to an overgrowth of the 
commensal-bacterial population 12, 24. Indeed, in a mouse model deficient for cryptdins, (the murine 
ortholog for α-defensins), it has been found that these animals are highly susceptible for bacterial 
infections, especially after oral administration, and not through intravenous or intraperitoneal routes 25. 
Furthermore, NOD2 has been shown to directly activate the IL-1β converting enzyme (ICE) 26, which 
is needed for the conversion of pro-IL-1β into the functional IL-1β 27. Subsequently, it has been shown 
in studies using human PBMCs that NOD2 deficiency leads to a decreased IL-1β expression 28, 29. 
Together, these data point to an important role of NOD2 in host defense at the level of various cell 
types and factors, but the importance of each effect from the mutation on associated risk with CD is 
not yet clear. 
Recently it has been implicated by Watanabe et al. that NOD2 activation leads to an inhibition of 
specifically TLR2 signaling in mice 30. MDP, as a derivative of the TLR2 ligand peptidoglycan, is also 
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recognized by TLR2 31, so that both NOD2 and TLR2 recognize the same bacterial substance, which 
could provide an explanation for why NOD2 interact with specifically this TLR. In the absence of 
NOD2, the lack of efficient dampening of the TLR2 response could conceivably lead to an unwanted 
strong immune response, which ultimately could lead to CD. In a follow up study by the same group, it 
was shown that NOD2 deficient mice actually need TLR2 signaling in order to develop colitis. They 
showed that Nod2-/- mice, adaptively transferred with OVA specific CD4+ T cells, develop a transient 
Th1 driven colitis when infected with a recombinant E.Coli strain, expressing OVA (ECOVA), and that 
this colitis induction by ECOVA can be prevented either by introducing a TLR2 deficiency in the mice, 
or by addition of anti IL-12p40 monoclonal antibodies 32. These findings further substantiate the initial 
finding that there is a close interaction between NOD2 and TLR2 signaling involved in downregulation 
of the immune response. 
Since the observations of Watanabe et al. were only seen in mice, we wanted to expand these 
studies to human cells. Monocytes isolated from individuals with or without mutations in NOD2 were 
stimulated with different doses of TLR ligands, combined with different doses of NOD2 stimulation. 
We found that strong NOD2 stimulation specifically affects the TLR2 signaling in a down modulating 
fashion, and that this effect was not seen in NOD2 deficient patients. 
 
 
Materials and Methods 
Preparation of human monocytes 
After approval of the Medical Ethical Committee of the Free University Medical Center, Crohn’s 
disease (CD) patients and healthy volunteers with known NOD2 statuses (See Supplementary Table 1) 
were recruited from our outpatient clinic. Written informed consent was obtained from all individuals 
before venous blood was drawn. Human peripheral blood mononucleated cells (PBMCs) were 
isolated from 50 ml of heparinized peripheral blood by density gradient centrifugation using Ficoll-
Paque Plus (Amersham Biosciences). Monocytes were isolated from the PBMCs using a 52% 
gradient of Percoll (Amersham Biosciences). Purity of monocytes was assessed using Flow 
cytometric analysis of the cell surface antigen CD14, using a PC5-labelled anti CD14 mAb (IOTest, 
Beckman Coulter). Monocytes were cultured in triplicate in 96 wells flat-bottom plates (105 cells/well) 
in 100 µl RPMI (Invitrogen), supplemented with 1% Penicillin/Streptomicyn (Invitrogen). The cells 
were first allowed to rest overnight in culture medium, and then stimulated for 3 hours or 1 day (in 
separate plates). Cells were stimulated with muramyl dipeptide (MDP, InvivoGen) Lipopolysaccharide 
from Salmonella enterica serotype Enteritidis (LPS, Sigma), Pam3CSK4 (Pam, InvivoGen) or 
peptidoglycan from S. Aureus (PGN, BioChemika) poly I:C (InvivoGen) or Imiquimod (InvivoGen). Cell 
viability was checked using trypaan blue staining. 
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Measurement of cytokines 
ELISA assays for IL-6, TNF-α (DuoSet ELISA Development System, R&D Systems), IL12p40 and 
IL12p70 (OptEIA Sets, BD Biosciences) were performed according to manufacturers 
recommendations with culture supernatant in 1:4, 1:10, 1:20, and 1:50 dilutions for IL-12p70, TNF-α, 
IL-12p40, and IL-6, respectively. 
 
NF-κB activation 
Nuclear extracts were isolated from the monocytes using the Nuclear Extraction kit, and translocation 
was assessed using the NF-κB Family detection kit (both Active Motiv), according to manufacturers 
recommendations. Briefly, after 20 minutes of stimulation, supernatant was removed, the cells were 
washed with ice cold PBS with phosphatase inhibitors, and cells lysates were prepared in a hypotonic 
buffer and detergent, nuclei were separated from the lysates by high speed centrifugation and lysed. 
After centrifugation, the concentration of nuclear extract in the supernatants was determined by using 
a BCA protein assay (Pierce). Translocation was assessed with the ELISA-based NF-κB Family 
detection kit. The appropriate binding antibodies were coated on the plates and 5 µg of nuclear 
extract was used to detect the subunits. Measurements were done in an ELISA plate reader (Bio-
Kinetics Reader Microplate EL 312e, Bio-Tek Instruments, USA) at 570 nm for the BCA assay and at 
450 nm for the NF-κB Translocation assay. 
 
Statistical Analysis 
Results were described as means and minimum/maximum values. Statistical differences were 
calculated using Graphpad Prism 4 (GraphPad Software Inc., San Diego). Two-tailed p-values for 
differences in cytokine production were calculated using the Wilcoxon rank test for paired values and 
were considered to be significant at the p < 0.05 level. 
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Results 
Genotype dependent effects on cytokine production after TLR2 and TLR4 stimulation 
combined with NOD2 stimulation 
To study the effect of NOD2 co-stimulation on TLR responses, we isolated monocytes from 5 healthy 
donors and 15 Crohn’s disease patients divided in 3 groups of 5 carrying 0, 1, or 2 mutant NOD2 
alleles, respectively.  
After isolation and an overnight rest the cells were stimulated with suboptimal doses of TLR ligands, 
together with different doses of MDP. Culture supernatants were harvested after 3 or 24 hours and 
the production of TNF-a, IL-6, and IL-12 was determined. 
The dose of MDP needed for optimal stimulation differed from person to person, and was in the range 
from 1 to 25 µg/ml MDP. For clarity of the graphs, we show here only the dose that resulted in the 
highest cytokine production for that particular individual together with the response without MDP (TLR 
stimulation only), as well as the response with the maximal dose of MDP (100 µg/ml). 
 
Figure 1. TNF-α production in relation to NOD2 genotype in monocytes stimulated with 
Pam3CSK4 in conjunction with different doses of MDP 
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Monocytes were isolated from 5 healthy controls as well as from a total of 15 Crohn’s disease patients with 
different NOD2 genotypes. Cells were allowed to rest overnight, and stimulated for 3 hours with pure synthetic 
TLR2 ligand (Pam3CSK4; 50 pg/ml) and MDP (0 or 100 µg/ml and an intermediate dose ranging between 1-25 
µg/ml). Cell culture supernatants were harvested and analyzed by ELISA for cytokine production. Each panel 
includes 5 different donors stimulated with the 3 different MDP doses. Panel A, healthy controls; B, Crohn’s 
disease patients without NOD2 mutation; C, heterozygous NOD2 deficient patients; D, homozygous NOD2 
deficient patients. 
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Table 1 Average values of cytokine production by NOD2 competent monocytes 
  0 MDP 
absolute value (range) 
(pg/ml) 
1-25 MDP 
absolute value (range) 
(pg/ml) 
p value compared to 0 MDP 
100 MDP 
absolute value (range) (pg/ml) 
p values compared to 0 MDP 
and 1-25 MDP resp. 
TLR2 692,6 (28-2761) 1625 (176-4073) 
0,002 
665,8 (85-1857) 
0,9/0,004 
 
TNF-α 
TLR4 996,7 (43-3063) 1679 (161-5862) 
0,0098 
1703 (260-5582) 
0,004/0,7 
TLR2 543,7 (100-2217) 1661 (518-5640) 
0,004 
634 (109-1883) 
0,32/0,0078 
 
IL-6 
TLR4 1513 (100-4223) 2328 (441-5716) 
0,0117 
2461 (521-8396) 
0,006/0,7 
TLR2 140,4 (15-320) 242 (23-693) 
0,23 
166,1 (0-569) 
0,8/0,004 
 
IL-12p70 
TLR4 109,6 (0-522) 174,4 (0-630) 
0,04 
216,6 (13-961) 
0,0098/0,4 
TLR2 7883 (1611-18610) 11870 (2432-30650) 
0,04 
8312 (546-22280) 
0,8/0,002 
 
IL-12p40 
TLR4 5521 (1381-15800) 10600 (2481-23330) 
0,03 
11540 (2347-22830) 
0,5/0,1 
 
 
Shown in Figure 1 is the TNF-α response of the monocytes from different groups of CD patients and 
healthy controls after stimulation with 50 ng/ml of the TLR2 ligand Pam3CSK4. Adding the 
intermediate dose of MDP resulted in substantial upregulation of TNF-α responses in 13 out of 15 
individuals (either patients or healthy controls) carrying at least one wildtype allele. Overall, the mean 
TNF-α response among these individuals increased from 865 (range: 28-2761) pg/ml after Pam3CSK4 
stimulation only to 1556 (range: 176-4073) pg/ml after Pam3CSK4 + 1-25 µg/ml MDP, p<0,0001) 
(Table 1). Strikingly, adding 100 µg/ml MDP resulted in a marked reduction of TNF-α responses as 
compared to the intermediate dose and at this concentration of MDP, TNF-α values returned to, or 
below the baseline level that was seen after Pam3CSK4 stimulation alone (754 pg/ml [range: 85-
1857], p = 0,0002 as compared with the intermediate dose). 
 
Table 2 Average values of cytokine production by NOD2 heterozygous monocytes 
  0 MDP 
absolute value (range) 
(pg/ml) 
1-25 MDP 
absolute value (range) 
(pg/ml) 
p value compared to 0 MDP 
100 MDP 
absolute value (range) (pg/ml) 
p values compared to 0 MDP 
and 1-25 MDP resp. 
TLR2 1221 (428-1674) 1420 (513-2169) 
0,06 
931,8 (591-1349) 
0,3/0,3 
 
TNF-α 
TLR4 1964 (931-2642) 2375 (920-3495) 
0,12 
2354 (1041-3731) 
0,3/1 
TLR2 1237 (356-2150) 1440 (813-2277) 
0,25 
1157 (515-2923) 
1,1/0,6 
 
IL-6 
TLR4 1297 (273-2581) 1785 (875-3063) 
0,12 
1886 (907-3405) 
0,12/0,4 
TLR2 27 (0-98) 81,4 (0-276) 
0,25 
31,6 (0-103) 
1,1/0,12 
 
IL-12p70 
TLR4 73,6 (19-115) 155,4 (110-224) 
0,06 
134 (12-256) 
0,3/0,8 
TLR2 8459 (4211-14080) 15700 (8027-30650) 
0,06 
9377 (2453-22280) 
1/0,06 
 
IL-12p40 
TLR4 7323 (1169-15800) 10850 (3865-23330) 
0,06 
 8975 (2233-22830) 
0,06/0,8 
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The magnitude of this response was particularly evident in individuals carrying two wildtype alleles 
and less pronounced in heterozygous individuals, which is indicative of a gene-dosage effect. Indeed, 
as shown in Table 2, the increase in TNF-α secretion in heterozygous individuals was only marginal 
(from a mean of 1221 pg/ml to 1420 pg/ml), whereas in wildtype individuals the mean production 
increased from 692 pg/ml to 1625 pg/ml (Table 1). 
As expected, adding MDP did not result in significant upregulation of TNF-α in monocytes from NOD2 
deficient patients. Thus, in this group of individuals mean TNF-α production after Pam3CSK4 
stimulation alone was 783 pg/ml (range: 351-1313), and 914 pg/ml (range 357-1991) after stimulation 
with Pam3CSK4 + 1-25 µg/ml MDP (p = 0.6). Adding the highest dose of MDP did not result in a 
significant increase in TNF-α production either (mean 1029 pg/ml [range: 355-2104]; p = 0.2) (Table 3, 
Figure 1d). So, in sharp contrast to the findings seen in individuals carrying at least 1 NOD2 wildtype 
allele, no up- and downregulation by MDP of the TLR2 induced response was seen in NOD2-/- 
individuals. 
 
Table 3 Average values of cytokine production by NOD2-/- monocytes 
  0 MDP 
absolute value (range) 
(pg/ml) 
1-25 MDP 
absolute value (range) 
(pg/ml) 
p value compared to 0 MDP 
100 MDP 
absolute value (range) (pg/ml) 
p values compared to 0 MDP 
and 1-25 MDP resp. 
TLR2 783 (351-1313) 914 (357-1991) 
0,6 
1029 (355-2104) 
0,2/0,4 
 
TNF-α 
TLR4 2789 (454-5083) 3340 (499-6275) 
0,6 
3412 (523-6693) 
0,6/0,6 
TLR2 794 (322-2112) 1125 (402-3260) 
0,12 
1380 (320-4051) 
0,37/0,625 
 
IL-6 
TLR4 3321 (1670-6845) 4620 (1700-10689) 
0,12 
4952 (3481-9800) 
0,12/0,625 
TLR2 89 (59-156) 84 (34-138) 
0,8125 
126 (67-188) 
0,12/0,12 
 
IL12-p70 
TLR4 457 (61-1670) 527 (112-1837) 
0,06 
498 (134-1715) 
0,3/0,4 
TLR2 3135 (513-3663) 2727 (2362-4034) 
0,8125 
2918 (2661-3850) 
0,6/0,4 
 
IL12-p40 
TLR4 9054 (669-3063) 8417 (372-23416) 
0,625 
8830 (1210-25903) 
0,8125/0,8125 
 
 
To exclude the possibility that the high dose of MDP is in fact lethal for the cells, cell viability was 
determined and was found not to be different between the intermediate and high MDP dose. In 
addition, as shown in Figure 2, the decrease in cytokine production after the high dose of MDP is only 
seen in Pam3CSK4/MDP co-stimulation, and not in LPS/MDP co-stimulation. Thus, cells from 
functional NOD2 expressing individuals that received LPS as a TLR4 stimulus combined with the high 
dose of MDP did not show the remarkable reduction in TNF-α production (mean 1910 pg/ml 
[range:161-5862]) as compared to the intermediate dose of LPS/MDP (mean 1920 pg/ml [range 260-
5582]; p = 0,8, Table 1). 
Taken together, these findings indicate that NOD2 signaling influences TLR2 signaling in a biphasic 
fashion, first augmenting the response, and at a higher dose, diminishing the response. This response 
is TLR2 specific, independent from disease status and is abrogated in NOD2-/- individuals. 
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Figure 2. TNF-α production in relation to NOD2 genotype in monocytes stimulated with LPS 
in conjunction with different doses of MDP. 
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Monocytes were isolated from 5 healthy controls as well as from a total of 15 Crohn’s disease patients with 
different NOD2 genotypes. Monocytes were allowed to rest overnight, and were stimulated for 3 hours with TLR4 
ligand (LPS, 10 pg/ml) and MDP (0 or 100 µg/ml and an intermediate dose ranging between 1-25 µg/ml). Cell 
culture supernatants were harvested and analyzed by ELISA for cytokine production. Each panel includes 5 
different donors stimulated with the 3 different MDP doses. Panel A, healthy controls; B, Crohn’s disease patients 
without NOD2 mutation; C, heterozygous NOD2 deficient patients; D, homozygous NOD2 deficient patients. 
 
 
In addition to TNF-α, we also tested the IL-6 response (Figure 3). The same biphasic response to 
MDP stimulation combined with Pam3CSK4 as seen for TNF-α production was seen for IL-6 in NOD2 
competent individuals. After an initial increase in IL-6 production after addition of the intermediate 
dose of MDP (698 pg/ml [range100-2217] after Pam3CSK4 alone as compared to 1592 pg/ml range: 
518-5640] after Pam3CSK4 + 1-25 µg/ml MDP, p = 0,001), a significant reduction in IL-6 production 
was seen when the highest dose of MDP was compared with the intermediate doses (783pg/ml 
[range: 109-2923] p = 0,004). Little effect was seen in the NOD2-/- monocytes (794 pg/ml [range: 322-
2112] after Pam3CSK4 alone, 1125 pg/ml [402-3260] after Pam3CSK4 + 1-25 µg/ml MDP; p = 0,1, and 
1380 pg/ml range: 320-4051] after Pam3CSK4 + 100 µg/ml MDP; p = 0,4 as compared to the 
intermediate dose of MDP, Table 3). Again, these effects on IL-6 production were not seen in the co-
stimulations of MDP in conjunction with LPS (Figure 3 and Tables 1-3). 
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Figure 3. IL-6 production in relation to NOD2 genotype in monocytes stimulated with 
 Pam3CSK4 in conjunction with different doses of MDP. 
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Monocytes were isolated from 5 healthy controls as well as from a total of 15 Crohn’s disease patients with 
different NOD2 genotypes. Monocytes were allowed to rest overnight, and were stimulated for 3 hours with pure 
synthetic TLR2 ligand (Pam3CSK4; 50 pg/ml) and MDP (0 or 100 µg/ml and an intermediate dose ranging 
between 1-25 µg/ml). Cell culture supernatants were harvested and analyzed by ELISA for cytokine production. 
Each panel includes 5 different donors stimulated with the 3 different MDP doses. Panel A, healthy controls; B, 
Crohn’s disease patients without NOD2 mutation; C, heterozygous NOD2 deficient patients; D, homozygous 
NOD2 deficient patients. 
 
 
In the original study by Watanabe et al. it was demonstrated that Nod2 deficient mice exhibited 
increased IL-12 responses as compared with wildtype mice. In a next series of experiments we 
therefore determined IL-12 secretion in human monocytes, after 24 hours of stimulation with the 
different co-stimulation regimes. Contrary to the findings in mice, no increased secretion of IL-12 was 
found in NOD2-/- individuals. In fact, as can be seen from Figures 4 and 5, a similar pattern as seen 
with TNF-α and IL-6 responses was found for this cytokine. Thus, IL-12p40 increased from 8075 
pg/ml (range: 1611-18611) after Pam3CSK4 alone to 13148 pg/ml (range: 2432-30648) after 1-
25µg/ml MDP (p < 0,0001) and returned to 8667 pg/ml (546-22283) pg/ml after 100 µg/ml MDP for IL-
12p40 (p < 0,0001) in individuals carrying at least one wildtype allele. For IL-12p70 these values were 
102 pg/ml (range: 0-326) after Pam3CSK4 alone, 188 pg/ml (range: 0-693) after 1-25 µg/ml MDP and 
121 pg/ml (range: 0-569) after 100 µg/ml MDP, p = 0,0043, Table 4???). It must be noted however 
that similar to the findings in mice, the IL-12p70 responses were generally low. Again, no measurable 
effect of MDP on the IL12p40 and IL12p70 production was found in monocytes from NOD2-/- patients. 
Similarly, this biphasic response was not seen after simultaneous stimulation with LPS and MDP. 
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Figure 4. IL-12p70 production in relation to NOD2 genotype in monocytes stimulated with  
Pam3CSK4 in conjunction with different doses of MDP.  
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Figure 5. IL-12p40 production in relation to NOD2 genotype in monocytes stimulated with  
Pam3CSK4 in conjunction with different doses of MDP. 
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Monocytes were isolated from 5 healthy controls as well as from a total of 15 Crohn’s disease patients with 
different NOD2 genotypes. Monocytes were allowed to rest overnight, and were stimulated for 24 hours with pure 
synthetic TLR2 ligand (Pam3CSK4; 50 pg/ml) and MDP (0 or 100 µg/ml and an intermediate dose ranging 
between 1-25 µg/ml). Cell culture supernatants were harvested and analyzed by ELISA for cytokine production. 
Each panel includes 5 different donors stimulated with the 3 different MDP doses. Panel A, healthy controls; B, 
Crohn’s disease patients without NOD2 mutation; C, heterozygous NOD2 deficient patients; D, homozygous 
NOD2 deficient patients. 
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This indicates that also for IL-12, NOD2 interacts in a biphasic manner with TLR2. Furthermore, the 
fact that these cells continue producing IL-12p40 and IL-12p70 after 24 hours of incubation with high 
doses of MDP in conjunction with LPS is indicative of the fact that the high concentration of MDP is 
not toxic. 
 
Table 4 Average values of cytokine production by monocytes expressing at least one functional 
NOD2 allele 
  0 MDP 
absolute value (range) 
(pg/ml) 
1-25 MDP 
absolute value (range) 
(pg/ml) 
p value compared to 0 
MDP 
100 MDP 
absolute value (range) 
(pg/ml) 
p values compared to 
0 MDP and 1-25 MDP 
resp. 
TLR2 865 (28-2761) 
 
1556 (176-4073) 
<0,0001 
754 (85-1857) 
0,5/0,0002 
 
TNF-α 
TLR4 1319 (43-3063) 1910 (161-5862) 
0,0009 
1920 (260-5582) 
0,0034/0,8 
TLR2 783,3 (0-2217) 1592 (518-5640) 
0,0005 
783 (109-2923) 
0,5/0,004 
 
IL-6 
TLR4 1548 (0-4223) 2160 (441-5716) 
0,0007 
2296 (521-8396) 
0,0007/0,5 
TLR2 102 (0-326) 188 (0-693) 
0,078 
121 (0-569) 
0,9/0,0043 
 
IL-12p70 
TLR4 97 (0-522) 168 (0-630) 
0,0012 
189 (12-961) 
0,0043/0,67 
TLR2 8075 (1611-18611) 13148(2432-30648) 
0,0026 
8667 (546-22283) 
0,7/<0,0001 
 
IL-12p40 
TLR4 6722 (1169-15799) 10765 (2481-23328) 
0,0015 
9829 (2333-22826) 
0,09/0,25 
 
 
NF-κB activation 
In addition to the cytokine responses, we also assessed the NF-κB activation. For this purpose, cells 
from a wild-type donor, a NOD2 heterozygous donor and a NOD2 deficient donor were stimulated 
with either Pam3CSK4, Pam3CSK4 and a low dose of MDP (1 µg/ml), and Pam3CSK4 with the high 
dose of MDP (100µg/ml). Cells were stimulated for 20 minutes after which nuclear extracts were 
isolated. The amount of translocated NF-κB subunits was then determined. As can be seen from 
Figure 6, for the wildtype, and to a lesser extent for the heterozygous donor, the p50 subunit exhibited 
a similar pattern as the cytokine responses, e.g. an elevated translocation was seen after 
simultaneous stimulation with Pam3CSK4 and a low dose of MDP, while adding a higher dose of MDP 
resulted in a less pronounced translocation. A similar pattern was seen for the p65 subunit. Again, this 
response was abrogated in NOD2-/- individuals. This effect was not seen in the other tested subunit, 
c-Rel. In fact, c-Rel was hardly expressed by these cells, suggesting that the p50 and p65 units are 
the most important in NOD2 regulated activation. 
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Figure 6. Translocation of NF-κB subunits in relation to NOD2 genotype in monocytes. Monocytes 
were isolated from a non-mutated donor, a heterozygous donor and a NOD2 deficient donor. 
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Monocytes were allowed to rest overnight, and then stimulated with MDP alone (100 µg/ml, dotted bar), 
Pam3CSK4 (50 pg/ml, striped bar), Pam3CSK4 + 1 µg/ml MDP (grey bar), or Pam3CSK4 + 100 µg/ml MDP (black 
bar), or left unstimulated (neg. control, open bar). After 20 minutes incubation, nuclear extracts were isolated, and 
the relative translocation of the NF-κB subunits p50, p65, and c-Rel was assessed by comparing the OD values 
in a NF-κB specific ELISA. 
 
 
Discussion 
The strong genetic associations of the NOD2 gene and Crohn’s disease clearly point to an important 
role for alterations in innate immunity in the etiology of the disease13-15. How the alterations in the 
NOD2 protein exert their effects is not completely clear, not in the last place because this sensor of 
the bacterial peptidoglycan component MDP is expressed in various cell types, including Paneth cells 
as well as macrophages and dendritic cells. Furthermore, activation of NOD2 results in activation of 
multiple pathways, including the NF-κB and MAPK pathways, leading to a variety of responses 3, 4. 
Several studies have made it clear that the NOD2 mutations found in man result in a loss of NF-κB 
signaling function leading to impaired cytokine production after NOD2 stimulation, and to an impaired 
costimulatory effect of NOD2 signaling on TLR mediated cytokine production 3, 16-23. This seems 
contradictory to the elevated levels of NF-κB activation-dependent Th1 cytokines, like TNF-α, IL-1β, 
IL-6, IL-12, IL-18, and IFN-γ found in the inflamed tissues from patients with Crohn’s disease 33-37. 
In mice, deficiency for NOD2 does not lead to spontaneous intestinal inflammation, however they are 
more susceptible to dextran sodium sulfate (DSS) induced colitis and 38 impaired antibacterial 
responses were found after oral exposure to pathogens 25. This suggests that in spite of various other 
bacterial sensing receptors, NOD2 is required for the optimal regulation of the antimicrobial response, 
possibly through expression of cryptdins by the Paneth cells. NOD2 has also been suggested to play 
 Chapter 7 
 130 
a role as a negative regulator of TLR2 signaling, leading to excessive NF-κB dependent IL-12 
production associated with the strong Th1 response seen in murine colitis 30, 32. In contrast, in man no 
indications for a negative regulatory interaction between NOD2 and TLR2 exist, and all data on the 
simultaneous activation through NOD2 and TLRs, including TLR2, show a positive synergistic effect. 
Our data presented in this paper may bridge this controversy and clearly show for the first time that 
TLR2 signaling and NOD2 signaling are linked, and that high doses of NOD2 ligands negatively 
interfere with TLR2 signaling. The NOD2 ligand MDP itself only marginally leads to upregulation of 
cytokine production, but stimulation with MDP in combination with TLR2 or TLR4 ligands dramatically 
enhances this production. In monocytes which are activated with TLR ligands and moderate levels of 
the MDP a synergistic effect is seen, correlating with earlier reports. However, when high doses of 
MDP are used this synergistic effect is lost in the case of TLR2 signaling, but not in the case of TLR4. 
Crohn’s disease patients with both NOD2 alleles mutated do not show this downregulation, whereas a 
gene dosage effect is seen in patients with one allele affected. The results clearly show that high 
doses of MDP do interact with TLR2 signaling in a negative fashion and that this is based on 
downregulation of the NF-κB pathways. 
On could argue that the MDP concentration added is fairly high, and that the effect seen in cytokine 
production are not due to an active inhibition of the TLR2 signaling, but to toxic effects from the high 
MDP concentrations. The cells that received the high MDP dose however, remained viable, and could 
still produce high levels of cytokines in combination with TLR4 stimulation, even after prolonged 
periods of incubation, as was shown by the IL-12 production. Furthermore, the NOD2 deficient cells 
did not produce less cytokines after high dose treatment compared to intermediate dose treatment, 
indicating that the effects seen are indeed indicative of a NOD2-TLR2 interaction. The importance of 
the linkage between TLR2 and NOD2 signaling pathways, which we show here for the fist time in 
man, may be related to the fact that both TLR2 and NOD2 recognize closely related structures with 
MDP being a derivative of the TLR2 ligand peptidoglycan31. 
The biphasic response seen with lower and intermediate ligand stimulation being synergistic and only 
at high ligand levels leading to negative regulation points to complex signaling pathways. The loss of 
regulatory function of the NOD2 molecule as inferred from our experiments can explain the excessive 
Th1 responses seen in IBD patients and the strong linkage of the mutation of NOD2 and disease. It 
remains to be seen whether this function is important at the initial stage of recognition of microbial 
pathogens or plays a role at later stages of inflammation. The biphasic effects of NOD2 stimulation on 
TLR2 signaling could also be reflected in the overall effects of NOD2 mutation on the pathogenesis of 
CD. 
First, an increase in susceptibility to infection by commensal bacteria could be caused by a reduced 
barrier function of the intestinal epithelium, due to impaired α-defensin production by Paneth cells 12, 
24
, or a reduced IL-1β responses to bacterial challenge 26-29 combined with a less strong initial 
potentating of TLR responses 3, 16-23. This way NOD2 variants could lead to a weaker mucosal 
defense, leading to overgrowth of commensal bacteria. 
Second, when there is an ongoing mucosal immune response, and the negative regulation of NOD2 
on specifically TLR2 is lacking, this can result in an unwanted strong response 30, 32. Without a proper 
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downmodulation of the immune response, this provides an activated immune setting for ongoing 
inflammation as seen in Crohn’s disease. That the expression of NOD2 can be induced in T cells 
under the influence of pro-inflammatory factors such as TNF-α 9, 12, adds another level of complexity 
to the etiology of Crohn’s disease and suggests that NOD2 could also play a role in later stages of the 
disease when the adaptive immune system gets involved. 
Clearly, NOD2 is a key player in innate immune responses of many cell types. The lack of an initial 
strong response, combined with subsequent insufficient TLR2 inhibition by due to NOD2 defects 
could be an attractive mechanism that plays an important part in CD pathogenesis. To determine the 
exact role(s) of NOD2 in the etiology of CD, it will be important to dissect the particular role of NOD2 
and its interaction with TLR2 in the various cell types involved in the intestinal homeostasis, such as 
epithelial Paneth cells and hemopoietic immune cells. 
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Supplementary Table 1 Genotypes of Crohn’s disease patients 
  
NOD2 heterozygous patients Genotype 
C1 L1007frs/+ 
C2 L1007frs/+ 
C3 L1007frs/+ 
C4 G908/+ 
C5 G908/+ 
  
NOD2 deficient patients  
D1 L1007frs/G908 
D2 L1007frs/G908 
D3 L1007frs/G908 
D45 L1007frs/R702W 
D5 L1007frs/L1007frs 
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The studies described in this thesis were intended to contribute to a better understanding of the 
genetic and immunological mechanisms underlying intestinal inflammation. 
The predisposition to develop IBD, of which Crohn’s disease (CD) and ulcerative colitis (UC) are the 
two major components, is largely genetically determined. The major difficulties in identifying these 
factors rely on the fact that CD and UC are complex genetic diseases which means that there are 
different genetic factors contributing to disease susceptibility. These susceptibility factors do not 
necessarily have to occur in each patient; in fact, the strongest genetic risk factor identified so far 
occurs only in a minority of patients. In addition, it is well appreciated that individual patients may vary 
widely in clinical manifestation of the disease, referred to as clinical heterogeneity. Finally, disease is 
greatly influenced by environmental factors, life style and gut flora. These factors combined have 
hampered identification of the disease genes as well as understanding their role in disease 
pathogenesis. The current knowledge on the etiology of IBD is summarized in Chapter 1. 
The pitfalls in unraveling the pathogenesis of IBD can in part be circumvented by the use of animal 
model systems. The advantage of these models is that they constitute a lower degree of genetic 
complexity and in addition, disturbing environmental factors can be kept stable. However one has to 
keep in mind that such models do not always fully reflect human disease, and that extrapolation has 
to be done with caution. Nevertheless, these models have been successfully applied to IBD research 
and have provided substantial information relevant to human disease. An overview of the various 
models used in IBD is given in Chapter 2. 
An important observation is that different strains of mice show different grades of susceptibility to 
colitis, indicating that there must be underlying genetic differences that cause this variation. In our 
search for novel genes involved in IBD, it is exactly the latter of these features of mice we applied in 
the first part of our studies (Chapter 3). 
In this study, we performed a genome screen on a G-protein α inhibitory chain 2 (Gαi2, encoded by 
Gnai2) deficient mouse model for colitis. C3H/HeN mice homozygous for the Gnai2 deficiency, when 
reared under specific-pathogen-free conditions, develop colitis as early as 6 weeks of age, whereas 
Gnαi2-/- C57BL/6J mice maintained under identical circumstances, are highly resistant. 
The colitis in C3H/HeN Gnai2-/- mice is characterized by severe diarrhea and weight loss, frequently 
accompanied by rectal prolapse and dilation of the colon. Microscopically, massive infiltrations of 
lymphocytic cells are seen, accompanied by depletion of goblet cells. Also, there is formation of crypt 
elongation, with high vascular density and transmural bowel wall thickening with ulceration. In 
general, only the distal half of the colon is involved, with a sharp demarcation between the involved 
and non-involved areas (See also Figure 2 in Chapter 3). Immunologically, the inflammation is 
characterized by a Th1 type inflammation with markedly high levels of IL-12, and low levels of IL-10. 
Gαi2 normally inhibits IL-12 production and thus in the absence of this molecule, IL-12 production and 
the Th1 response is greatly exaggerated 1. This could be one explanation as to why Gnai2-/- mice 
develop colitis. A second possible explanation could lay within defects in B cell development. It has 
been shown that Gnai2-/- mice display a reduction in specific types of B cells, that have the capacity to 
produce IL-10. Indeed, Gnai2-/- mice show a decreased in vitro LPS-induced B cell IL-10 responses 2. 
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By means of genome-wide microsatellite methodology we performed a genetic analysis to identify 
genetic susceptibility loci in Gnai2-/- (C3H/HeN x C57BL/6J) F2 generation intercrosses. This genetic 
screening procedure allowed identification of a highly significant susceptibility locus on chromosome 
3, provisionally named Gpdc1. It is interesting to point out that exactly the same locus on 
chromosome 3 was identified in a different mouse model, the IL-10 deficient mouse model for colitis 3, 
indicating that the gene(s) located in this quantitative trait locus (QTL) have a profound effect on 
susceptibility to intestinal inflammation in the presence of another gene defect . In addition to this QTL 
on chromosome 3, other loci on chromosomes 1 (Gpdc2), 9 (Gpdc3), and the X-chromosome were 
found. 
Based on both their function in immune regulation or epithelial barrier function, there are several 
genes present in the identified loci that would make attractive candidate genes. The most prominent 
for the locus on chromosome 3 showing strongest linkage are the genes encoding the NF-κB p105 
transcription factor (Nfkb1, also discussed in more detail below), epithelial growth factor (Egf), and 
guanylate binding protein-1 (Gbp1).The gene most interesting due to its location closest to the peak 
linkage in Gpdc1, as well as its eminently important role in immune activation is the gene encoding 
Nfkb1. NF-κB designates a group of critical transcription factors controlling various promoters of pro-
inflammatory cytokines, cell-surface receptors, transcription factors, and adhesion molecules 4. The 
fact that IL-12 is a cytokine that is under transcriptional regulation of NF-κB makes this gene of even 
more interest, since in the Gnai2-/- model, the IL-12 expression is clearly altered 1. Clearly, any 
mutation affecting the Nfkb1 gene would have major implications for a great variety of immunological 
and/or inflammatory processes, and could be explanatory for the strain differences in susceptibility in 
C57BL/6J mice and C3H/HeN mice. 
To address this possibility, we sequenced the coding region of Nfkb1 and aligned the sequences of 
both strains to each other and to the known sequences from GenBank. This study is described in 
Chapter 4, as an Addendum to Chapter 3. We found 5 single nucleotide polymorphisms (SNPs) of 
which one lays in the 3’-UTR of the gene whereas the remainder occur in the coding region. All the 
SNPs identified in the coding region of the gene are silent mutations, i.e. mutations that do not cause 
a change in amino acid composition of the protein. 
It must be noted however that we only sequenced the cDNA, omitting the 24 introns, the promoter 
and the 3’UTR. Mutations in the promoter, the introns, and even the 3’UTR could be involved in 
generating different splice variants or the expression of the gene. Ongoing studies in congenic mouse 
strains in which the QTL found on chromosome 3 is being transferred from the susceptible strain onto 
the resistant strain and vice versa will be helpful to further discern whether Nfkb1 is involved in colitis 
susceptibility in the Gnai2-/- model, and if so if it could affect the IL-12 production in such a way that it 
would explain the elevated levels seen in both murine colitis and human CD. 
Indirect evidence that this gene might be important in the susceptibility to colitis comes from a recent 
study by Karban et. al. 5, who found an elevated frequency for a mutation in the promoter of the 
human gene NFKB1 in UC patients. These findings enthused us to investigate whether this 
polymorphism was also present in a group of Dutch Caucasian IBD patients from our outpatient clinic. 
As described in Chapter 5, this study demonstrates that the allele frequency of the –94 ATTG-
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deletion was also elevated in our cohort of UC patients, whereas this difference was not observed in 
CD. The association found in UC appeared to be a little stronger in men, and patients homozygous for 
the –94 ATTG-deletion allele (men and women together) had a significantly younger age of onset of 
disease. 
The exact mechanism underlying the association between NFKB1 gene polymorphism and 
susceptibility to UC remains so far to be determined, but one can think of several explanations. 
NF-κB activation is found to be upregulated in IBD patients, in the intestinal mucosa of both CD and 
UC patients 6, 7. This is seemingly in contradiction with the higher prevalence of the promoter 
polymorphism, since the deletion variant associated with UC showed strongly diminished binding of 
nuclear proteins isolated from normal human colonic tissue and cell lines 5. 
These effects can be explained in several ways. NFKB1 codes for the p105/p50 subunit of NF-κB 
complexes 8. To exert its effect, p50 binds to p65 to form biologically active heterodimers which 
translocate from the cytoplasm of the cell to the nucleus. Here, they bind to NF-κB binding sites in 
promoter sequences of genes coding for inflammatory proteins, and regulate their transcription. 
Alternatively, p50 is able to form homodimers which block transcription by binding to the NF-κB sites 
in the nucleus 9. Should the diminished NFKB1 transcription now lead to less available p50, fewer 
inhibitory p50/p50 homodimers can be formed, and this could in turn lead to a stronger activation of 
transcription of inflammatory genes, leading to the strong NF-κB induced immune response, as seen 
in UC. 
Alternatively, low levels of p50 could lead to a poor innate immune response. Bacteria that normally 
would have been recognized and eliminated by this first line of defense are now providing sustained 
antigenic signals leading to an ongoing inflammation. For example, mice lacking Nfkb1 are highly 
susceptible to colitis induction 10-12. On the other hand, mice overexpressing NF-κB p50 also show 
chronic inflammation and higher susceptibility to bacterial infections 13. Clearly, NF-κB needs to be 
regulated very accurately, and any disturbance of the balance can lead to aberrant immune 
responses 
NF-κB activation is involved in many inflammatory processes and is mandatory for the transcription of 
many cytokines involved in both UC and CD. As described in Chapter 2, it is well known from animal 
models of intestinal inflammation that virtually any disturbance of cytokine responses can lead to an 
increased susceptibility to intestinal inflammation. Therefore, genetic disturbances in key regulatory 
elements that drive these responses are likely candidates. Recognizing the importance of a disturbed 
Th1 mediated immune response in the etiology of intestinal inflammation, we expanded our studies on 
this subject. In Chapter 6 we studied polymorphism in the transcription factor interferon regulatory 
factor 1 (IRF1) and the IL-12 p40 chain (IL12B) genes in the susceptibility to celiac disease (CeD). 
CeD is an immune-mediated disorder of the small intestine caused by permanent intolerance to 
gluten, a dietary protein found in wheat, rye and oats 14. This disturbed immune response is 
characterized by a Th1 mediated immune response, however, the driving mechanism behind this Th1 
response has not been completely unraveled. Similar to IBD, genetic factors play a key role in CeD 
susceptibility 15. This genetic component can in part be attributed to a strong association with the HLA 
genes, but similar to IBD, CeD is a complex genetic disorder. Several chromosomal regions have 
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been identified that harbor susceptibility genes to CeD, including a locus on chromosome 5q31-33 
(designated CELIAC2) 16-23. This QTLs harbors, among others, the genes IRF1 as well as IL12B. IRF-1 
is a member of the IRF family of transcription factors, and IRF-1 binding sites are present in the IL12B 
promoter 24. 
Given the linkage to this region and the profound Th1 response found in CeD, both IRF1 and IL12B 
would be likely candidates for susceptibility to CeD. We therefore studied previously described 
polymorphisms in these genes in a Dutch Caucasian population, however, we could not link these 
polymorphisms to an elevated susceptibility to CeD. This suggests that a primary defect in these 
genes is not responsible for the observed linkage with this region in CeD nor that they are at the basis 
of the exaggerated Th1 response found in both CD and CeD. 
 
Finding a gene and a mutation that is linked to a particular disease is only the first step in unraveling 
disease pathogenesis. As alluded to earlier, mutations in NOD2 are strongly associated with 
susceptibility to Crohn’s disease. The exact mechanisms by which NOD2 variants lead to CD however 
remain to be defined. NOD2 is expressed in several cell types in the intestine, including Paneth cells, 
and cells from the myeloid lineage 25-28. Recognition of its ligand muramyl dipeptide (MDP) by NOD2 
can lead to secretion of antimicrobial products by Paneth cells, and immune activation and cytokine 
secretion by macrophages and antigen presenting cells 29, 30. Lack of proper functioning of NOD2 has 
been shown to lead to a defective α-defensin production in Paneth cells 31, 32 and less production of 
pro-inflammatory cytokines 29, 33-39. This could in turn facilitate invading bacteria, and contribute to the 
ongoing inflammation as seen in IBD. 
Another explanation was provided by Watanabe et al. demonstrating that lack of NOD2 signaling in 
murine cells results in a lack of regulation of TLR2 mediated activation, resulting in an unwanted high 
production of IL-1β and IL-12, again leading to an exaggerated inflammatory response 40, 41. They 
demonstrated that NOD2 activation normally has an inhibitory effect on TLR2 mediated activation, in 
particular through inhibition of IL-12 responses. This effect is lost in NOD2 mutated mice, leading to a 
profound IL-12 response. This could provide a plausible explanation for the exaggerated IL-12 
responses seen in CD patients. 
Since it was unclear whether the latter explanation also applied to human disease, we tested this 
hypothesis in humans. As described in Chapter 7, we isolated and stimulated freshly isolated human 
monocytes from healthy controls and CD patients with or without mutations in the NOD2 gene. We 
found that cells with functional NOD2 respond in a biphasic manner to MDP. Thus, at a low or 
intermediate dose of MDP the cytokine production of the cells after TLR2 stimulation is enhanced. 
However when cells were incubated with higher doses of MDP, we saw a remarkable reduction in 
cytokine production after TLR2 stimulation. The biphasic effects of NOD2 stimulation were also 
reflected in NF-κB activation, as measured by NF-κB subunit translocation to the nucleus. In sharp 
contrast however, in monocytes from NOD2 mutated patients this initial potentiation was not 
downmodulated after addition of the high dose of MDP, indicating that also in humans, NOD2 is a 
regulating factor for TLR2 activation that can downmodulate cytokine production. We thus show here 
for the first time that human monocytes can respond in a biphasic manner, an effect that is lost in 
 Summary and Discussion 
 141 
patients carrying two mutated NOD2 alleles. This study bridges the initial ‘loss of function’ theories 
based on human PBMC studies with the ‘gain of function’ theories based on murine studies. 
In summary it is clear from the many genetic and functional studies that inflammatory bowel disease is 
a complex affection and that its etiology is far from known. This not only stems from the fact that a 
multitude of genes have now been identified to be associated  with the disease, but also because of 
the multitude of cell types involved, both at the level of the intestinal epithelium, but also at the level of 
the many players of the immune system. Better knowledge of the involvement and function of the 
various gene products associated with IBD on barrier function and immune system will help to unravel 
the underlying mechanisms and especially the coordinated action of geneticists and immunologists 
will lead to adequate prevention or therapy of the disease. 
 
Figure 1 Overview of genes studied in this thesis 
Simplified overview of the activation route in 
which all the genes studied in this thesis play 
a part. 
From bottom to top, IL-12 is a pro-
inflammatory Th1 type cytokine that is 
formed by two subunits, IL-12p40 and IL-
12p35. A promoter polymorphism in the 
gene coding for IL-12p40, IL12B was studied 
in Chapter 6, as well as IRF1. IRF1 encodes 
for the transcription factor IRF-1, that is 
involved in activating IL12B transcription. 
Likewise, IL-12 expression can also be 
induced by NF-κB. We determined the 
prevalence of a promoter polymorphism of 
the human form of NF-κBp50 (NFKB1) in 
IBD patients in Chapter 5, and sequenced 
the murine Nfkb1 in search for variant that 
could provide an explanation for the strain 
difference in colitis susceptibility between 
C57BL/6J and C3H/HeN mice (Chapter 4). 
This after we discovered a QTL on 
chromosome 3 in a Gnai2-/- colitis model, 
using the same strains. Nfkb1 resides in this 
QTL, close to the area that showed the 
strongest linkage with colitis susceptibility. 
Next to these genetic studies, we explored 
the theory that NOD2 signaling interferes 
with TLR2 signaling, and that this has its 
effects on specifically IL-12 production. 
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kinase; IL, interleukin; IRF, interferon 
regulatory factor; ISRE, interferon-stimulated 
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IBD (Inflammatory Bowel Disease) is een verzamelnaam voor verschillende aandoeningen van het 
maagdarmkanaal, gekenmerkt door chronische ontstekingen van de darmwand. Genetische aanleg 
voor verstoringen van de darmwand-functie en het immuunsysteem spelen een belangrijke rol bij het 
ontstaan van de ziekte, maar hoe dit precies tot stand komt is nog grotendeels onbekend. Het doel 
van dit proefschrift was om meer inzicht te verkrijgen in de genetica achter deze ziekte en hoe 
verschillen in genexpressie het immuunsysteem kunnen beïnvloeden. 
 
In hoofdstuk 1 worden aan de hand van een literatuuroverzicht de meest recente inzichten 
beschreven over het ontstaan van de ziekten, met de nadruk op de erfelijke component van IBD. 
De belangrijkste ziekten binnen IBD zijn de ziekte van Crohn en Colitis Ulcerosa. De voornaamste 
symptomen van beide ziekten zijn buikpijn, diarree, occult bloedverlies (bloedverlies via de 
ontlasting), gewichtsverlies, koorts en vermoeidheid. Naast de klachten gerelateerd aan de ontsteking 
in de darmen komen bij IBD patiënten ook veel andere ontstekingsklachten buiten het 
maagdarmkanaal voor, zoals ontstekingen van de gewrichten (artritis), de ogen, de lever en de huid. 
Wereldwijd zijn er ongeveer drie miljoen patiënten, en de ziekten komen het meeste voor bij 
caucasische (blanke) mensen en Joden uit Europa en Noord-Amerika. Ondanks dat de symptomen 
grotendeels overeenkomen, zijn de ziekte van Crohn en Colitis Ulcerosa twee verschillende ziekten. 
 
De ziekte van Crohn 
De ziekte van Crohn is genoemd naar de Amerikaanse arts Burril B Crohn, die de ziekte voor het 
eerst in 1932 beschreven heeft. De ziekte van Crohn is een chronische ontsteking van het 
maagdarmkanaal. In de meeste gevallen is het laatste stuk van de dunne darm, het terminale ileum, 
aangedaan. Bij sommige patiënten zijn ook andere delen van de dunne darm en stukken van de dikke 
darm (het colon) ontstoken. Bij een kleine groep patiënten kunnen de ontstekingen zelfs in de 
slokdarm en de mond ontstaan. Typerend voor de ziekte van Crohn is dat aangetaste stukken darm 
worden afgewisseld met stukken gezonde darm. De ontstekingen geassocieerd met de ziekte van 
Crohn treffen niet alleen het darmslijmvlies, maar ook de onderliggende darmwand en spierlagen. 
De ziekte wordt meestal ontdekt op jong volwassen leeftijd, tussen het 15de en 35ste levensjaar, en 
komt iets meer voor bij vrouwen dan bij mannen. In Nederland komen er naar schatting ongeveer 
duizend patiënten per jaar bij. Vooralsnog zijn er geen afdoende middelen om de ziekte te genezen. 
De behandeling bestaat over het algemeen uit het eerst zo snel mogelijk wegnemen van de actieve 
ontsteking met krachtige ontstekingsremmende medicatie, zoals steroïden (prednison en 
aanverwante middelen), om te voorkomen dat er te veel schade aan de darmen ontstaat. Verder 
kunnen er medicijnen voorgeschreven worden om symptomen als diarree, misselijkheid en buikpijn te 
verhelpen. Indien noodzakelijk kan er een onderhoudsbehandeling voorgeschreven worden, met 
medicijnen die het afweersysteem zodanig tot rust brengen dat de ontstekingsreacties ook milder 
worden. In sommige gevallen van ernstige ziekte kan het noodzakelijk zijn dat ernstig aangedane 
stukken darm chirurgisch moeten worden verwijderd. 
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Colitis Ulcerosa 
Colitis Ulcerosa is een chronische ontsteking van het slijmvlies van de dikke darm. De ziekte komt 
alleen in de dikke darm (colon) voor. Net zoals bij de ziekte van Crohn zijn er verschillende gradaties 
in ernst van de ziekte. In de meest milde gevallen is alleen het laatste gedeelte van de darm, de 
endeldarm aangedaan (proctitis). Bij de iets ernstigere vorm is ook de laatste helft van de dikke darm, 
die zich aan de linkerkant van het lichaam bevindt, ontstoken (left-sided colitis), en in de ernstigste 
gevallen is het complete colon ontstoken (pancolitis). 
Jaarlijks wordt in Nederland naar schatting bij vijftienhonderd nieuwe patiënten de diagnose gesteld. 
Meestal openbaart de ziekte zich tussen het 15de en 40ste levensjaar, met een tweede piek tussen het 
50ste en 60ste levensjaar. De ziekte komt bij mannen en vrouwen evenveel voor. 
Net zoals bij de ziekte van Crohn, is er voor Colitis Ulcerosa nog geen genezende behandeling 
mogelijk. Ook Colitis Ulcerosa wordt voornamelijk bestreden met ontstekingsremmers en middelen 
om het afweersysteem te beïnvloeden. Wanneer deze behandeling niet het gewenste effect heeft, 
kan worden overgegaan tot het verwijderen van de dikke darm. Na het verwijderen van de darm is de 
ziekte verdwenen, aangezien er geen dikke darmslijmvlies meer is. De patiënt zal dan echter wel een 
stoma krijgen, of er kan een inwendig reservoir gemaakt worden van een stuk dunne darm, een 
zogenoemde ‘pouch’. Deze pouch functioneert dan als een soort endeldarm, en de patiënt kan de 
ontlasting normaal lozen via de anus, alleen wel met frequenter toiletbezoek. 
 
Het ontstaan van de ziekten 
Ondanks dat er de afgelopen jaren veel vooruitgang is geboekt in het begrip over het ontstaan van 
IBD, is het voorlopig nog niet bekend hoe de ziekten ontstaan. Wat wel duidelijk is geworden, is dat er 
meerdere factoren een rol spelen in het ontstaan. Deze kunnen worden onderverdeeld in een drietal 
groepen 
1 Omgevingsfactoren 
2 Microbiële factoren 
3 Patiëntgebonden factoren 
 
Omgevingsfactoren 
Onder omgevingsfactoren verstaan we factoren zoals leefomgeving en leefgewoonten. Een logische 
gedachte zou zijn dat het dieet een belangrijke factor kan zijn voor het ontstaan van een ziekte die de 
darmen aantast. Echter, er is geen bewijs dat voeding van invloed is op het ontstaan van IBD. IBD 
patiënten hoeven strikt genomen dan ook geen speciaal dieet te volgen, maar in sommige gevallen 
verdragen patiënten sterk gekruid of erg vet voedsel minder goed, en hebben ze er baat bij voeding 
met deze stoffen te mijden. 
Een leefgewoonte die wel aantoonbaar van invloed is op IBD is roken. Roken verergert de mate van 
ontstekingen in de ziekte van Crohn, maar opvallend genoeg blijken patiënten met Colitis Ulcerosa 
soms baat te hebben bij roken. In deze patiënten lijkt roken, naast alle schadelijke effecten dat het 
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elders in het lichaam heeft, juist een beschermend effect te hebben tegen de ziekte. Welke stoffen in 
sigarettenrook precies verantwoordelijk zijn voor dit effect, en hoe deze aangrijpen, is nog onduidelijk. 
 
Microbiële factoren 
Ons maagdarmkanaal huisvest een zeer groot aantal bacteriën, ongeveer 100 biljoen 
(100.000.000.000.000), tien keer zoveel als het totaal aantal lichaamscellen. Het overgrote gedeelte 
van deze bacteriën is onschadelijk, en zelfs noodzakelijk bij het verteren van ons voedsel en het 
aanmaken van bepaalde vitaminen die we zelf niet kunnen maken. Uit recent onderzoek blijkt dat de 
normale darmflora betrokken zou kunnen zijn bij het ontstaan van IBD. IBD patiënten hebben in 
sommige gevallen meer bacteriën in hun darmen dan gezonde personen, en antibiotica kuren kunnen 
een positieve invloed hebben op het beloop van de ziekte. Ook het consumeren van ‘goede’ 
bacteriën, in de vorm van probiotica in melkproducten lijkt in sommige gevallen een gunstige effect te 
hebben op de ernst van de ziekte. 
Er zijn echter ook micro-organismen met pathogene (ziekmakende) eigenschappen. Er is geen 
sluitend bewijs dat deze pathogenen IBD kunnen veroorzaken, maar er zijn wel aanwijzingen dat 
infectie met een bepaalde bacterie, Mycobacterium tuberculosis, vaker voor komt bij Crohn patiënten. 
Opvallend is hier om op te merken dat een nauw verwante vorm van deze bacterie, Mycobacterium 
avium subspecies paratuberculosis, bij runderen de ziekte van Johne’s veroorzaakt, een aandoening 
van de darmen die verassend veel overeenkomsten met de ziekte van Crohn vertoont. Het is echter 
nog de vraag of een infectie bij mensen met M. tuberculosis de ziekte van Crohn veroorzaakt, of dat 
het omgekeerde het geval is, en dat mensen met de ziekte van Crohn gevoeliger zijn voor infectie 
met deze bacterie. 
 
Patiëntgebonden factoren 
De manier waarop de externe omgevingsfactoren en microbiële factoren een bijdrage leveren aan het 
ontstaan van IBD is waarschijnlijk grotendeels afhankelijk van hoe een persoon op deze factoren 
reageert. Een belangrijke rol is hier weggelegd voor het afweersysteem, of immuunsysteem. 
 
Het immuunsysteem en IBD 
Het immuunsysteem verdedigt het lichaam tegen allerlei indringers van buitenaf. De omgeving waarin 
het dat moet doen bij IBD is echter uitermate complex. In ons voedsel bevinden zich ontelbare 
lichaamsvreemde stoffen, en onze darmen zitten vol met bacteriën de nodig zijn voor het goed 
functioneren van het verteringstelsel. Hieruit moet het immuunsysteem de schadelijke bacteriën 
herkennen en elimineren, terwijl het de onschadelijke stoffen en bacteriën met rust moet laten. Een te 
zwakke afweer kan er toe leiden dat pathogenen de vrije hand krijgen en infecties en ziekte 
veroorzaken, terwijl een te sterke afweerreactie en ontsteking schade aan het eigen weefsel kunnen 
veroorzaken. Het moge duidelijk zijn dat het immuunsysteem heel nauwkeurig gereguleerd moet 
worden, en dat iedere afwijking van die regulatie tot ziekte kan leiden. 
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Het immuunsysteem kan worden gezien als een leger met verschillende divisies, bestaande uit 
verschillende celtypes, alle met hun eigen functie. 
De eerste divisie, het aangeboren immuunsysteem verzorgt de eerste verdediging. Deze tak van het 
immuunsysteem werkt relatief aspecifiek. Het herkent pathogenen op algemene kenmerken. Deze 
kenmerken zijn specifiek voor microbiologische organismen. Zo bestaat de celwand van bacteriën uit 
bepaalde moleculaire bouwstenen die niet bij menselijke cellen voorkomen, maar binnen het rijk der 
bacteriën algemeen gebruikt zijn. Deze stoffen worden ook wel Pathogeen geAssocieerde 
Moleculaire Patronen (PAMP) genoemd. De ‘verkenner’ cellen van het aangeboren afweersysteem, 
de Antigeen Presenterende Cellen (APCs) herkennen deze bouwstenen met behulp van receptoren, 
eiwitten op de celmembraan, die alleen de PAMPs herkennen, de Pathogen Recognizing Receptoren, 
ofwel PRRs. Een belangrijke groep van deze PRRs zijn de Toll-like receptoren (TLRs), waar 
hieronder nog op terug gekomen wordt. Wanneer een bacterieel product bindt aan deze receptoren, 
raakt de APC geactiveerd en kan hij een immuunrespons in gang zetten. Om de immuunrespons op 
te starten, en andere cellen van het immuunsysteem aan te trekken en aan te sporen tot reageren, 
kunnen de APCs signaalstoffen, cytokinen uitscheiden. In de immunologie worden tientallen 
verschillende cytokinen beschreven, die afhankelijk van hun eigenschap, andere afweercellen kunnen 
aantrekken en aansporen tot het aanvallen van pathogenen, of er juist voor zorgen dat de activiteit 
van afweercellen wordt gedempt zodat de immuunreactie niet te sterk wordt. Cytokinen spelen dus 
een uitermate belangrijke rol in de regulatie van de immuunrespons. 
Afhankelijk van het soort pathogeen, bijvoorbeeld of het een virus of een bacterie betreft, of dat de 
bacterie wel of niet de cellen binnendringt, worden er verschillende cytokinen uitgescheiden en wordt 
er een verschillende immuunrespons opgestart. Bij de ziekte van Crohn is dit een zogenoemde T 
helper 1 (Th1) respons. Een Th1 respons wordt ook wel een cel-gemedieerde respons genoemd. 
Belangrijk bij deze respons zijn macrofagen, die pathogenen kunnen ‘opeten’ en zo onschadelijk 
maken, en NK (natural killer) cellen en cytotoxische T cellen die door direct cel contact de 
pathogenen kunnen elimineren. De cytokinen die bij een Th1 respons horen, en die ook in hoge 
concentraties bij de ziekte van Crohn patiënten gevonden worden zijn interleukine 12 (IL-12) 
interferon-γ (IFN-γ) en Tumor Necrosis Factor-α (TNF-α). 
Bij Colitis Ulcerosa is er sprake van een Th2 respons. Een Th2 respons wordt ook wel een humorale 
immuunrespons genoemd, omdat er bij dit type afweerreactie veel antilichamen gevormd worden, die 
zich in de lichaamsvloeistoffen (de humora) bevinden. De cytokinen die bij dit ziektebeeld horen zijn 
IL-13 en IL-4. De ziekte van Crohn en Colitis Ulcerosa verschillen dus naast lokalisatie en type 
ontsteking ook in type immuunrespons. 
 
Naast de gespecialiseerde cellen van het afweersysteem heeft het darmslijmvlies, het epitheel, ook 
een rol in de afweer tegen pathogenen. Allereerst zitten de cellen van het darmslijmvlies zeer stevig 
tegen elkaar vast met speciale structuren, de tight junctions, zodat de bacteriën er niet tussendoor 
kunnen. Ten tweede kunnen de slijmbekercellen (ook wel Paneth cellen genoemd) die 
verantwoordelijk zijn voor het produceren van het mucus, de laag slijm die de darmwand bedekt, ook 
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antibacteriële stoffen uitscheiden. Deze antibacteriële stoffen, defensinen, moeten er voor zorgen dat 
de bacteriën niet te dicht bij de darmwand kunnen komen en zich daar niet kunnen nestelen en delen. 
De integriteit en functionaliteit van de darmwand is dus van groot belang bij het afslaan van aanvallen 
van pathogenen. Binnen IBD is ook aangetoond dat de barrièrefunctie van de darmwand aangetast 
kan zijn bij patiënten, waardoor de pathogenen makkelijker binnen zouden kunnen dringen en een 
ontsteking zouden kunnen veroorzaken. 
 
Genetica en IBD 
Normaal gezien reageert het immuunsysteem in de darm adequaat op aanvallen van pathogenen. De 
reactie is sterk genoeg om de pathogenen te verwijderen, en wordt daarna weer geremd, om te 
voorkomen dat een te lange en te sterke afweerreactie schade aan het eigen weefsel gaat 
aanrichten. Gezien de sterke ontstekingsreacties in IBD is het voor de hand liggend aan te nemen dat 
de regulatie van de immuunrespons bij IBD op zijn minst verstoord is. Zoals gezegd reageert ieder 
persoon anders op invloeden van buitenaf, en is de een gevoeliger voor infecties dan de ander, of dit 
nu komt door een verstoring van het immuunsysteem of van de barrièrefunctie van de darmwand. Dit 
verschil in gevoeligheid kan grotendeels veroorzaakt worden door erfelijke factoren. 
 
Er zijn talrijke aanwijzingen dat IBD (ten dele) erfelijk bepaald is. Allereerst is er het feit dat de ziekten 
vaak binnen een familie voorkomen. Ongeveer 10 tot 20 % van de patiënten met IBD heeft een 
familielid met dezelfde ziekte. Ook binnen bepaalde etnische bevolkingsgroepen komt de ziekte meer 
voor, voornamelijk bij Joden en caucasiërs terwijl Aziaten en negroïden nauwelijks zijn aangedaan. 
Sterke aanwijzingen dat de ziekten genetisch bepaald zijn, komen uit studies waarin eeneiige en 
twee-eiige tweelingen werden vergeleken. Eeneiige tweelingen zijn genetisch identiek, terwijl twee-
eiige tweelingen ongeveer de helft van hun genen delen. Het blijkt dat eeneiige tweelingen vaak 
allebei de ziekte hebben, terwijl het risico dat twee-eiige tweelingen allebei de ziekte hebben net zo 
groot is als voor normale broers en zussen. 
 
Wat zijn nu precies de erfelijke factoren die IBD kunnen bepalen, en hoe kunnen we ze vinden? 
Alle erfelijke factoren liggen opgeslagen in het DNA. Het totaal van DNA wat iemand bij zich draagt 
noemen we het genoom. Het genoom bestaat uit 23 chromosomen paren, en ieder chromosoom is 
een lange code van 4 bouwstenen A(denosine), C(ytosine), G(uanine) en T(hymidine), die ‘basen’ 
worden genoemd. Op ieder chromosoom liggen enkele duizenden genen, die allen voor hun eigen 
eiwit coderen. Wanneer een gen ‘actief’ is, of ‘tot expressie komt’, zal het eiwit waarvoor het gen 
codeert aangemaakt worden door de cel. Welke genen, in welke cel, op welk moment tot expressie 
komen, hangt af van de soort cel, welke functie die cel heeft en welke informatie de cel op dat 
moment van buitenaf krijgt. 
Net zoals mensen kunnen verschillen van oogkleur, zitten er soms kleine verschillen in de code 
(basenvolgorde) van een gen. Deze verschillen worden polymorphismen genoemd. Deze 
polymorphismen kunnen een invloed hebben op hoeveel een gen tot expressie komt (de hoeveelheid 
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eiwit die wordt aangemaakt) of op de structuur van het eiwit (de functionaliteit van een eiwit). Deze 
veranderingen in genetische factoren kunnen iemand gevoeliger maken voor IBD. Hoe kunnen we nu 
op zoek gaan naar genetische factoren die van invloed zijn op het ontstaan van IBD? 
Een eerste methode kan zijn om de basenvolgorde van een bepaald gen waarvan we het vermoeden 
hebben dat het een invloed zou kunnen hebben op de ziekte te bepalen  en te gaan vergelijken 
tussen patiënten met IBD en gezonde personen. Genen die betrokken zijn bij de afweerreactie zijn 
bijvoorbeeld interessante kandidaten om dat mee te doen. Wanneer er een verschil in de DNA code 
gevonden wordt binnen dit gen, kan gekeken worden of deze variatie vaker bij IBD patiënten 
voorkomt. Wanneer dit het geval is, wil dat zeggen dat dat gen betrokken is bij de gevoeligheid voor 
de ziekte. Er zijn echter een goede 40.000 genen bekend, en om alle genen stuk voor stuk af te gaan 
is ondoenlijk. 
Een andere methode die daarom gebruikt wordt is ‘genomic screening’. Bij deze techniek wordt het 
complete DNA vergeleken van leden van een familie waarbinnen er meerdere personen aangedaan 
zijn. Zo kunnen er hele stukken DNA (als het ware hoofdstukken binnen een boek) worden 
aangewezen die verschillen tussen gezonde en zieke personen. De genen die betrokken zijn bij de 
ziekte moeten zich binnen deze ‘hoofdstukken’ bevinden. We noemen deze hoofdstukken ook wel 
‘gevoeligheids loci’. Op deze manier kan het aantal genen wat afgezocht moet worden naar 
polymorfismen drastisch verkleind worden. 
Daarnaast bestaat de mogelijkheid om voor duizenden genen tegelijkertijd te bepalen in welke mate 
ze tot expressie komen. Door te kijken of er verschillen zijn in expressie tussen patiënten en gezonde 
personen, kunnen ook aanwijzingen gevonden worden welke genen betrokken zijn bij de gevoeligheid 
voor IBD. 
Er zijn tot nog toe een aantal genen gevonden die in zekere mate betrokken zijn bij de gevoeligheid 
voor IBD. Een overzicht hiervan wordt gegeven in hoofdstuk 1. Er is slecht nog maar één gen 
gevonden dat onomstotelijk met IBD, en meer specifiek met de ziekte van Crohn geassocieerd is. Dit 
gen is NOD2. NOD2 codeert voor een PRR die bacteriële stoffen die zich binnen in de cel bevinden 
herkent. Mutaties of polymorfismen in dit gen komen bij ongeveer een kwart van de Crohn patiënten 
voor. Hoe het komt dat mensen met mutaties in dit gen ziek worden is nog niet bekend. Hier zal later 
nog op terug gekomen worden. 
 
Ondanks de huidige vooruitgang van de techniek, en onze kennis omtrent de immunologie en 
genetica, is er nog niet veel bekend over het ontstaan van IBD. De reden waarom het uitermate 
moeilijk is gebleken om de oorzaken van IBD te vinden kan op verschillende vlakken gezocht worden. 
Ten eerste is de menselijke populatie uitermate divers. Iedereen heeft zijn geheel eigen unieke 
genetische code en eigen levensstijl, die de gevoeligheid voor en het beloop van de ziekte kunnen 
beïnvloeden. Ten tweede bestaat de mogelijkheid dat ‘de ziekte van Crohn’ en ‘Colitis Ulcerosa’ in 
feite verzamelnamen zijn voor een aantal ziekten met vergelijkbare symptomen, allen met hun eigen 
oorzaak, in plaats van dat ze slechts één ziekte vertegenwoordigen. Ten derde komen de 
polymorfismen in de genen waarvan is aangetoond dat ze in meer of mindere mate invloed hebben 
op de gevoeligheid voor de ziekte vaak voor bij een zeer klein percentage van de patiënten, en is het 
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in veel gevallen waarschijnlijk een combinatie van genen die de gevoeligheid voor de ziekte bepaalt, 
en niet slechts één gen. Dit alles heeft tot gevolg dat studies in humane IBD patiënten uitermate 
ingewikkeld zijn. Daarnaast moeten zeer grote groepen patiënten bestudeerd worden voordat de 
complexe mix van meerdere genen ontrafeld kan worden, in combinatie met het bepalen welke 
omgevingsfactoren een rol spelen in het ontstaan van IBD. 
 
Een manier om deze complexiteit te omzeilen is het gebruik van modellen om IBD te bestuderen. In 
hoofdstuk 2 wordt een overzicht gegeven van de beschikbare modellen voor IBD. Binnen het 
onderzoek naar IBD worden veel muismodellen gebruikt. Er zijn verscheidene voordelen aan het 
gebruik van muismodellen. Een groot voordeel van het gebruik van muismodellen is dat alle muizen 
van één stam genetisch identiek zijn. Heel wat eenvoudiger dan de complexe humane situatie. 
Daarnaast kunnen de omgevingsfactoren relatief eenvoudig constant gehouden worden. Tot slot is 
het relatief simpel grote aantallen dieren te bestuderen. Een nadeel van het gebruik van 
muismodellen is uiteraard dat het om muizen gaat, en dat muizen niet hetzelfde zijn als mensen, en 
ook niet exact hetzelfde ziektebeeld ontwikkelen. Vandaar dat we in muizen ook spreken van de 
gevoeligheid voor intestinale ontsteking of colitis, in plaats van de gevoeligheid voor IBD. Een 
belangrijke observatie echter, is dat er gevoeligheidsverschillen tussen de verschillende 
muizenstammen bestaan. Dit wil zeggen dat er dus genetische verschillen moeten zijn tussen deze 
muizenstammen die verantwoordelijk zijn voor de gevoeligheid. Deze eigenschap kan gebruikt 
worden in de zoektocht naar de genen die verantwoordelijk zijn voor intestinale ontsteking. Wanneer 
een bepaald gen betrokken is bij de muizenvorm van de ziekte, is de kans groot dat dit gen ook 
betrokken is bij de humane vorm. In hoofdstuk 3 hebben we gebruik gemaakt van deze eigenschap. 
Wanneer in twee verschillende muizenstammen het gen voor G-protein α inhibitory chain 2 (Gαi2, 
gecodeerd door het gen Gnai2) kunstmatig wordt uitgeschakeld, ontwikkelt de ene stam, de C3H/HeN 
stam ontstekingen in de dikke darm (colitis), terwijl de andere stam, de C57BL/6J stam, gezond blijft. 
Door nu het complete genoom van deze twee stammen te vergelijken hebben we een aantal 
gebieden (loci) kunnen identificeren die geassocieerd zijn met de gevoeligheid voor colitis. In deze 
loci moeten dus genen liggen die verantwoordelijk zijn voor het verschil in gevoeligheid voor colitis. 
Het gebied met de sterkste associatie lag op chromosoom 3. We hebben dit gebied Gpdc1 genoemd. 
Binnen Gpdc1 liggen verscheidene genen die, gebaseerd op hun functie, interessante 
kandidaatgenen zouden zijn voor de gevoeligheid voor colitis. Een daarvan is Nfkb1. Nfkb1 codeert 
voor de transcriptiefactor NF-κBp50, een eiwit dat betrokken is bij de regulatie van de expressie van 
een groot aantal genen die betrokken zijn bij de afweerreactie. Wanneer bijvoorbeeld een receptor op 
een APC een bacterie herkent, wordt via verschillende signaaleiwitten het NF-κB complex 
geactiveerd, dat bestaat uit NF-κBp50 (Nfkb1) en NF-κBp65 (Nfkb2). Het NF-κB complex verplaatst 
zich vanuit het cytoplasma naar de celkern, en bindt daar aan het DNA. Hierdoor wordt de cel 
aangezet om het gen waarbij NF-κB gebonden heeft te activeren en zo de productie van deze stoffen 
te starten. Vaak zijn dit genen die voor afweerfuncties coderen, 
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In hoofdstuk 4 hebben we getracht om polymorfismen in Nfkb1 te vinden die het verschil in colitis 
gevoeligheid tussen de twee stammen zouden kunnen verklaren. We hebben daarvoor de 
basenvolgorde van het Nfkb1 gen van de C3H/HeN stam en de C57BL/6J stam bepaald en met 
elkaar vergeleken, om te zien of er verschillen in de sequentie zaten. We hebben echter geen 
verschillen kunnen vinden die tot een verandering in het eiwit zouden kunnen leiden, wat een 
veranderd functioneren van NF-κBp50 met zich mee zou kunnen brengen. Het Nfkb1 gen is echter 
een relatief groot gen, en het gebied in het genoom juist voor en juist achter het gen kan ook mutaties 
bevatten. Deze mutaties zouden weliswaar niet voor een veranderd eiwit kunnen zorgen, maar 
kunnen wel invloed hebben op de expressie van het gen. 
Rond dezelfde tijd dat wij de muisvariant van het Nfkb1 gen bestudeerden, werd er een zogenoemd 
promoter polymorfisme beschreven in de humane variant van het NFKB1 gen. De promoter van een 
gen is een gebied in het genoom wat net voor het gen zelf ligt, wat van invloed is op de expressie van 
het gen. De machinerie van de cel die nodig is om een gen af te lezen heeft de promoter nodig om 
aan te binden om het gen daarna daadwerkelijk af te kunnen lezen. Dit promoter polymorfisme 
bestaat uit een deletie van een klein stukje van de promoter van NFKB1 (een –ATTG deletie, 94 
basenparen voor de start van het gen) en bleek betrokken te zijn bij de gevoeligheid voor Colitis 
Ulcerosa in een noord Amerikaanse patiëntengroep. Omdat polymorfismen niet altijd in alle 
patiëntengroepen voorkomen besloten wij te kijken of wij dezelfde associatie met Colitis Ulcerosa in 
onze Nederlandse caucasische patiënten terug konden vinden. Dit bleek het geval. De deletie van 
een klein stukje van de promoter bleek vaker voor te komen in voornamelijk mannelijke UC patiënten, 
en gaf aanleiding tot het zich openbaren van de ziekte op een jongere leeftijd. Deze studie is 
beschreven in hoofdstuk 5. 
Hoe het komt dat het polymorfisme in de promoter van NFKB1 leidt tot een verhoogde gevoeligheid 
voor Colitis Ulcerosa is nog niet duidelijk. De –ATTG deletie zorgt ervoor dat NFKB1 minder effectief 
afgeschreven kan worden. Echter, in IBD patiënten wordt juist een verhoogde NF-κB activering 
gevonden. Dit fenomeen kan op verschillende manieren verklaard worden. Naast dat NF-κBp50 
tezamen met NF-κBp65 een complex kan vormen wat genexpressie kan activeren, kan NF-κBp50 ook 
aan zichzelf binden. Dit complex kan ook aan het DNA binden, maar heeft juist een remmende 
werking op de genexpressie. Wanneer er minder NF-κBp50 beschikbaar is, kan de verhouding tussen 
de activerende en remmende complexen verschuiven, en uiteindelijk toch tot een verhoogde staat 
van NF-κB activering leiden. 
Anderzijds kan de verminderde productie van NF-κBp50 leiden tot een verminderde activering van 
afweerstoffen. Hierdoor kunnen de bacteriën een voorsprong krijgen op het immuunsysteem, en dit 
kan tot een ergere infectie leiden. Deze kan door het NF-κB defect niet goed worden opgeruimd, en 
blijft dus bestaan. Uiteindelijk zou er daardoor een continue staat van activering kunnen ontstaan. 
 
Hoe de verhoogde gevoeligheid ook tot stand komt, het is duidelijk dat de afweerrespons strak 
gereguleerd moet worden. Alle genen die hierbij betrokken zijn kunnen dan ook als kandidaat gezien 
worden voor de gevoeligheid voor IBD. Dit blijkt ook wel uit de grote verscheidenheid aan 
diermodellen met verschillende gendefecten die allemaal tot colitis leiden. Een overeenkomst in deze 
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genen is echter wel dat ze over het algemeen op de één of andere manier iets te maken hebben met 
de regulatie van de productie van cytokinen. 
 
In hoofdstuk 6 hebben we de rol van de transcriptiefactor IRF-1 en één van de twee ketens van het 
cytokine IL-12, namelijk IL-12p40, onderzocht in de gevoeligheid voor coeliakie. Coeliakie is een 
ontstekingsziekte van de dunne darm, veroorzaakt door een overgevoeligheid voor gluten, een stof 
die voorkomt in tarwe, rogge en gerst. Ondanks dat men weet tegen welke stof de afweerreactie 
gericht is, is de genetisch achtergrond van deze ziekte, net zoals bij IBD, nog grotendeels onbekend. 
De genen IRF1 en IL12B (coderend voor IL-12p40) liggen in een gebied dat in ander studies is 
aangeduid als een gevoeligheidslocus voor coeliakie, CELIAC2, op chromosoom 5. In de promotor 
van IL12B bevinden zich gebieden waar de transcriptiefactor IRF-1 aan kan binden. IRF1 kan dus de 
expressie van IL12B reguleren. Gezien het belang van het cytokine IL-12 in het aansturen van 
immuunresponsen, en de ligging van deze twee genen in een gebied dat als gevoeligheidslocus 
wordt aangeduid, zijn dit interessante genen om te bestuderen, en te kijken of eerder beschreven 
polymorfismen in deze genen betrokken zijn bij de gevoeligheid voor coeliakie. Echter, we konden in 
onze Nederlandse caucasische patiëntengroep geen aanwijzingen vinden dat deze genen betrokken 
zijn bij de gevoeligheid voor coeliakie. 
 
Het vinden van een gen wat betrokken is bij de gevoeligheid voor een ziekte is slechts de eerste stap 
in het begrijpen van het ontstaan van de ziekte. Zo is ondanks het feit dat NOD2 het eerste gen is 
waarvan een duidelijke betrokkenheid beschreven is bij het ontstaan van de ziekte van Crohn, het 
nog verre van duidelijk hoe mutaties in NOD2 leiden tot de ziekte. 
NOD2 komt tot expressie in verschillende celtypen en is een receptor voor het bacteriële product 
muramyl dipeptide (MDP). In slijmbekercellen in de darmwand leidt herkenning van MDP door NOD2 
tot het afscheiden van antibacteriële stoffen. Slecht functionerend NOD2 als gevolg van mutaties in 
het NOD2 gen zouden kunnen leiden tot minder productie van antibacteriële stoffen. Hierdoor zouden 
de bacteriën de kans kunnen krijgen een infectie in de darm te veroorzaken, die uiteindelijk tot de 
ziekte van Crohn zou kunnen leiden. 
In bepaalde cellen van het afweersysteem, macrofagen en dendritische cellen, komt NOD2 ook tot 
expressie. Hier kan het herkennen van MDP door NOD2 de reactie van de cellen op de activerende 
signalen van andere receptoren, de TLRs, versterken en de cellen extra aanzetten tot het tot 
expressie brengen van cytokinen en het opstarten van een immuunrespons. Wanneer deze extra 
activering weg zou vallen, zouden de bacteriën ook in dit geval een voorsprong op het 
immuunsysteem krijgen, wat tot langdurige ontsteking kan leiden. 
Een andere mogelijkheid is echter dat NOD2 signalering de TLR activering, met name de TLR2 
activering, negatief reguleert, dus in feite remt. Het is aangetoond in muizen dat wanneer de NOD2 
signalering wegvalt, de IL-12 productie niet meer geremd wordt, en dat deze remming alleen op TLR2 
van toepassing is. 
In hoofdstuk 7 wilden we testen of dit proces ook in humane cellen plaats kon vinden. Om dit te 
onderzoeken hebben we monocytaire cellen uit het bloed van Crohn patiënten met en zonder 
 Nederlandse Samenvatting 
 155 
mutaties in NOD2 geïsoleerd en in kweek gebracht, alsmede cellen van gezonde controle personen, 
met normaal NOD2. Wanneer cellen van gezonde personen of IBD patiënten zonder NOD2 mutatie 
via hun TLR2 gestimuleerd werden tegelijkertijd met een lage of intermediaire doses van MDP, werd 
de TLR2 gemedieerde cytokine respons versterkt. Wanneer de dosis MDP verder verhoogd werd 
echter, werd er beduidend minder cytokine geproduceerd door de cellen. Dit remmende effect werd 
ook gezien in de NF-κB activering van de cellen. Cellen die geen functioneel NOD2 tot expressie 
konden brengen, vertoonden dit effect niet. Weliswaar werd de cytokine-productie wel enigszins 
verhoogd door het toevoegen van MDP, maar de remming van de TLR2 respons bij de hoge dosering 
van MDP werd niet gezien. Deze resultaten laten voor het eerst zien dat ook in menselijke cellen 
NOD2 de TLR2 activering negatief kan reguleren, en dat deze regulatie wegvalt in monocytaire cellen 
van patiënten die geen functioneel NOD2 hebben. 
 
Samenvattend kunnen we stellen dat ondanks de vele genetische, immunologische en 
epidemiologische studies die gedaan zijn de complexe oorsprong van inflammatoire darmziekten nog 
verre van duidelijk is. Vele genen en vele celtypen kunnen betrokken zijn bij de het ontstaan van IBD, 
en de functie van de genen hoeft niet noodzakelijkerwijs hetzelfde te zijn in verschillende celtypen. 
Een betere kennis van de functie van alle genen die geassocieerd zijn met de ziekten en hun rol in de 
immunologische achtergrond van IBD, tezamen met een betere herkenning en indeling van de 
verschillende subtypen van IBD, zal helpen bij te dragen aan het begrip van de ziekten, en uiteindelijk 
kunnen leiden tot een adequate preventie van of therapie voor de ziekte. 
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